

HOSPITAL-BASED IMPLEMENTATION OF NEWBORN HEARING SCREENING
IN A COHORT OF INFANTS ADMITTED TO THE NICU: OUTCOMES AND
IMPLICATIONS FOR POLICY AND PRACTICE

A Dissertation

by

LIZA MICHELLE CREEL

Submitted to the Office of Graduate and Professional Studies of
Texas A&M University
in partial fulfillment of the requirements for the degree of

DOCTOR OF PHILOSOPHY

Chair of Committee,	Robert Ohsfeldt
Committee Members,	Sean Gregory
	Hongwei Zhao
	Jean Brender
Head of Department,	Michael Morrissey

August 2015

Major Subject: Health Services Research

Copyright 2015 Liza Michelle Creel

ABSTRACT

Hearing loss affects approximately 1-3 live births per 1,000. Infants admitted to the NICU are at greater risk of hearing loss than infants in the newborn nursery. Family history, as well as very low birth weight and exposure to certain therapies such as assisted ventilation, are also risk factors associated with hearing loss. Many states mandate newborn screening for hearing loss after birth due to evidence that early diagnosis and intervention improve communication skills and school performance, but following these infants over time can be challenging.

This retrospective study describes temporal trends in primary screening outcomes including screening rates, loss to follow-up, and screen sensitivity and specificity. It also evaluated the likelihood of newborn hearing screening, loss to follow-up, false-positive and false-negative results, as well as hearing loss diagnosis among at-risk infants. Time-to-diagnosis for infants with and without screening was also assessed. The study utilizes a database of births and follow-up encounters for infants born in a large Texas integrated health system between 1996 and 2007.

Most newborn hearing screening program outcomes have improved since implementation in 1996. Outcomes differ by group, with black infants having higher probabilities of being lost to follow-up and receiving a false-positive result, but a lower probability of hearing loss than the overall study population. Infants diagnosed with persistent pulmonary hypertension had a higher probability of a false-negative result. Infants with craniofacial anomalies and neonatal infections have 5-7 times higher

probability of hearing loss than those without the diagnoses. The overall incidence of hearing loss among the study population was 5%. Survival estimates demonstrate that infants identified through screening have a higher probability of early diagnosis. Infants with false-negative screens have the same probability of early diagnosis as infants with no screen.

The study findings can inform both policy and practice. Newborn hearing screening leads to earlier diagnosis of infants with hearing loss, but improving targeted follow-up of high risk NICU infants may lead to earlier diagnosis of infants with delayed onset of hearing loss. Community-based providers can monitor high risk NICU infants after discharge for potential hearing loss.

DEDICATION

I dedicate this dissertation to my family. Thank you for your encouragement and support of my ongoing desire for knowledge, and for always pushing me to do the best I can while still helping others. To my grandfather, Gordon C. Creel, PhD – I wish you were here to see this and to help me decipher Latin words.

ACKNOWLEDGEMENTS

I would like to thank my committee chair, Dr. Ohsfeldt, and my committee members, Dr. Gregory, Dr. Zhao, and Dr. Brender, for their guidance and support throughout the course of this research.

I also want to extend my gratitude to the Baylor Scott and White Health System, who provided access to the database, and Dr. Catherine McNeal, Dr. Madhava Beeram, and Dr. David Krauss for the historical knowledge and clinical expertise they provided.

Finally, thanks to my parents for their encouragement; to my grandmother for always giving me perspective on life; to my brother who reminds me that everyone deserves a chance; and to Angela, Bill, Charlie, and Baby Henry for providing me with more meals than I made myself and for making my time in College Station something I will always remember fondly.

TABLE OF CONTENTS

	Page
ABSTRACT	ii
DEDICATION	iv
ACKNOWLEDGEMENTS	v
TABLE OF CONTENTS	vi
LIST OF FIGURES	viii
LIST OF TABLES	ix
CHAPTER I INTRODUCTION	1
CHAPTER II LITERATURE REVIEW	5
Risk Factors Associated with Hearing Loss.....	5
Infant and Maternal Characteristics Affecting Hearing Loss.....	6
NICU Interventions Affecting Hearing Loss	6
Universal Screening Programs	11
Follow-up after a Positive Hearing Screen	15
Recommended Protocol for Newborn Hearing Screening and Follow-up.....	18
Studying At-Risk Populations	19
Existing Databases	22
CHAPTER III METHODS	26
Specific Aim 1.....	26
Specific Aim 2.....	28
Outcome Measures	31
Statistical Analyses.....	33
Specific Aim 3.....	39
Limitations of Methodology.....	42
CHAPTER IV RESULTS	44
Specific Aim 1.....	44
Specific Aim 2.....	50
Study Sample Profile.....	50

Temporal Trends	54
Prediction Models.....	61
Specific Aim 3.....	80
Time-to-Diagnosis by Year	81
Survival Estimates by Hearing Screen Status	83
Cox Proportional Hazards Regression	84
Survival Estimates for Significant Model Covariates	86
CHAPTER V DISCUSSION AND CONCLUSIONS.....	90
Specific Aim 1.....	90
Study Limitations	92
Implications for Research Practice.....	92
Specific Aims 2 and 3	93
Study Limitations	97
Policy Implications.....	98
Clinical Implications	99
Future Research.....	100
REFERENCES.....	102

LIST OF FIGURES

	Page
Figure 1. Database Review, Study Abstraction Process	44
Figure 2. Annual Publications by Study Design	45
Figure 3. Study Trends, Top Ten Clinical Focus Areas, 1990-2014	49
Figure 4. Newborn Hearing Screening Rates, 1996-2007.....	55
Figure 5. Loss to Follow-up Rates, NICU, 1996-2007	56
Figure 6. Screen Program Specificity and False-Positive Rate, NICU, 1996-2007.....	58
Figure 7. Screen Program Sensitivity and False-Negative Rate, NICU, 1996-2007	60
Figure 8. Median Time-to-Diagnosis, NICU Graduates	82
Figure 9. Kaplan-Meier Survival Estimates, by Hearing Screen Status	84
Figure 10. Kaplan-Meier Survival Estimates, by Race/Ethnicity	87
Figure 11. Kaplan-Meier Survival Estimates, by Length of Stay	88
Figure 12. Kaplan-Meier Survival Estimates, by CFA Diagnosis	89

LIST OF TABLES

	Page
Table 1. Model Exclusion Criteria and Sample Sizes	30
Table 2. ICD-9CM Codes used to Identify Hearing Loss	32
Table 3. Infant Factors	33
Table 4. Primary Clinical Areas of Focus for Studies Using Multicenter Neonatal Databases	47
Table 5. Characteristics of Newborn Population Admitted to Health Care System between 1988 and 2009	52
Table 6. Descriptive Statistics for Hearing Loss (HL) in the NICU cohort, 1996-2007..	53
Table 7. Results of Logistic Regression Analysis, Likelihood an Infant Received a Hearing Screen (n=28,335).....	63
Table 8. Average Marginal Effects for the Logistic Model of Screening Receipt.....	65
Table 9. Results of Logistic Regression Analysis, Likelihood an Infant is Lost to Follow-up (n=5,102).....	67
Table 10. Average Marginal Effects for the Logistic Model of Being Lost to Follow- up	69
Table 11. Results of Logistic Regression Analysis, Likelihood of a False-Positive Screen Result (n=5,002)	71
Table 12. Average Marginal Effects for the Logistic Model of Receipt of a False- Positive Screen Result	73
Table 13. Results of Logistic Regression Analysis, Receipt of a False-Negative Screen Result (n=5,002)	75
Table 14. Average Marginal Effects for the Logistic Model of Receipt of a False- Negative Screen Result.....	76
Table 15. Results of Logistic Regression Analysis, Likelihood an Infant Receives a Hearing Loss Diagnosis (n=4,855)	78

Table 16. Average Marginal Effects for the Logistic Model of Diagnosis of Hearing Loss	79
Table 17. Median Time to Hearing Loss Diagnosis, in Years	81
Table 18. Cox Proportional Hazards Model Results, Hearing Loss Diagnosis (n=4,855)	86

CHAPTER I

INTRODUCTION

Hearing loss affects approximately 1-3 live births per 1,000.¹ Early diagnosis of and intervention for hearing loss is critical since early intervention is linked to improved communication outcomes and school performance.²⁻⁷ There are two types of hearing loss, conductive and sensorineural. Conductive hearing loss is caused by problems in the middle or outer ear.^{8,9} As an example, conductive hearing loss can be caused by a buildup of fluid within the middle ear, which is common in neonates. Conductive hearing loss can be reversible and may even resolve without treatment.⁹ Alternatively, sensorineural hearing loss is caused by damage to the nerve endings that detect sound in the ear and is typically permanent.^{8,9} Either type of hearing loss can occur in one or both ears and may be congenital, syndromic, or nonsyndromic.⁹ Infants and children may also be affected by a mix of both conductive and sensorineural hearing loss.⁹ Hearing loss can also be progressive or have delayed onset.⁸

Infants admitted to the NICU are at greater risk of hearing loss than infants in the newborn nursery.¹⁰ Family history, as well as very low birth weight and exposure to certain therapies such as assisted ventilation, are risk factors associated with hearing loss.¹⁰ The US Preventive Services Task Force (USPSTF), the Joint Committee on Hearing (JCIH), and the Secretary's Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (SDACHDNC) have all recommended universal

newborn hearing screening,^{1, 10, 11} due to the associated risks, the availability of screening technology, and efficacy of treatment options.¹

Texas mandated universal newborn hearing screening in 1999¹² and HB 411 modified the newborn hearing screening program from an opt-in to an opt-out program in 2011.¹³ HB 411 also outlined the process for follow-up of infants with a positive screen in 2011.¹³

In 2011, the Texas Early Hearing Detection and Intervention (TEHDI) program reported that 58.2% of newborns, infants, and children that needed follow-up care after newborn screening received such care.¹⁴ This leaves 40.8% of children that were lost to follow-up due to: 1) truly not receiving any follow-up services, or 2) receiving services that were not reported to the TEHDI program.

This study evaluates hospital-based implementation of newborn hearing screening before and after the passage of HB 411. This study is a longitudinal, retrospective database analysis of health and development of infants admitted to the NICU after birth, a special population of children with unique needs and utilization patterns. Analyses are performed using a highly comprehensive database of birth admissions over the period 1988-2009, from a large single health care system in Texas, serving an ethnically and racially diverse rural and exurban population. This database contains key data from admission to discharge as well as linked diagnosis data from follow-up encounters through 2013. This database of over 50,000 infants, including more than 9,000 NICU admissions. Seventy-eight percent of infants admitted to this

NICU have associated follow-up encounters within the same health system available for analysis.

The primary outcomes of interest in the study are overall screening rates, loss to follow-up rates, screen sensitivity (and related false-negative rate), screen specificity (and related false-positive rate), and time-to-diagnosis for infants with hearing loss, adjusted for infant characteristics and clinical factors postulated as predictors of the outcomes. The specific aims and related hypotheses for the study include:

Specific Aim 1: Describe existing database systems established to monitor and evaluate treatment of and outcomes in premature and low birth weight infants.

Research questions: What current large-scale databases exist to allow research and quality improvement in treatment of premature and low birth weight infants? How do these compare with a single center database?

Specific Aim 2: Assess temporal trends in screening rates, loss to follow-up, and test sensitivity and specificity after implementation of newborn hearing screening, and evaluate the likelihood of newborn screening, loss to follow-up, a false-positive result, a false-negative result, and hearing loss adjusting for infant characteristics and clinical factors.

Hypothesis 1: Changes in policy and clinical practice improve newborn screening rates, loss to follow-up, and test sensitivity and specificity.

Hypothesis 2: The likelihood of receiving a newborn hearing screen, being lost to follow-up, receiving a false-positive screen result or false-negative screening results, and

receiving a diagnosis of hearing loss vary based on infant characteristics and clinical factors.

Specific Aim 3: Evaluate time-to-diagnosis for infants that receive a positive screen result prior to hospital discharge, and identify correlates of earlier diagnosis.

Hypothesis: Time-to-diagnosis is earlier in infants that receive a positive newborn screen, but still varies by group (e.g. race/ethnicity).

In Chapter II below, I summarize the existing literature related to infant and childhood hearing loss, universal newborn hearing screening recommendations and the program in Texas as well as the health system in which this study occurred, and the history of and challenges in studying outcomes for infants at high-risk of hearing loss and other developmental outcomes. Chapter III describes the methodology utilized to test the hypotheses described above. Chapters IV and V include the study results and a discussion of the findings and related implications for policy and practice.

CHAPTER II

LITERATURE REVIEW

This chapter summarizes the existing literature and research on hearing loss in infants and children. It also describes early detection of hearing loss and the efforts of state newborn hearing programs, recommendations for early intervention and hearing loss diagnosis, and known challenges in the long-term study of infants at greater risk of hearing loss.

Risk Factors Associated with Hearing Loss

Risk for congenital, delayed onset, or progressive hearing loss in childhood may be increased by any of the following:¹⁰ (a) family history, (b) NICU admission greater than five days or any of the following treatments within the NICU, regardless of length of stay – ECMO, assisted ventilation, exposure to ototoxic medications or loop diuretics, and hyperbilirubinemia, (c) in utero infection, (d) craniofacial anomalies, (e) physical findings associated with syndromes known to include hearing loss, (f) presence of certain syndromes associated with hearing loss, (g) neurodegenerative disorders, (h) post-natal infections such as bacterial meningitis, (i) head trauma, and (j) chemotherapy. The relative risk of each of these factors varies by study, however. Several recent studies have focused on examining the incidence of these risk factors in children with hearing loss¹⁵⁻¹⁹. Among these studies there is an inconsistency in results, suggesting that further study is necessary to fully understanding the contribution of certain risk factors to hearing loss in the first several years of life.

Infant and Maternal Characteristics Affecting Hearing Loss

Other infant and maternal characteristics may also influence an infant's risk of hearing loss. Family history is a known risk factor for hearing loss.¹⁰ Up to half of all hearing loss is attributable to genetic factors causing syndromes associated with hearing loss or increasing susceptibility to environmental factors that may cause hearing loss.²⁰ Studies suggest that the prevalence of hearing loss in children under the age of 20 may be higher in Hispanic infants and those in lower income households, but studies measuring these differences vary in design and study population.²¹ Naarden and Decoufle found that low birth weight infants, specifically those born at less than 2,500 grams had a higher prevalence of bilateral sensorineural hearing loss, and that rates of hearing impairment were consistently higher among low birth weight black children compared to low birth weight white children.²² Finally, NICU infants may be particularly susceptible to delayed-onset hearing loss.²³

NICU Interventions Affecting Hearing Loss

There are many advances in neonatology that have improved outcomes for infants born premature and/or at low birthweight. These infants have complex medical conditions and comorbidities associated with prematurity, respiratory distress for example, that significantly increase risk for mortality and morbidity. Technological interventions used to treat these infants in the NICU, such as assisted ventilation and extracorporeal membrane oxygenation (ECMO) therapy, have led to decreased mortality among low birth weight infants, but significant morbidities including hearing loss persist. In fact, an increased incidence of hearing loss among infants admitted to the

NICU has been observed.²⁴ The following sections summarize both assisted ventilation and ECMO therapy in an effort to demonstrate the effectiveness of new NICU interventions and their potential to increase the likelihood of hearing loss in infants admitted to the NICU. These examples were chosen since they are used to treat respiratory distress, which affects up to 7% of newborns and has a high incidence in preterm infants.²⁵ This current study focuses on implementation and outcomes of newborn hearing screening within a population of NICU infants and, therefore, a brief discussion of two associated risk factors is relevant.

The potential causes of respiratory distress include underdevelopment of the lungs, surfactant deficiency, transient tachypnea, infections, meconium aspirations syndrome, respiratory distress syndrome (hyaline membrane disease), and birth asphyxia.^{25, 26} Among preterm infants, respiratory distress syndrome accounts for up to 30% of respiratory distress and may represent the greatest risk for mortality.²⁵ Treatment of respiratory distress varies depending on severity. Antenatal corticosteroids, surfactant administration, oxygenation, and, in severe cases, mechanical ventilation or ECMO are potential treatments.²⁶ Both assisted ventilation and ECMO are treatments primarily utilized in the NICU, and each is a known risk factor for hearing loss. Each of these neonatal treatment advances and their importance to studies of newborn hearing loss are described below.

Assisted Ventilation

Despite significant improvements in morbidity and mortality after the introduction of surfactant and increased use of antenatal steroids, the need for respiratory

support remains high among preterm infants.^{27, 28} Assisted ventilation allows for the provision of respiratory support to infants who are unable to breathe well on their own. Assisted mechanical ventilation was first introduced in the 1960s and now includes a variety of mechanisms for ventilation, some more invasive (e.g. requiring intubation) than others.²⁸ Mechanical ventilation does have risks, including lung injury, pneumonia, chronic lung disease (including bronchopulmonary dysplasia), and mortality.^{29, 30}

Limited population-based epidemiologic data exists on ventilation strategies and outcomes. However, the NICHD Neonatal Research Network has collected data on premature and low birth weight infants for over two decades and has been used for epidemiologic study. Among very low birth weight infants, the length of ventilation using intubation techniques has decreased over time as has the percent of infants with respiratory distress syndrome, although respiratory distress syndrome remains particularly high among extremely low birth weight infants (500-1000g).³¹ Over the same time, mortality before discharge has decreased (although this study does not link decreased mortality to respiratory treatment improvements specifically) but morbidities such as bronchopulmonary dysplasia have not changed.³¹

Several studies have found possible associations between assisted ventilation and hearing loss in patients with congenital diaphragmatic hernia, although the incidence of hearing loss varied significantly by study.³²⁻³⁴ In a Dutch study of risk factors for hearing loss in NICU graduates born at less than 30 weeks gestational age or with a birthweight less than 1000g, the authors found a significant association between assisted ventilation

of at least five days and hearing loss.³⁵ Similarly, a study from China found that NICU admission along with assisted ventilation was a risk factor for hearing loss.³⁶

Extracorporeal Membrane Oxygenation

In extreme cases of neonatal respiratory distress, ECMO may be used as a mechanism for external life support. ECMO was first used successfully in 1976.³⁷ ECMO is used to bypass the heart and lung while maintaining respiratory function and blood oxygenation.³⁸ Clinical indications for ECMO include congenital diaphragmatic hernia, heart malformations, meconium aspiration syndrome, severe pneumonia, severe air leak syndrome, and severe pulmonary hypertension.^{37, 38} ECMO is not indicated for very preterm or low birthweight infants. In most cases, infants with gestational age less than 34 weeks or birth weight less than 2000g are not candidates for ECMO, due to increased risk for and incidence of intracranial hemorrhage.³⁷

ECMO use has declined since 1990, especially among patients with respiratory distress syndrome and sepsis or pneumonia.³⁷ Infants eligible for ECMO treatment are already at extreme risk for death given their underlying medical conditions, but additional risks associated with ECMO treatment include bleeding, due to the use of heparin, blood clot formation, intracranial hemorrhage, infection, and transfusion problems.³⁸ In the long-term, infants treated with ECMO may experience neurodevelopmental disorders such as cerebral palsy.³⁹ Despite these risks, approximately 77% of ECMO patients survive although this varies by condition for which ECMO was indicated.³⁷ A 2008 systematic review of ECMO trials found that use of ECMO provides strong benefit for infants in terms of mortality and decreased

likelihood of severe morbidity.⁴⁰ A cost-effectiveness study using data from the United Kingdom Collaborative ECMO Trial found that ECMO is cost-effective compared to conventional management.⁴¹

Associations between ECMO, and prolonged ECMO treatment, and hearing loss also appear to be positive.⁴²⁻⁴⁴ Infants undergoing ECMO therapy demonstrate a greater risk of hearing loss, possibly associated with low levels of carbon dioxide in the blood prior to ECMO.³⁹ There is some evidence that ECMO therapy, especially, can result in delayed onset of hearing loss.⁴²⁻⁴⁴ For example, one study found that approximately half of infants identified with sensorineural hearing loss after ECMO therapy has previously passed a hearing test.⁴² Due to the potential for delayed onset, the JCIH has recommended additional audiologist assessment for infant with these risk factors, ideally between 24 and 30 months of age.¹⁰

Both neonatal technologies (assisted ventilation and ECMO) have an impact on early screening and, potentially, long-term outcomes related to hearing. Both technologies are used to save infant lives, thus leading to more infants living for a longer period of time. However, assisted ventilation and ECMO may also induce unfavorable long-term outcomes such as hearing loss. It is not clear whether or not treatment for respiratory distress or the underlying cause of respiratory distress (e.g. poor lung function which limits oxygen intake) actually lead to increased risk for hearing loss. Nonetheless, assisted ventilation and ECMO appear to be good indicators of risk for hearing loss, and there is enough evidence to warrant recommendations for universal

screening with targeted follow-up assessments for infants undergoing either treatment in the NICU.^{1, 10}

Universal Screening Programs

Early identification of and treatment for hearing loss is important for preventing and improving long-term problems with speech, language, and/or communication.²⁻⁷ Treatments include interventions such as hearing aid placement and cochlear implants to provide amplification, as well as speech therapy. Early intervention using these treatments, or others as indicated, may also improve school performance.^{7, 45}

In response to the growing body of evidence demonstrating the importance of early intervention, newborn screening for hearing loss has become prevalent across the United States and internationally. The US Preventive Services Task Force (USPSTF), the Joint Committee on Infant Hearing (JCIH), and the Secretary's Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (SDACHDNC) have all recommended universal newborn hearing screening.^{1, 10, 11, 46} Most states, including Texas, have mandated universal newborn hearing screening or, if the state does not mandate screening, report high rates of screening for infants.

Newborn screening involves both biochemical screening tests using a small amount of blood taken from a newborn after birth and tested by the state, and point-of-care tests where technology is used at the bedside to screen for disorders such as hearing loss or critical congenital heart defects. In point-of-care screening, a technician, nurse, or other professional performs and interprets the screening result. There are two types of technologies typically used in universal newborn hearing screening programs,

otoacoustic emission testing (OAE) and auditory brainstem response testing (ABR). OAE testing relies on obtaining responses from the cochlea when sound is presented, while ABR is used to detect electrographic activity of sound as it moves along the auditory brainstem.⁹

In newborn screening, legal mandates, clinical practice guidelines, and screening technologies influence program administration, including documentation of follow-up, and clinical practice. The following paragraphs summarize laws, clinical practice guidelines, and changing screening technologies that have or may influence early detection of hearing loss.

Texas mandated universal screening in 1999 through House Bill 714, but the program did not require participation for hospitals with less than 1,000 births per year and required parents to opt-in to the screening with written consent.¹² The bill required full implementation by April 1, 2001, required informed consent from the parents, and outlined no specific protocols for screening infants admitted to the NICU. The bill also required birthing facilities that performed newborn hearing screening to report the screening results to parents, the newborn's physician, and the state health department.

In 2011, the Texas Legislature amended Chapter 47 of the Health and Safety Code with House Bill 411 to change the program to no longer require informed consent, thus mandating hearing screening unless the parents choose not to participate. Additionally, HB 411 specifically outlined the follow-up protocols and the responsibilities of both the state and birthing facilities.¹³ The time frame of this study

does not allow for measuring outcomes after implementation of HB 411; however, its relevance to the study is important in terms of continued investigation.

The Joint Committee on Infant Hearing (JCIH), through its periodic statements, has recommended specific time frames within which infants should be screened, receive confirmatory testing, and receive intervention services.¹⁰ In addition, the JCIH has recommended separate screening protocols for infants admitted to the NICU versus infants admitted to the well-baby nursery.¹⁰ These practice guidelines are often disseminated through the peer-reviewed literature or professional meetings and may influence clinical practice before and after legal mandates require such practice. For example, the first JCIH statement on infant hearing screening was issued in 1995 through the journal *Pediatrics*.⁴⁷ The health system included in this study began newborn hearing screening, albeit not universally, in 1996, three years prior to HB 714 passing in Texas.

Birthing centers also make relevant organizational decisions or policies that influence screening outcomes. The health system in which this study was performed made decisions regarding staff training and use of specific screening protocols. We know from physicians working within the health system at the time that somewhere around the year 2001, the organization recognized a pattern of high false-positive rates. As a result, they implemented a staff training program to improve not only the screening protocol used but also interpretation of results.

Similarly, screening program outcomes may be impacted by the screening technology used to perform the hearing screen. In 2007, the JCIH recommended that

NICU infants be screened using ABR since their risk for hearing loss is greater than for non-NICU infants and the ABR testing methodology may be more sensitive to detecting the types of hearing loss for which NICU infants are at greatest risk.¹⁰ In the health system where this study took place, we know that the change to ABR screening in the NICU occurred prior to 2007, but the exact date is unknown.

This study will look specifically at the timing of these policy mandates and organizational changes to identify whether or not they influenced screening program outcomes including screening rates, false-positive rates, and false-negative rates. Unfortunately measurement of the program effects of changing screening technology is not possible since the available records do not differentiate between screening technologies. However, this contextual information may help to explain results. In addition, the study looks at infant characteristics impacting the likelihood that an infant receives hearing screening, receives a false-positive result, or receives a false-negative result. Evaluation of screening program outcomes is important for quality improvement at the organizational-level and for informing future organizational and policy changes that impact hospital-based screening efforts. Success of screening programs, however, should not be measured solely at the point of intervention but should look at outcomes of the program after the infant leaves the hospital, where they presumably receive follow-up services to confirm a diagnosis of hearing loss and to treat the hearing loss if confirmed.

Follow-up after a Positive Hearing Screen

Beyond screening for hearing loss, state programs are tasked with providing or ensuring follow-up for infants that fail the hearing screen. These follow-up services include confirmatory testing and enrollment in early intervention programs. Historically, newborn hearing screening programs have a high number of infants “lost to follow-up,” ranging from approximately 35-45 percent from 2009 to 2012.⁴⁸ Other reports indicated that the rate of loss to follow-up may be as high as 50% of all infants with a positive hearing screen, but this includes both infants that do not receive follow-up services and those that are lost to documentation, meaning that the receipt of follow-up services is not documented and therefore the status of those infants is unknown.⁴⁹ In 2011, the Texas Early Hearing Detection and Intervention (TEHDI) program reported that 58.2% of newborns, infants, and children that needed follow-up care after newborn screening in Texas received such care.¹⁴ This results in 40.8% of children that were lost to follow-up. Lower rates of loss to follow-up lead to an increasing number of infants with hearing loss being identified⁵⁰ and, presumably, receiving intervention services earlier.

A 2008 technical report issued by the American Speech-Language-Hearing Association described a systematic review of existing literature on factors associated with loss to follow-up. The working group that prepared the report cited three potential areas in which issues can arise that impact loss to follow-up, including systems issues such as communication between providers, family issues such as socioeconomic status, and quality assurance issues such as electronic systems for reporting follow-up status.⁵¹

Most relevant to this study are the individual-level factors that may influence receipt of follow-up services.

Several studies have examined the demographic and socioeconomic factors affecting whether infants receive follow-up services. Texas does not, at least publicly, report on loss to follow-up or enrollment in early intervention services by demographic or socioeconomic characteristics. However, a 2002 study from the Houston area compared newborn hearing screening and follow-up services at two centers, one serving a primarily indigent population and the other serving primarily private pay and Medicaid patients. The study found that infants born at the center serving mostly indigent patients were more likely to be lost to follow-up and less likely to be fitted for a hearing aid when one was indicated.⁵²

The Centers for Disease Control and Prevention (CDC) produces an annual report on state newborn hearing screening and early intervention programs. Using their 2011 survey, demographic data indicate that the percentage of infants evaluated after a failed newborn hearing screen increased with increasing maternal age and increasing maternal education.⁵³ The percentage of infants evaluated after a failed newborn hearing screen varied by race/ethnicity, with infants of mothers of American Indian or Alaska Native and White Hispanic race/ethnicity having the lowest percentage.⁵³ The percentage of infants enrolled in early intervention services increased with increasing maternal age and increasing maternal education, but that it also varied slightly by race and ethnicity.⁵⁴

A study of the Massachusetts newborn hearing screening follow-up program, which is statewide and multi-center, found that infants were more likely to be lost to follow-up if their mothers were non-white, received public insurance, smoked during pregnancy, or lived outside of the urban center (Boston).⁵⁵ Even though this study found that living outside of the urban center was a risk factor for being lost to follow-up, they found that living in or near the urban center actually decreased the odds of receiving early intervention services.⁵⁵ Other studies have found that socioeconomic factors, such as public insurance, decrease the likelihood of follow-up,⁵⁶⁻⁵⁸ as well as infant race, infant birth weight, infant gender, and ventilator status.⁵¹

The potential for delayed onset hearing loss means that some infants may not screen positive for hearing loss during the newborn period, thus increasing the likelihood of a false-negative at the first newborn screen. To be fair, this probably should not be counted as a false-negative since, presumably, the disease may not have developed prior to screening. Rather, this demonstrates the importance of targeted follow-up for infants with known risk factors. Although targeted follow-up is recommended by JCIH, the high lost to follow-up rates in state newborn screening program create a challenge for following infants through diagnosis and intervention.

Future research on the etiology of newborn and childhood hearing loss is essential to improving screening, whether population-based or targeted, and long-term outcomes. Screening programs are currently focused on the newborn period and the potential for delayed onset may indicate a need to expand the scope of state newborn screening programs. Neonatal interventions such as ECMO are designed to decrease

mortality but may also be increasing morbidity, indicating a need for continued investigation into the pathophysiology by which clinical treatment causes hearing loss. This information may help researchers and providers identify clinical treatment modifications that reduce risk for hearing loss, and may assist screening programs in identifying appropriate time points for screening evaluations.

Recommended Protocol for Newborn Hearing Screening and Follow-up

The JCIH and the Centers for Disease Control and Prevention recommend a specific protocol for newborn hearing screening, and use this protocol to set national benchmarks for both quality improvement and Healthy People 2020. The protocol, titled “1-3-6,” is as follows:^{10, 59}

1. Infants will receive newborn hearing screening before 1 month of life.
2. Infants that fail the newborn hearing screen will receive audiologic evaluation by 3 months of age.
3. Infants that have confirmed hearing loss should be fit for amplification (if desired by the family) within 1 month of diagnosis.
4. Infants with confirmed hearing loss should be enrolled in early intervention services by 6 months of age.

States, including Texas, manage early intervention programs to assist families in enrolling infants into services that help with the child’s speech, language, and social skills. This also includes connecting parents with other families affected by hearing loss. Additionally, the JCIH recommends that infants with risk factors associated with hearing loss, e.g. NICU admission, be monitored for hearing loss by their primary care

physician.¹⁰ NICU follow-up clinics, where available, may also perform these hearing assessments.

There are group differences in receipt of follow-up services. Previous studies have examined time-to-treatment performance within systems. Sininger, et. al. found that infants that received newborn hearing screening received diagnosis of hearing loss, were fitted for a hearing aid, and were enrolled in early intervention earlier than infants not receiving a newborn hearing screen.⁶⁰ Spivak, Sokol, Auerback, & Gershkovich looked at referral for evaluation and fitting of hearing aids and found that less than one half of all infants were fit for a hearing aid on time (by 6 months of age).⁵⁶ They also found associations between unilateral hearing loss and late diagnosis and late hearing aid fitting as well as loss to follow-up; and conductive hearing loss and Medicaid coverage and an infant being lost to follow-up.⁵⁶ Knowledge of these differential effects of infant factors can inform future efforts to improve services delivery after newborn screening.

Studying At-Risk Populations

Infants admitted to the NICU and specifically infants with LBW are at increased risk for hearing loss and other short- and long-term morbidities. Studying of the impacts of prematurity and LBW is challenging due to the relatively small number of infants born with prematurity and/or LBW, and the difficulty in following those infants long-term.

Each year, prematurity and LBW impact a small but significant proportion of all live births in the United States. In the United States and internationally, improving outcomes for these infants remains a high priority. Healthy People 2020 includes

objectives to reduce LBW and premature births.⁶¹ These objectives include targets to reduce overall preterm births from 12.7% to 11.4% as well as specific objectives to reduce both very preterm and late preterm births by ten percent, and to reduce the number of LBW (8.2 to 7.8%), and very LBW (VLBW) infants (1.5 to 1.4%).⁶¹

In the United States, overall infant mortality has declined from 100 per 1,000 live births in 1900 to 6.05 per 1,000 births in 2011⁶² while remaining one of the highest infant mortality rates among industrialized countries.⁶³ The development of medical and technological interventions has improved the survivability of premature and LBW infants. From 2000 to 2010 the infant mortality rate among preterm infants decreased from 37.88 deaths under age 1 per 1,000 live births to 34.22 per 1,000 live births, a decrease of almost 10 percent.⁶⁴ For infants born under 32 weeks, the mortality rate decreased almost eight percent from 2000 to 2010, from 180.95 per 1,000 live births to 165.57 per 1,000 live births.⁶⁴ While overall infant mortality rates have decreased, they are still comparatively high and short- and long-term morbidities associated with prematurity and LBW have persisted.^{64, 65} There are a number of potential morbidities that affect nearly every organ system and include conditions such as poor neurodevelopmental outcomes, retinopathy of prematurity, severe intraventricular hemorrhage, hearing loss, bronchopulmonary dysplasia, respiratory distress syndrome, patent ductus arteriosus, necrotizing enterocolitis, and sepsis are associated with LBW and prematurity. These outcomes may be complicated by interventions to improve mortality such as ventilation⁶⁵⁻⁷³, transfusions and catheters - common interventions provided during a typical neonatal intensive care unit (NICU) hospitalization.

Monitoring both short- and long-term outcomes of infants affected by preterm birth, LBW and VLBW is critical to advancing scientific and medical knowledge with respect to the development of more effective treatment guidelines, to improve quality of these treatments over time, and to minimize short- and long-term morbidities. Effective research can also inform integrated health care practices where surviving infants are treated through childhood and even into adulthood. However, studying infants affected by prematurity or LBW can be challenging due to small, single-center sample sizes, unknown quality of some administrative data, or limited availability of long-term follow-up data.

To address these challenges, a number of large-scale databases were developed to allow structured study of premature and LBW infants, including but not limited to those admitted to the NICU. In 1997, Wright and Papile summarized existing neonatal databases and their uses.⁷⁴ Their review provided detailed descriptions of four neonatal databases: the Kaiser Permanente Neonatal Minimum Data Set (KPNMDS), the Vermont Oxford Network (VON), the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NICHD NRN), and the National Perinatal Information Center (NPIC). Since 1997, there have been tremendous advances in neonatal care that have contributed to declines in infant mortality associated with prematurity or LBW, including the use of high-frequency ventilation and cooling caps. These clinical improvements are accompanied by an increasing number of studies aimed at evaluating neonatal intervention, understanding

the progression of disease, and investigating outcomes of those infants affected by prematurity or LBW.

Existing Databases

Of the four originally described by White and Papile, we are reviewing research progress using three, KPNMDS, NICHD NRN, and VON. The National Perinatal Information Center was not included in our review as their focus is on the perinatal period and not premature or LBW infants. The three databases have varying program goals, funding sources, strategies for data collection, and length of follow-up, but all focus on improving medical knowledge about and the quality of care provided to premature, LBW, and NICU admitted infants.

The Kaiser Permanente Neonatal Minimum Data Set (KPNMDS) originated in 1992 and is internally funded through the Kaiser Permanente (KP) system.⁷⁵ The KPNMDS was developed to obtain reliable data about the NICU admission, and to support research and quality improvement efforts. The database includes both inborn and outborn admissions to at least six KP NICUs in Northern California, although the total number of NICUs participating in KPNMDS has increased since Wright and Papile described the database in 1997. The KPNMDS includes data on the full NICU admission, and some prospective studies using KPNMDS data extend follow-up for months or years after discharge from the NICU. The primary criterion for inclusion in the database is NICU admission, not a specific birth weight or gestational age. KPNMDS supports both retrospective and prospective studies.

The Vermont Oxford Network (VON) originated in 1989 and seeks to “improve the quality and safety of medical care for newborn infants and their families through a coordinated program of research, education, and quality improvement projects.”⁷⁶ VON maintains two international databases, the Very Low Birth Weight Database and the Expanded Database, with a total of over two million infant cases.⁷⁶ The Very Low Birth Weight Database includes inborn and outborn (if admitted within 28 days of birth) infants with birth weights below 1500 grams or gestational ages between 22 weeks 0 days and 29 weeks 6 days.⁷⁷ The Expanded Database includes all infants from the Very Low Birth Weight Database as well as infants born at more than 1500 grams and admitted to a NICU at a participating center, or “who die at any location in the center within 28 days of birth without first having gone home.”⁷⁷ In 2012, VON reported 369 centers reporting data on 153,093 infants into the Expanded Database, and 909 centers reporting data on 60,007 infants into the VLBW Database.⁷⁷ VON members pay an annual membership fee and are eligible to use the data for studies, given strict adherence to data use guidelines set forth by VON leadership.⁷⁸ In general, VON includes infant data through discharge, death, or one year of age although some prospective studies using VON have longer follow-up periods. VON supports both retrospective and prospective studies. NICUs may apply to participate in VON using a membership application and must pay a membership fee.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) began in 1986 and includes a registry to house data from multiple clinical trials funded through NICHD. NICHD

supports the NRN financially. Originally, the NRN registry included data for inborn and outborn infants having a birth weight between 401 and 1500 grams.⁷⁴ Since 2008, the database has included only inborn infants with a gestational age between 22 0/7 to 28 6/7 weeks and/or a birth weight between 401 grams to 1000 grams.⁷⁹ It also includes follow-up data at 18-26 months, depending on the year of study and if the participating study site(s) assessed outcomes at such age as part of their research protocol.^{74, 79} As of August 1, 2014, the NRN website listed 20 participating sites.⁸⁰ NICHD NRN supports both retrospective and prospective studies, specifically clinical intervention and epidemiologic studies funded through NICHD. Participation in the NICHD NRN requires funding through NICHD, which is typically provided through a competitive grant process.

All three databases use standardized forms and definitions for data submission by participating sites. In general, data use is open to participating sites contributing data to the database as long as database-specific requirements are met.

These databases have continued to expand and become more widely used since they were first reviewed in 1997. In the systematic review described under Specific Aim 1, I seek to provide a summary of how the databases are being used to advance scientific and clinical knowledge about the epidemiology of prematurity and LBW and the clinical treatment of those infants, in an effort to characterize the probability of using one of these databases to study screening for and diagnosis of newborn hearing loss. A further purpose is to offer clinical and health services researchers insight into how research on

preterm and LBW infants has evolved, and to offer strengths and opportunities for continued research using these and other databases.

CHAPTER III

METHODS

This study focuses on three specific aims, as outlined in Chapter 1. The description of methodology employed for each is described below.

Specific Aim 1

Specific Aim 1: Describe existing database systems established to monitor and evaluate treatment of and outcomes in premature and low birth weight infants.

Research questions: What current large-scale databases exist to allow research and quality improvement in treatment of premature and low birth weight infants? How do these compare with a single center database?

Specific Aim 1 is motivated by the need to understand how existing, multi-center databases have been used to study the epidemiology of and outcomes for infants affected by LBW and prematurity. To achieve this, we employed a systematic review process to identify and characterize studies that have utilized data from one of three databases. The three databases of interest in the review are the Kaiser Permanente Neonatal Minimum Data Set (KPNMDS), the Vermont Oxford Network (VON), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NICHD NRN).

We conducted a literature search using PubMed and Google Scholar of studies published over the time period January 1990 to August 15, 2014. Search terms included official names for each of the databases and their abbreviations, if applicable. For

example, the Kaiser Permanente Neonatal Minimum Data Set was searched for using the full name as well as “KP Neonatal Minimum Data Set” and “Kaiser Permanente Neonatal MDS.” None of the databases were searched for simultaneously, although several studies were returned during separate database searches.

Article titles and abstracts were reviewed for inclusion in our study. Initial inclusion criteria only required that the article include the name of one of the three databases and there was some evidence from the abstract that the study used or participated in the database network. Initial results were compared with publication lists maintained by the database managers. Both VON and NICHD NRN maintained such lists, which were last reviewed on August 15, 2014. In both cases, additional studies were added into our review.

After title and abstract review, all articles were read to determine if the study used the database of interest as a data source for measuring the research question. The database could be used as a primary source of data or as a source of comparison or benchmark data. If either condition was true, the article was included in our study. Exclusion criteria included the following: descriptive articles summarizing database use or methodology, articles using similar but tangential databases such as the VON Encephalopathy Registry or Moderately Premature Infant Project database, articles referencing only definitions or tools (e.g. SNAP-II and SNAPPE-II) derived from or used within one of the databases, studies evaluating instrumentation or measurement technology, studies evaluating quality improvement processes implemented at study

sites participating in one of the database networks, review articles or meta-analyses, and non-English articles.

Studies were categorized as having either a retrospective or prospective study design. Retrospective studies were further sorted into categories based on use of the database as a primary data source or using it or its published findings as a comparison or benchmark for another study. A primary and secondary clinical focus area was also assigned to each individual study, in an effort to determine trends in research. To capture the overall clinical or outcome focus of the study, clinical focus area categories were applied first by the primary investigator, then reviewed by three other investigators for consistency.

The outcomes from Specific Aim 1 were reviewed when identifying and assessing the data source for the analyses in Specific Aims 2 and 3. The data elements of each database, as well as their stated length of follow-up on infants, were also considered. These factors were used to justify use of the single-center, longitudinal database used to analyze the hypotheses under Specific Aims 2 and 3.

Specific Aim 2

Specific Aim 2: Assess temporal trends in screening rates, loss to follow-up, and test sensitivity and specificity after implementation of newborn hearing screening, and evaluate the likelihood of newborn screening, loss to follow-up, a false-positive result, a false-negative result, and hearing loss adjusting for infant characteristics and clinical factors.

Hypothesis 1: Changes in policy and clinical practice improve newborn screening rates, loss to follow-up, and test sensitivity and specificity.

Hypothesis 2: The likelihood of receiving a newborn hearing screen, being lost to follow-up, receiving a false-positive screen result or false-negative screening results, and receiving a diagnosis of hearing loss vary based on infant characteristics and clinical factors.

The study under Specific Aim 2 utilizes a retrospective database of NICU and newborn nursery admissions over the period 1989 to 2009, from a large single health care center in Texas. This database contains key data from admission to discharge, including the date of the newborn hearing screen and the bilateral hearing screen results. For infants with at least one NICU admission, records are linked to the inpatient and ambulatory electronic medical record (EMR) in the same health system, allowing for detailed follow-up information regarding diagnoses received and morbidities these infants face as they mature through childhood. This database houses information on 51,244 infants, including 9,219 infants with at least one NICU admission. Seventy-eight percent (78%) of all infants with a NICU admission have associated post-discharge follow-up encounters available for analysis. There is a mean of ten years of follow-up data on each infant for which follow-up is available. All patient and treatment factors as well as diagnoses were abstracted from this database.

This study included inborn and outborn births between 1996 and 2007. Infants born prior to 1996 were excluded from analysis since newborn hearing screening did not begin in the center until 1996. Infants born after 2007 were excluded because the data

were incomplete for years following 2007. Further exclusion criteria were applied for each outcome of interest. To assess loss to follow-up, infants who were never admitted to the NICU, died prior to discharge, or received no hearing screen were excluded from analyses. Infants with no follow-up were further excluded from analyses of test sensitivity and specificity. Table 1 includes the exclusion criteria and sample sizes for each measure described below.

Table 1. Model Exclusion Criteria and Sample Sizes

Model	Exclusion Criteria	Final Sample Size
Screening Rates Logistic Model for Receipt of Newborn Hearing Screen	Births prior to 1996 and after 2007 (n=21,498) Remaining individuals with incomplete data	28,335
Loss to follow-up Rates Logistic Model for Being Lost to Follow-up	Births prior to 1996 and after 2007 (n=21,498) Non-NICU admissions (n=23,482) Deaths prior to discharge (n=73) Remaining individuals with incomplete data (n=667)	5,102
Sensitivity Rates Specificity Rates False-Negative Rates False-Positive Rates Logistic Model for Receipt of False-Negative Screen Result Logistic Model for Receipt of False-Positive Screen Result	Births prior to 1996 and after 2007 (n=21,498) Non-NICU admissions (n=23,482) Deaths prior to discharge (n=73) Infants with no follow-up (n=689) Remaining individuals with incomplete data (n=767)	5,002
Logistic Model for Receipt of Hearing Loss Diagnosis Cox Proportional Hazards Regression Model	Births prior to 1996 and after 2007 (n=21,498) Non-NICU admissions (n=23,482) Deaths prior to discharge (n=73) Infants with no follow-up (n=689) Remaining individuals with incomplete data (n=647)	4,855

Outcome Measures

Specific Aim 2 explores temporal trends in four outcomes of interest to newborn hearing screening programs: screening rates, loss to follow-up, test sensitivity, and test specificity. The formulas used to calculate each of the outcomes are described below.

$$\text{Annual newborn hearing screening rate} = \frac{\text{\# of infants receiving hearing screen in year}_i}{\text{\# of infants eligible for screening in year}_i}$$

Screening completion, or receipt of a hearing screen, was measured by identifying whether or not an infant has a screening result recorded during their birth admission. If a result is present, screening completion was coded as “yes.” The number of eligible infants was defined as the total number of infants admitted to either the NICU or newborn nursery.

$$\text{Annual loss to follow-up} = \frac{\text{\# of infants receiving follow-up services after a positive screen}}{\text{\# of infants with a positive screen in year}_i}$$

Receipt of follow-up services was defined as an infant having ever received follow-up within the health care system in which they were born. The screening result will be measured by analyzing the exiting hearing screen result from the infant’s record. In the database, screening result is coded as PP (pass in both ears), FP or PF (pass in one ear and fail in one ear), or FF (fail in both ears). These results were recoded into pass (PP) or fail (FP, PF, or FF).

Sensitivity and specificity are typical measures of test or screening effectiveness. Sensitivity reflects the ability of a test to accurately identify individuals with the disease, and specificity indicates the ability of a test to accurately identify individuals without the

disease. These are closely linked to false-positive and false-negative rates. These outcomes were calculated using the following formulas:

$$\text{Annual test sensitivity} = \frac{\# \text{ of infants with hearing loss who had a positive screen in year}_i}{\text{total \# of infants screened in year}_i \text{ and identified with hearing loss}}$$

$$\text{False-negative rate} = 1 - \text{sensitivity}$$

$$\text{Annual test specificity} = \frac{\# \text{ of infants without hearing loss who had a negative screen in year}_i}{\text{total \# of infants screened in year}_i \text{ without hearing loss}}$$

$$\text{False-positive rate} = 1 - \text{specificity}$$

Confirmed hearing loss is defined as having a prevalent diagnosis as identified using ICD-9CM codes from the follow-up record. A total of 10 ICD-9CM codes were identified as primary codes for hearing loss.⁸¹ These ten ICD-9CM codes are listed Table 2. Given the sample sizes in this study, hearing loss was coded as a binary variable if an individual was given any of these hearing loss diagnoses. Separate analyses were not performed for different types of hearing loss.

Table 2. ICD-9CM Codes used to Identify Hearing Loss

389.00	Conductive hearing loss, unspecified
389.10	Sensorineural hearing loss, unspecified
389.11	Sensorineural hearing loss, bilateral
389.12	Neural hearing loss, bilateral
389.14	Central hearing loss, bilateral
389.15	Sensorineural hearing loss, unilateral
389.16	Sensorineural hearing loss, asymmetrical
389.18	Sensorineural hearing loss of combined types, bilateral
389.2	Mixed conductive and sensorineural hearing loss
389.9	Unspecified hearing loss

Specific Aim 2 also includes analyses to assess the likelihood of receiving a newborn hearing screen, receiving of a positive screen result, being lost to follow-up, receipt of a false-positive result, receiving a false-negative result, and receiving of a hearing loss diagnosis, adjusting for infant characteristics. Both infant characteristics and co-occurring diagnoses are included in the analysis. Co-occurring diagnoses were identified using ICD-9CM codes. Table 3 summarizes the factors assessed.

Table 3. Infant Factors

Birth Year
Gender
Birthweight
Race/Ethnicity
Length of Stay
Apgar (1 minute and 5 minute)
Treatment Factors associated with hearing loss or common in NICU
Ventilation Status
Oxygen Status
Primary Diagnoses from the birth encounter associated with hearing loss or therapies associated with hearing loss (e.g. ECMO)
Cytomegalovirus Dx (ICD-9CM: 771.1)
Craniofacial Anomaly Dx (ICD-9CM: 756.0)
Neonatal Infection Dx (ICD-9CM: 760.2, 771.82)
Hyperbilirubinemia Dx (ICD-9CM: 774.6, 774.2)
Sepsis Dx (identified through database notation, not diagnosis code)
Respiratory Distress Dx (ICD-9CM: 769)
Meconium Aspiration Dx (ICD-9CM: 770.12)
Persistent Pulmonary Hypertension Dx (ICD-9CM: 747.83)

Statistical Analyses

Temporal Trends

Tests for temporal trends were performed to characterize the data and identify any year in which the outcomes were significantly different from the first year of

screening. Generalized linear models were used to test for trends in each of the rates from the first year of screening (1996) through 2007. All statistical analyses were performed using STATA 13.⁸² Results with p-values less than 0.05 were considered significant. The empirical models are as described below.

Annual Screening Rates

Screening rates were calculated for each year and the model includes the admitting unit (newborn nursery or NICU) as a covariate. Birth year is used as a trend variable to mark changes. Attempts were made to use an indicator variable for pre- or post-policy change but these were excluded due to collinearity. The model specification is below:

$$Y = \beta_0 + \beta_1(X_1) + \beta_2(X_2) + \varepsilon$$

Where:

Y = Annual screening rate

X₁ = birth year

X₂ = admitting unit

Annual Loss to Follow-up

Rates of loss to follow-up were calculated for each year and only for infants admitted to the NICU. Again, covariates indicating policy changes were excluded due to collinearity, so birth year itself is used as a trend variable to mark changes. This was the only covariate included in the model. The model is defined below.

$$Y = \beta_0 + \beta_1(X_1) + \varepsilon$$

Where:

Y = Annual rate of loss to follow-up

X₁ = birth year

Annual Test Sensitivity

Sensitivity rates were calculated for each year and only for infants admitted to the NICU and with at least one follow-up encounter. Covariates indicating policy changes were excluded due to collinearity, and birth year itself is used as a trend variable to mark changes. The model is as follows.

$$Y = \beta_0 + \beta_1(X_1) + \varepsilon$$

Where:

Y = Annual sensitivity rate

X₁ = birth year

Annual Test Specificity

Specificity rates were calculated for each year and only for infants admitted to the NICU and will at least one follow-up encounter. Covariates indicating policy changes were excluded due to collinearity, and birth year itself is used as a trend variable to mark changes. The model specification are:

$$Y = \beta_0 + \beta_1(X_1) + \varepsilon$$

Where:

Y = Annual specificity rate

X₁ = birth year

Prediction Models

Separate multivariate logistic regression models were used to assess the likelihood of an infant receiving a newborn hearing screen, being lost to follow-up, receipt of a false-positive result, receiving a false-negative result, and receiving of a hearing loss diagnosis, while adjusting for infant characteristics and birth year (as an indicator of policy/organizational change). These epidemiologic inquiries are useful for identify risk factors for the outcomes of interest. Robust standard errors were used to estimate variance of the maximum likelihood functions.

Where significant differences were identified, marginal effects were calculated to identify the difference in probabilities. Marginal effects are historically used in economic analysis but can be useful for interpreting results in health services research and weighing decision options.⁸³ Analyzing marginal effects allows researchers to determine the “incremental difference in outcomes between defined groups” (page 98).⁸⁴ Here, I use average marginal effects, which estimate the marginal effect based on the calculated average for each individual in the sample,⁸⁴ to contextualize the differences in terms of probability of outcomes for groups within each significant model covariate. The models for each analysis are presented below.

Receipt of Newborn Hearing Screen

The outcome variable of interest in this model is receipt of a newborn hearing screen. This analysis was performed using infants admitted to both the newborn nursery and NICU, therefore the admitting unit is included as a covariate. The model also includes infant characteristics for adjustment.

$$Y = \beta_0 + \beta_1(X_1) + \beta_2(X_2) + \beta_3(X_3) + \varepsilon$$

Where:

Y = newborn hearing screen completion (1 = yes, 0 = no)

X₁ = birth year

X₂ = admitting unit

X₃ = vector of infant characteristics including gender, birthweight, race, Apgar scores, length of stay, oxygen status, ventilation status, and disorders reported as risk factors for hearing loss (see Table 3); in this model I also include an interaction for birth year and admitting unit

Loss to Follow-up

The outcome variable of interest in this model is lost to follow-up. This analysis was performed using infants admitted to only the NICU, as follow-up records are only available for the NICU population. While other studies have found that distance from urban centers was associated with receipt of follow-up services after hearing screening, the available location information (zip code) in our dataset was inconsistent and there were a large number of infants for which this information was missing. Therefore, distance was not included in our model.

$$Y = \beta_0 + \beta_1(X_1) + \beta_2(X_2) + \varepsilon$$

Where:

Y = screen result (1 = lost, 0 = not lost)

X₁ = birth year

X_3 = vector of infant characteristics including gender, birthweight, race, Apgar scores, length of stay, oxygen status, ventilation status, and disorders reported as risk factors for hearing loss (see Table 3).

False-Positive Result

The outcome variable of interest in this model is receipt of a false-positive result. This analysis was performed using infants admitted to only the NICU, as follow-up records are only available for the NICU population.

$$Y = \beta_0 + \beta_1(X_1) + \beta_2(X_2) + \varepsilon$$

Where:

Y = screen result (1 = false-positive, 0 = true-positive)

X_1 = birth year

X_2 = vector of infant characteristics including gender, birthweight, race, Apgar scores, length of stay, oxygen status, ventilation status, and disorders reported as risk factors for hearing loss (see Table 3)

False-Negative Result

The outcome variable of interest in this model is receipt of a false-negative result. This analysis was performed using infants admitted to only the NICU, as follow-up records are only available for the NICU population.

$$Y = \beta_0 + \beta_1(X_1) + \beta_2(X_2) + \varepsilon$$

Where:

Y = screen result (1 = false-negative, 0 = true-negative)

X_1 = birth year

X_2 = vector of infant characteristics including gender, birthweight, race, Apgar scores, length of stay, oxygen status, ventilation status, and disorders reported as risk factors for hearing loss (see Table 3)

Confirmed Hearing Loss

The outcome variable of interest in this model is receipt of a hearing loss diagnosis. This analysis was performed using infants admitted to only the NICU, as follow-up records are only available for the NICU population. Screen result and birth year were not included in the model since the neither is an associated cause of hearing loss.

$$Y = \beta_0 + \beta_1(X_1) + \beta_2(X_2) + \varepsilon$$

Where:

Y = hearing loss (1 = hearing loss diagnosis, 0 = no hearing loss diagnosis)

X_1 = birth year

X = vector of infant characteristics including gender, birthweight, race, Apgar scores, length of stay, oxygen status, ventilation status, and disorders reported as risk factors for hearing loss (see Table 3)

Specific Aim 3

Specific Aim 3: Evaluate time-to-diagnosis for infants that receive a positive screen result prior to hospital discharge, and identify correlates of earlier diagnosis.

Hypothesis: Time-to-diagnosis is earlier in infants that receive a positive newborn screen, but still varies by group (e.g. race/ethnicity).

Specific Aim 3 centers around understanding whether or not receipt of a positive hearing screen is associated with earlier diagnosis of hearing loss, and identifies infant factors and comorbidities associated with earlier diagnosis. The study group included in this analysis included all infants admitted to the NICU in the health care center and having at least one follow-up encounter after discharge from the NICU. Infants born prior to 1996 and after 2007 were excluded from the study due to incomplete birth or follow-up data. A total of 5,502 infants were eligible for inclusion in the study. There were 647 infants with incomplete records on at least one of the variables, resulting in 4,855 infants included in the sample.

Infant characteristics of interest to the study include both demographic factors as well as those that have been shown to affect both hearing status and the likelihood of receiving follow-up services. Table 3 lists the infant characteristics included. Birth year is also included in the analysis as a categorical variable to identify trends in earlier diagnosis given policy and organizational changes. The presence or absence of diagnoses known to increase risk for hearing loss, either congenital or delayed-onset, were also included based on reports of the Joint Committee on Infant Hearing and other studies.^{10, 15-19, 42} Both ventilation status and oxygen status were also included as treatment factors in the model.

Specific Aim 3 employs survival analysis with the Cox proportional-hazard regression technique.⁸⁵ This method accounts for the variable lengths of follow-up available for each individual and allows for censoring, which describes the point at

which the individual leaves the study and assumes future diagnosis is possible even though it was not captured in the study.

The time-to-event of interest in this study is the time between NICU discharge and hearing loss diagnosis. Discharge date was selected as the starting point for time measurement since the hearing screen is typically performed in the days prior to discharge and I assume that referral for confirmatory testing would be provided at that point. Diagnosis date was ascertained by identifying the first hearing loss diagnosis in the infant record and abstracting the associated date from the database. Individual records were coded as either having a documented hearing loss diagnosis or being censored after the date of their last follow-up encounter. Individual and treatment factors were included in the Cox Proportional Hazards model to identify correlates of early diagnosis. STATA software was used for analyses.⁸² Results with p-values less than 0.05 were considered significant.

The proportional hazards assumption is inherent to the Cox Proportional Hazard regression model and states that the hazard for any one individual is proportion to the hazard for any other individual, and that this proportionality is constant over time.⁸⁵ The proportional hazards assumption was assessed by graphic modeling, specifically using log-log plots,⁸⁵ and using statistical tests performed with the *estat phtest* command in STATA 13. Both assessments found that the baseline hazards for the categories of screen result (no screen, screen negative, screen positive) were not proportional and the proportional hazards assumption for this predictor was not met. As a result, a stratified Cox Proportional Hazards model was used to estimate differences in diagnosis based on

infant and treatment factors, presumably similar to the results from the logistic model evaluating risk factors associated with a hearing loss diagnosis (see Specific Aim 2). The model was stratified by screen result and, therefore, hazard ratios are not available for this variable. However, through stratification, all results are adjusted for screen status. Independent survival curves were prepared for each significant covariate, as well as for screen result. Log-rank tests for equality of survival curves were conducted to see if there were statistically significant differences in the survival estimates for different groups.

Median time-to-diagnosis and annual ranges, were also calculated for each year included in the study. These were plotted on a graph with a trend line to demonstrate the direction of changes over time.

Limitations of Methodology

This methodology is limited by several factors. First, I use ICD-9CM codes as an indicator of disease. ICD-9CM codes can be unreliable due to the fact that they are applied for billing purposes and may not always be an accurate indicator of disease status.⁸⁶ Full chart reviews were impractical in the study and, therefore, disease status could not be confirmed. Second, one of the well-known risk factors for hearing loss is family history, which could not be measured using these data. As a result, the models may include some level of misspecification due to a known but unmeasurable confounder. Finally, test of goodness of fit produced non-significant results for all models except in the logistic models for receipt of a newborn hearing screen and receipt of a false-positive result. The sample sizes included in the analyses for each model were

large, which may bias goodness of fit results. However, this may indicate that the models are somehow misspecified.

CHAPTER IV

RESULTS

The results presented below are organized by specific aim. Sample sizes for each part of the study or individual model are noted in each section. A discussion of results and their implications for policy and practice are in Chapter V.

Specific Aim 1

A final total of 343 studies published between 1990 and 2014 were included in the review. Figure 1 summarizes the abstraction process and the final number of studies included across databases.




Figure 1. Database Review, Study Abstraction Process

The total number of publications using the databases has increased, from three in 1991 to 41 in 2013 (the last full calendar year included in our review). Both prospective and retrospective studies have also increased, with retrospective studies comprising more of the total number of studies in most years. Around 2005, there was a slight decline in the number of studies published, but publications began to increase again after 2006.

Figure 2 summarizes the year-by-year results.




Figure 2. Annual Publications by Study Design

Seventy-one percent (71%) of the studies used a retrospective study design and these studies tended to have an epidemiologic focus. Among retrospective studies, the database was sometimes used as a comparison group or benchmark for a single-center

study. For example, Pietz, Achanti, Lilien, Stepka, and Mehta studied the incidence of necrotizing enterocolitis (NEC) in a single NICU over the course of twenty years. Their study looked specifically at the incidence of bowel perforation and NEC among a population of infants that were unlikely to have been treated with indomethacin, a nonsteroidal anti-inflammatory drug that can be used to treat very premature infants. Use of indomethacin in this particular NICU was discouraged and the authors emphasize the need to compare results to other centers that may use indomethacin more frequently. The study authors compared results from their NICU to overall results from VON, which likely included infants treated in NICUs employing more typical practice (for the time) of using indomethacin, and tested for differences in rates of NEC.⁸⁷ Alternatively, retrospective studies also used the databases to study population health research questions. For example, Stoll, et. al. utilized the NICHD Neonatal Research Network database to retrospectively examine trends in morbidity and mortality among LBW infants.⁶⁵ Smith, et. al., used the KPNMDS to study temporal trends in bronchopulmonary dysplasia rates over eight years.⁸⁸

Approximately 31% of studies utilized a prospective study design where the database was used as a sampling frame, or was used to house study data and answer a specific clinical research question. In their study of neurodevelopmental outcomes among extremely LBW infants (i.e., < 2000 g), Mercier, et. al., used the VON database as a sampling frame from which infants were identified for follow-up assessments.⁸⁹ Lorch, Srinivasan, and Escobar published a study on the epidemiology of apnea and

brachycardia in premature infants, which used the KPNMDS as a primary data source throughout the infants' admission to the NICU.⁹⁰

Studies focused on a variety of clinical conditions, interventions, and outcomes, with just over 70% of studies concentrating on ten categories (summarized in Table 4). The top ten areas of research focus were respiratory treatments/outcomes; neurodevelopmental, growth, or language outcomes; outcomes of very LBW or extremely LBW; encephalopathy; neonatal infections; intestinal disease; sepsis; antenatal corticosteroid treatment; retinopathy of prematurity, and hyperbilirubinemia. The remaining 30% of studies focus on other specific conditions and interventions and account for a large amount of diversity in study focus areas. Approximately 10% of the studies were in a category alone, leaving 90% in categories with two or more studies.

Table 4. Primary Clinical Areas of Focus for Studies Using Multicenter Neonatal Databases

Primary Clinical Focus Area	Count	Percent (%)	Citations
Respiratory Treatments & Outcomes	67	19.53%	27, 70, 88, 91-153
Neurodevelopmental, Growth, or Language Outcomes	45	13.12%	66, 69, 89, 154-195
Outcomes of VLBW/ELBW	39	11.37%	65, 67, 68, 71, 72, 196-229
Encephalopathy	24	7.00%	230-253
Neonatal Infections	18	5.25%	254-271
Intestinal Disease	15	4.37%	87, 272-285
Sepsis	14	4.08%	286-299
Antenatal Corticosteroid Treatment	10	2.92%	300-309
Retinopathy of Prematurity	8	2.33%	310-317
Hyperbilirubinemia	8	2.33%	318-325
Other	95	27.70%	90, 326-420
Total	343	100%	

Among those studies in the top ten categories, some were given a secondary clinical focus area to further describe the research. This occurred frequently in the broader categories looking at outcomes. For example, studies focusing on respiratory treatment and outcomes may have specific research questions related to use of surfactant or comparing ventilation strategies. Studies of neurodevelopmental outcomes tended to have secondary clinical foci on specific clinical conditions such as NEC, intraventricular hemorrhage, or hyperbilirubinemia. Other top categories, such as intestinal disease, had fewer secondary categories due, presumably, to the focus of the topic area.

Studies in each category also varied in terms of the range of time in which they were published. The earliest published studies focus on intestinal disease and overall outcomes of VLBW and ELBW infants, and these tend to continue through the duration of time included in our review. Alternatively, studies of heart defects and encephalopathy using one of the three databases were not published until after 2000. Figure 3 below describes the range of years across which studies in the top categories were published.




Figure 3. Study Trends, Top Ten Clinical Focus Areas, 1990-2014

Despite extensive datasets and the ability for diverse research aims, these databases are not ideal for all outcome studies of prematurity and low birth weight. In the context of this study of hearing loss among NICU infants, there are several specific concerns. First, there is limited evidence that hearing screening status is available for infants in any of the databases. Given my intent to assess implementation and outcomes of the screening policy, screening status is necessary. Second, these three databases do not report maintaining consistent long-term follow-up of infants. While some studies follow infants for extended periods of time, this is not a requirement for participation in the databases and, therefore, researchers cannot count on follow-up data on a large proportion of infants. Finally, and related to follow-up, hearing loss is a relatively rare disorder detected in newborns with an incidence rate of 1-3 per thousand in the general

population. To detect significant results in the NICU population, which is already small, I needed a large sample size. Although the three databases reviewed have a large number of included infants, there is likely a small number with hearing-related screen information or diagnoses after discharge from the hospital. Due to these concerns, I feel justified in using a longitudinal database from the single center where hearing screen results were documented routinely in the medical record and where there is a mean of ten years of diagnostic follow-up on infants receiving follow-up services within the center.

Specific Aim 2

Here I present results for Specific Aim 2, which aims to look at temporal trends in newborn hearing screening, loss to follow-up, screen specificity and false-positive rate, and screen sensitivity and false-negative rate. In addition, I use logistic regression to predict the likelihood of an infant receiving a hearing screen, being lost to follow-up, receiving a false-positive and false-negative screen result, and receiving a diagnosis of hearing loss; and analyze the marginal effects in different groups.

Study Sample Profile

The database used in this study of hearing screening and hearing loss includes a total of 51,244 infants either born or transferred into a single health care system in Central Texas between 1988 and 2009. There are statistically significant differences between the newborn nursery and NICU infants in all characteristics of interest, including the number receiving a newborn hearing screen. A larger proportion of infants were admitted to the newborn nursery, which might be expected since most babies are

born healthy and do not require a higher level of care. A larger proportion of females and black infants were admitted to the NICU than the newborn nursery. As might be expected, the NICU also had a greater proportion of infants with low birth weight and an early gestational age (see Table 5). Table 5 also denotes where there were missing data for each variable, which did impact the relative sample sizes for each separate analysis.

Only one set of analyses, temporal trends in and likelihood of newborn hearing screening, include infants from the newborn nursery. All other analyses required data on confirmed hearing loss and, therefore, only NICU infants were included in the samples those portions of the study. Table 6 includes descriptive statistics for infants with and without confirmed hearing loss during the study period of 1996-2007. A total of 285 infants (4.9 percent) in the sample had a diagnosis of hearing loss in their record. There were no differences in gender, Apgar scores, or several of the treatment factors or comorbidities between infants with and without hearing loss (see Table 6). The groups did differ in race/ethnicity, birth weight, whether or not they received a screen, ventilation status, length of stay, and in the diagnosis of a craniofacial anomaly.

Table 5. Characteristics of Newborn Population Admitted to Health Care System between 1988 and 2009

	Newborn Nursery (n=42,025)	NICU (n=9,219)	Statistically Significant Difference? (Newborn Nursery vs. NICU)
Gender			
Male	20,673 (49.19%)	4,158 (45.10%)	Overall $p<0.001$
Female	21,335 (50.77%)	5,047 (54.75%)	
missing	17 (0.04%)	14 (0.15%)	
Race			
White	15,077 (35.88%)	3,514 (38.12%)	Overall $p<0.001$
Black	4,276 (10.17%)	1,387 (15.05%)	
Hispanic	7,370 (17.54%)	1,294 (14.04%)	
Other	894 (2.13%)	119 (1.29%)	
missing	14,408 (34.28%)	2,905 (31.51%)	
Delivery Route			
Vaginal	34,209 (81.40%)	5,704 (61.87%)	Overall $p<0.001$
Cesarean	7,806 (18.57%)	3,453 (37.46%)	
missing	10 (0.02%)	62 (0.67%)	
Birthweight			
>4,200g	1,810 (4.31%)	244 (2.65%)	Overall $p<0.001$
2,500-4,199g	39,146 (93.15%)	3,761 (40.80%)	
1,500-2,499g	1,066 (2.54%)	3,496 (37.92%)	
1,000-1,499g	2 (0.00%)	995 (10.79%)	
<1,000g	1 (0.00%)	723 (7.84%)	
Gestational Age			
>37 weeks	36,150 (86.02%)	2,948 (31.98%)	Overall $p<0.001$
35-37 weeks	5,297 (12.60%)	1,531 (16.61%)	
32-34 weeks	541 (1.29%)	2,313 (25.09%)	
28-31 weeks	35 (0.08%)	1,699 (18.43%)	
<28 weeks	2 (0.00%)	728 (7.90%)	
Newborn Hearing Screen			
Not screened	18,254 (56.56%)	5,883 (63.81%)	Overall $p<0.001$
Screened	23,768 (43.44%)	3,336 (36.19%)	
Birth Year			
Prior to 1996	14,396 (34.26%)	2,875 (31.19%)	Overall $p<0.001$
After 1996	27,629 (65.74%)	6,344 (68.81%)	

Table 6. Descriptive Statistics for Hearing Loss (HL) in the NICU cohort, 1996-2007

	Confirmed Hearing Loss (n=285)	No Confirmed Hearing Loss (n=5,480)	Statistically Significant Difference? (HL+ vs -)
Gender			
Male	158 (55.44%)	3,019 (55.04%)	p>0.05
Female	127 (44.56%)	2,461 (44.87%)	
missing	-	5 (0.09%)	
Race/Ethnicity			
White	185 (64.91%)	3,017 (55.00%)	p<0.001
Black	33 (11.58%)	1,186 (21.62%)	
Hispanic	58 (20.35%)	1,155 (21.06%)	
Other	8 (2.81%)	101 (1.84%)	
missing	1 (0.35%)	26 (0.47%)	
Birthweight			
>4,200g	10 (3.51%)	153 (2.79%)	p<0.001
2,500-4,199g	130 (45.61%)	2,441 (44.50%)	
1,500-2,499g	91 (31.93%)	2,017 (36.77%)	
1,000-1,499g	28 (9.82%)	509 (9.28%)	
<1,000g	26 (9.12%)	365 (6.65%)	
Apgar Scores			
1 minute, mean	7	7.41	p>0.05
5 minute, mean	8.42	8.49	p>0.05
Hearing Screening			
Not screened	10 (3.51%)	438 (7.33%)	p=0.015
Screened	275 (96.49%)	5,541 (92.67%)	
Comorbidities and Treatments			
Ventilation	74 (25.96%)	1,205 (20.15%)	p=0.017
Oxygen	100 (35.09%)	2,192 (36.66%)	p>0.05
Craniofacial Anomalies	7 (2.46%)	11 (0.18%)	p<0.001
Cytomegalovirus	1 (0.35%)	25 (0.42%)	p>0.05
Neonatal infection	2 (0.70%)	11 (0.18%)	p>0.05
Hyperbilirubinemia	39 (13.68%)	836 (13.98%)	p>0.05
Sepsis	19 (6.67%)	361 (6.04%)	p>0.05
Respiratory Distress	54 (18.95%)	1,027 (17.18%)	p>0.05
Length of Stay			
<=5 days	78 (27.37%)	2,097 (35.07%)	p=0.008
> 5 days	207 (72.63%)	3,882 (64.93%)	

Temporal Trends

Newborn Hearing Screening Rates

Since the health care system implemented newborn hearing screening in 1996, the annual rate of infants receiving a screen has increased to rates between 90 and 100 percent. Prior to 2001, the rates varied by admitting unit, with infants admitted to the NICU having higher rates of newborn hearing screening than infants admitted to the newborn nursery. Since 2001, rates in both units stabilized and are above 90 percent. Between 1999, when the screening mandate was passed in the Texas Legislature, and 2001, when full implementation of the law was required, there was a reduction in the screening rates for both admitting units, with the newborn nursery having the sharpest decline. Figure 4 shows the trends in screening rates since 1996. The fitted line is included to demonstrate the direction of the trend in overall screening rates across both units. As the graph shows, newborn hearing screening rates increased over the period 1996 to 2007.




Figure 4. Newborn Hearing Screening Rates, 1996-2007

The generalized linear model showed that each year after 1996 had a statistically significant improvement in newborn hearing screening rates, compared to 1996 and adjusted for admitting unit (p-values all equal < 0.001). The NICU is also associated with higher screening rates (p-value <0.001).

Loss to Follow-up Rates

Annual rates of loss to follow-up for infants admitted to the NICU decreased over the time period 1996 to 2007, demonstrating that fewer infants with positive newborn hearing screens were being lost due to either receiving no follow-up or not having documentation of follow-up services within the system. In all years except for

1996 the annual rate of loss to follow-up was less than 15 percent, much lower than the reported rate for Texas (40.2 percent in 2011). Figure 5 shows the annual rates and included a fitted line to demonstrate their downward trend.




Figure 5. Loss to Follow-up Rates, NICU, 1996-2007

The generalized linear model testing for changes in the loss to follow-up rate showed that all years had statistically significant reductions in loss to follow-up compared to 1996 ($p\text{-value} < 0.001$).

Screen Specificity and False-Positive Rate

Specificity of a screen or test indicates the extent to which the test accurately identifies individuals without the disease when they truly do not have the disease. In the case of newborn hearing screening, this is the ability of the screen to provide negative results to infants that do not have hearing loss.⁴²¹ The false-positive rate is the rate of infants that were identified through the screening program to potentially have hearing loss, but do not actually have hearing loss upon confirmatory testing (or, in this analysis, do not ever receive a hearing loss diagnosis). The higher the specificity, the lower the false-positive rate.⁴²¹

The specificity of the screening program among NICU infants has maintained a high specificity rate, never going below 90 percent. As such, the false-positive rate as remained below 10 percent, with a high in 1999. Figure 6 shows the trends graphically. The fitted lines demonstrate that there is a general trend toward an increasingly higher specificity, while the false-positive rate has declined.

We know from conversations with physicians in the health system that they recognized a high false-positive rate around 1999-2000. In response, the organization implemented a new staff training to improve performance and interpretation of the newborn hearing screen. After 1999 the rates begin to decline and stabilize around 2000.




Figure 6. Screen Program Specificity and False-Positive Rate, NICU, 1996-2007

The generalized linear model shows that there has been fluctuation in the specificity and the false-positive rate over time. Specificity was lower in 1997, 1998, 1999, 2000, and 2001, compared to the year 1996 (p -values <0.001). In the following years (2002-2007), the odds of increased specificity are all greater than 1 (p -values <0.001), indicating higher specificity in all years compared to 1996.

Similarly, the false-positive rate was higher from 1997-2001, compared to 1996 (p-values=0.000). In 2002, the odds of a lower false-positive rate become lower than one and remain so through 2007 (p-values<0.001).

Screen Sensitivity and False-Negative Rates

The sensitivity of a screen or test is the extent to which the test accurately identifies individuals that have the disease of interest.⁴²¹ The false-negative rate is 1-sensitivity and represents the proportion of individuals that had a negative test or screen result but eventually received diagnosis of the disease.⁴²¹ Tests with high sensitivity rates will have low false-negative rates.⁴²¹

In general, this study of newborn hearing screening found that the sensitivity of the screen was low over the study period and, similarly, that the false-negative rate remained quite high. There was variation over the years. Figure 7 shows the changes over time and includes fitted lines for both sensitivity and false-negative rates to demonstrate trend.




Figure 7. Screen Program Sensitivity and False-Negative Rate, NICU, 1996-2007

The generalized linear model shows that the odds of higher sensitivity were lower than one in all years except for 2001, compared to 1996 (p-values<0.001; year 1999 had exact same sensitivity as 1996). In 2001, the odds were slightly higher than 1 (1.04, p-value<0.001) and represent the highest annual sensitivity rate across the study period. The model to predict changes in false-negative rates shows that the odds of a higher false-negative rate were above one for all years except 2001, compared to 1996 (p-values<0.001). These results confirm that both the screen sensitivity and false-negative rate have not improved since the inception on newborn hearing screening

within the health care center in 1996 and may reflect the fact that NICU infants are at greater risk of delayed onset hearing loss.

Prediction Models

Next, I extend the focus on these program outcomes and present results of five separate logistic regression models to predict the likelihood of receiving a newborn hearing screen, being lost to follow-up, receiving a false-positive or false-negative screen result, and receiving a hearing loss diagnosis, all adjusted for birth year and infant characteristics. The results are intended to further inform hearing screening programs, both universal and through targeted follow-up.

Likelihood an Infant Received a Hearing Screen

A total of 28,335 infants with complete data were included in our analysis of the likelihood an infant received a hearing screen. As noted previously, this is the one outcome in the study where inclusion of both the newborn nursery and neonatal intensive care units is possible, providing the opportunity to adjust for admitting unit.

Across the study sample and period, the mean probability that an infant received a hearing screen was 0.859. Neither gender or race was associated with increased odds of receiving a screen, nor was birth weight. Both birth year and admitting unit, and their

interaction, were significantly associated with receipt of a screen, as were the 5-minute Apgar score, length of stay, ventilation status, and a diagnosis of hyperbilirubinemia.

Table 7 includes the regression results for these significant covariates.

Compared to the year 1996, infants born between 1997 and 2007 had greatly increased odds of receiving a hearing screen (OR range 118 to 19,169, p -values <0.0001). Infants admitted to the NICU were also more likely to receive a hearing screen (OR=118, p -value <0.0001). Higher 5-minute Apgar scores (OR=1.19, p -value <0.0001), a length of stay greater than five days (OR=13, p -value <0.0001), and a diagnosis of hyperbilirubinemia during the birth admission (OR=3.19, p -value <0.0001) were also associated with an increased odds of receiving a hearing screening. Infants that were on ventilation, regardless of the length, had lower odds of receiving a hearing screen (OR=0.25, p -value <0.0001). The interaction between birth year and admitting unit was significant in the model and each individual interaction was also significant, adding slight increases to the relative odds for each variable.

Table 7. Results of Logistic Regression Analysis, Likelihood an Infant Received a Hearing Screen (n=28,335)

Variable	Odds Ratio	P-value	[95% Conf. Interval]	
Birth Year (<i>referent is 1996</i>)				
1997	152.47	<0.0001	100.92	230.35
1998	3651.24	<0.0001	2195.72	6071.61
1999	505.90	<0.0001	331.90	771.12
2000	118.43	<0.0001	78.48	178.72
2001	1181.78	<0.0001	759.79	1838.13
2002	8764.76	<0.0001	4747.52	16181.28
2003	5997.30	<0.0001	3431.09	10482.83
2004	10492.02	<0.0001	5487.39	20060.97
2005	19169.58	<0.0001	8891.42	41328.92
2006	10047.66	<0.0001	5442.53	18549.37
2007	6044.29	<0.0001	3524.46	10365.70
Admitting Unit (<i>referent is Newborn Nursery</i>)				
NICU	188.37	<0.0001	109.41	324.32
Apgar (5 minute)	1.19	<0.0001	1.09	1.30
Length of stay >5 days	13.29	<0.0001	8.86	19.94
Ventilation	0.25	<0.0001	0.15	0.41
Hyperbilirubinemia Dx	3.19	<0.0001	1.67	6.10
Birth Year and Unit Interaction (<i>referent is 1996*NICU</i>)				
1997#NICU	0.02	<0.001	0.01	0.03
1998#NICU	0.00	<0.001	0.00	0.01
1999#NICU	0.01	<0.001	0.00	0.01
2000#NICU	0.02	<0.001	0.01	0.03
2001#NICU	0.01	<0.001	0.00	0.02
2002#NICU	0.00	<0.001	0.00	0.00
2003#NICU	0.00	<0.001	0.00	0.00
2004#NICU	0.00	<0.001	0.00	0.00
2005#NICU	0.00	<0.001	0.00	0.00
2006#NICU	0.00	<0.001	0.00	0.00
2007#NICU	0.00	<0.001	0.00	0.00

The estimated marginal effects of the significant variables are summarized in Table 8. The overall probability of receiving a hearing screen was 0.859. The average marginal effects provided in the table demonstrate the relative probability of the different groups described and, since they are all significant variables in the model, we can compare probabilities between groups. For example, an infant born in 1997 was over four times as likely to receive a hearing screen as an infant born in 1996 (probability of 0.698 in 1997 compared to probability of 0.157 in 1996). Similarly, infants born after 2002 were six times as likely to receive a hearing screen. The probability of receiving a hearing screen in the NICU was four percent higher (0.892) than the probability of receiving a screen in the newborn nursery (0.84). Infant that received assisted ventilation had an eight percent higher probability of receiving a hearing screen, although the reason for this difference is not clear. The probability of hearing screening for infants with a length of stay greater than five days was 10 percent higher than infant admitted for five or fewer days, possibly due to the extended amount of time during which the screen could be performed. A hyperbilirubinemia diagnosis was also associated with a five percent increase in the probability of screening.

Table 8. Average Marginal Effects for the Logistic Model of Screening Receipt

Variable	Margin	P-value	[95% Conf. Interval]	
Birth Year				
1996	0.157	<0.001	0.149	0.165
1997	0.698	<0.001	0.679	0.717
1998	0.977	<0.001	0.971	0.983
1999	0.873	<0.001	0.860	0.887
2000	0.647	<0.001	0.628	0.666
2001	0.941	<0.001	0.932	0.951
2002	0.986	<0.001	0.981	0.990
2003	0.984	<0.001	0.979	0.988
2004	0.985	<0.001	0.981	0.990
2005	0.986	<0.001	0.982	0.991
2006	0.981	<0.001	0.975	0.986
2007	0.969	<0.001	0.960	0.978
Admitting Unit				
Newborn Nursery	0.850	<0.001	0.847	0.853
NICU	0.892	<0.001	0.876	0.909
Length of Stay				
Five or less Days	0.835	<0.001	0.830	0.841
Greater than 5 days	0.933	<0.001	0.926	0.940
Ventilation Status				
No Ventilation	0.862	<0.001	0.859	0.864
Received Ventilation	0.761	<0.001	0.718	0.804
Hyperbilirubinemia Dx				
No hyperbilirubinemia	0.858	<0.001	0.856	0.861
Hyperbilirubinemia	0.908	<0.001	0.889	0.927

Likelihood an Infant is Lost to Follow-up

There were 5,102 eligible infants with complete data included in the analysis to determine the likelihood an infant is lost to follow-up. This includes only infants admitted to the NICU, since follow-up status could only be assessed for those infants. Compared to 1996, the odds an infant with a positive screen was lost to follow-up was

lower (ORs=0.19-0.37, p-values<0.0001) in all years except 1997, where the result was insignificant.

Infants born with a birthweight between 1,000 and 1,499 grams were less likely to be lost to follow-up than infants greater than 4,200 grams (OR=0.45, p-value=0.027), but no other birthweight categories had significant differences. Black infants had greater odds of being lost to follow-up (OR=1.34, p-value=0.013), while Hispanic infants had lower odds of being lost (OR 0.64, p-value=0.002) compared to whites.

Neither the 1-minute or 5-minute Apgar score, nor ventilation status were associated with an increased odds of being lost. Infants who received oxygen while in the NICU were more likely to be lost (OR=1.46, p-value=0.004). Infants that were admitted to the hospital for longer than five days had higher odds of being lost (OR=1.28, p-value=0.04). The only diagnosis from the birth encounter associated with loss to follow-up was hyperbilirubinemia, in which infants who received this diagnosis were less likely to be lost (OR=0.59, p-value=0.004). Table 9 includes the results of the logistic regression for significant variables.

Table 9. Results of Logistic Regression Analysis, Likelihood an Infant is Lost to Follow-up (n=5,102)

Variable	Odds Ratio	P-value	[95% Conf. Interval]	
Birth Year (<i>referent is 1996</i>)				
1997	0.72	0.098	0.49	1.06
1998	0.28	<0.0001	0.18	0.44
1999	0.32	<0.0001	0.19	0.52
2000	0.19	<0.0001	0.12	0.32
2001	0.29	<0.0001	0.18	0.45
2002	0.30	<0.0001	0.20	0.47
2003	0.36	<0.0001	0.23	0.56
2004	0.26	<0.0001	0.16	0.42
2005	0.37	<0.0001	0.24	0.56
2006	0.33	<0.0001	0.21	0.53
2007	0.34	<0.0001	0.19	0.60
Birthweight (<i>referent is 2,500g-4,199g</i>)				
>4,200g	1.08	0.794	0.61	1.92
1,500-2,499g	1.07	0.542	0.86	1.32
1,000-1,499g	0.49	0.003	0.31	0.78
<1,000g	0.71	0.271	0.39	1.30
Race (<i>referent is White</i>)				
Black	1.34	0.013	1.06	1.69
Hispanic	0.64	0.002	0.49	0.85
Other	0.63	0.288	0.27	1.47
Length of stay >5 days	1.28	0.04	1.01	1.62
Oxygen	1.46	0.004	1.13	1.90
Hyperbilirubinemia Dx	0.59	0.004	0.42	0.85

The overall probability of being lost to follow-up was 0.0919. After assessment of the average marginal effects, there were no differences in probability for infants born in 1996 or 1997; therefore, we are unable to compare probabilities across birth years. However, we can compare probabilities from individual years to the overall probability. Infants born from 1998 to 2007 had lower probabilities of being lost to follow-up than the sample as a whole. The probability of being lost to follow-up for black infants was three percent higher than that for the overall sample, and Hispanic infants had a lower probability of being lost. The probability of being lost for infants that received oxygen during their NICU admission was three percent higher than those that did not receive oxygen. Infants with a length of stay longer than five days had a two percent higher probability of being lost to follow-up than those with a shorter length of stay. Infants with a hyperbilirubinemia diagnosis had a lower probability two and half percent lower than those without the diagnosis. Table 10 includes the average marginal effects.

Table 10. Average Marginal Effects for the Logistic Model of Being Lost to Follow-up

Variable	Margin	P-value	[95% Conf. Interval]	
Birth Year				
1998	0.072	<0.001	0.048	0.095
1999	0.080	<0.001	0.051	0.109
2000	0.051	<0.001	0.030	0.071
2001	0.073	<0.001	0.050	0.096
2002	0.077	<0.001	0.054	0.100
2003	0.089	<0.001	0.063	0.115
2004	0.066	<0.001	0.043	0.089
2005	0.091	<0.001	0.066	0.115
2006	0.084	<0.001	0.058	0.110
2007	0.085	<0.001	0.048	0.122
Birthweight				
1,000-1,499g	0.050	0.010	0.030	0.070
Race/Ethnicity				
Black	0.120	<0.001	0.101	0.140
Hispanic	0.063	<0.001	0.049	0.078
Oxygen Status				
No Oxygen	0.082	<0.001	0.072	0.092
Received Oxygen	0.114	<0.001	0.095	0.133
Length of Stay				
Five or less Days	0.079	<0.001	0.066	0.093
Greater than 5 days	0.098	<0.001	0.088	0.108
Hyperbilirubinemia Dx				
No hyperbilirubinemia	0.097	<0.001	0.088	0.105
Hyperbilirubinemia	0.061	<0.001	0.042	0.080

Likelihood of a False-Positive Hearing Screen Result

A total of 5,102 eligible infants with complete data were included in the analysis to determine the likelihood of a false-positive screen result. It was not until the year 2002 that infants were at lower odds of receiving a false-positive screen. As mentioned

previously, the health care system had identified a high false-positive rate and implemented a staff training program to improve screening performance and interpretation. Likely a result of this organizational policy, infants born between 2002 and 2007 were less likely to receive a false-positive result (ORs=0.10-0.29, p-values with range of <0.0001 to 0.031). Table 11 includes the complete results of the regression analysis.

Gender was not associated with false-positive results but infants with a birth weight less than 1,000 grams (OR=4.66, p-value=0.013) and black infants (OR=1.49, p-value=0.048) had greater odds of a false-positive results. Those with a length of stay longer than five days were less likely to receive a false-positive result (OR=0.27, p-value<0.0001), as were infants that were on oxygen during their admission (OR=0.23, p-value<0.0001). Receipt of assisted ventilation (OR=2.60, p-value=0.008) and a diagnosis of persistent pulmonary hypertension (OR=44.15, p-value<0.0001) were associated with receipt of a false-positive result.

Table 11. Results of Logistic Regression Analysis, Likelihood of a False-Positive Screen Result (n=5,002)

Variable	Odds Ratio	P>z	[95% Conf. Interval]	
Birth Year (referent is 1996)				
1997	0.73	0.41	0.34	1.56
1998	0.77	0.493	0.37	1.61
1999	1.35	0.412	0.66	2.75
2000	0.95	0.881	0.46	1.96
2001	0.52	0.104	0.24	1.14
2002	0.12	<0.0001	0.04	0.35
2003	0.29	0.01	0.11	0.74
2004	0.12	0.001	0.03	0.41
2005	0.10	0.001	0.03	0.37
2006	0.26	0.007	0.10	0.69
2007	0.18	0.031	0.04	0.85
Birthweight (referent is 2,500-4,199g)				
>4,200g	1.06	0.903	0.40	2.81
1,500-2,499g	1.11	0.635	0.73	1.68
1,000-1,499g	1.30	0.560	0.54	3.11
<1,000g	4.97	<0.001	2.23	11.07
Race (referent is White)				
Black	1.49	0.048	1.00	2.20
Hispanic	0.98	0.925	0.62	1.54
Other	1.00			
Length of stay >5 days	0.27	<0.0001	0.17	0.42
Ventilation	2.60	0.008	1.28	5.26
Oxygen	0.23	<0.0001	0.12	0.44
Persistent Pulmonary Hypertension Dx	44.15	<0.0001	6.61	294.76

The overall probability of a false-positive screen result was 0.0302. Again, since not every birth year was significant in the logistic model, marginal effects are interpreted relative to the overall probability. From 2002 to 2007, the probability an infant received a false-positive screen result was lower than the overall probability. Black infants had a slightly higher probability than that for the overall sample. The probability of a false-positive screen in infants born at less than 1,000 grams was three times the overall probability. Infants that received oxygen had a three percent lower probability of a false-positive result than those not receiving oxygen, but infants that received assisted ventilation had a three percent higher probability of a false-positive result than those with no ventilation. Infants with a length of stay greater than five days had a four percent lower probability of receiving false-positive result compared to infants with a shorter stay. The probability of a false-positive screen for infants with a diagnosis of persistent pulmonary hypertension was almost 14 times the probability for infants without the diagnosis. See Table 12 for the complete results on marginal effects.

Table 12. Average Marginal Effects for the Logistic Model of Receipt of a False-Positive Screen Result

Variable	Margin	P-value	[95% Conf. Interval]	
Birth Year				
2002	0.009	0.016	0.002	0.016
2003	0.019	0.002	0.007	0.031
2004	0.008	0.056	0.000	0.017
2005	0.007	0.059	0.000	0.015
2006	0.017	0.005	0.005	0.030
2007	0.012	0.153	-0.005	0.029
Race/Ethnicity				
Black	0.039	<0.001	0.028	0.050
Birth Weight				
<1,000g	0.103	<0.001	0.045	0.102
Oxygen Status				
No Oxygen	0.043	<0.001	0.034	0.052
Received Oxygen	0.011	<0.001	0.006	0.016
Ventilation Status				
0	0.027	<0.001	0.022	0.032
1	0.063	<0.001	0.029	0.096
Length of Stay				
Five or less Days	0.058	<0.001	0.044	0.072
Greater than 5 days	0.018	<0.001	0.013	0.022
Persistent Pulmonary Hypertension Dx				
No Persistent Pulmonary Hypertension	0.030	<0.001	0.025	0.035
Persistent Pulmonary Hypertension	0.418	0.013	0.089	0.747

Likelihood of a False-Negative Hearing Screen Result

There were 5,011 eligible infants included in the analysis of false-negative results. Unlike the results for false-positive screens, there is not a specific year in which a change in the odds of a false-negative screen shift and remain so. In the years 2000, 2001, 2002, 2004, and 2007, infants had greater odds of receiving a false-negative screen result. Recall that NICU infants are at greater risk of hearing loss and that they are particularly susceptible to sensorineural hearing loss, which may have delayed onset. Hearing loss, in this study, was defined as the presence or absence of any hearing loss diagnosis, so we do not currently know if these false-negative results are due, in fact, to delayed onset, i.e. the infant truly did not have hearing loss at the time of their NICU admission.

Neither gender or birth weight had any association with false-negative results, but black infants had lower odds of receiving a false-negative screen (OR=0.32, p-value<0.0001). A longer length of stay (OR=1.86, p-value=0.001) and diagnosis of a neonatal infection (OR=10.65, p-value=0.002) were positively associated with receipt of a false-negative result. Table 13 summarizes these results.

Table 13. Results of Logistic Regression Analysis, Receipt of a False-Negative Screen Result (n=5,002)

Variable	Odds Ratio	P-value	[95% Conf. Interval]	
Birth Year (referent is 1996)				
1997	2.71	0.082	0.88	8.34
1998	2.41	0.125	0.78	7.44
1999	2.21	0.181	0.69	7.10
2000	3.57	0.022	1.20	10.60
2001	3.15	0.039	1.06	9.36
2002	3.07	0.044	1.03	9.16
2003	2.66	0.085	0.87	8.08
2004	3.10	0.044	1.03	9.31
2005	2.27	0.147	0.75	6.89
2006	2.45	0.112	0.81	7.41
2007	3.28	0.048	1.01	10.68
Race (referent is White)				
Black	0.32	<0.0001	0.19	0.53
Hispanic	0.77	0.155	0.53	1.10
Other	1.20	0.679	0.51	2.82
Length of stay >5 days	1.86	0.001	1.28	2.72
Oxygen	0.63	0.023	0.42	0.94
Neonatal Infection	10.65	0.002	2.37	47.94

The overall probability of a false-negative result was 0.0392. Compared to the overall probability, the probability of a false-negative result was higher in the years 2000, 2001, 2001, 2004, and 2007. Black infants had a lower probability of a false-negative result compared to the overall sample probability. Infants on oxygen had a one and a half percent lower probability of a false-negative result compared to infants with no oxygen, while infants with a longer length of stay had two times the probability of a

false-negative result compared to infants with a shorter stay. Infants that had a neonatal infection had a probability of a false-negative result over seven times higher than those without a neonatal infection (see Table 14).

Table 14. Average Marginal Effects for the Logistic Model of Receipt of a False-Negative Screen Result

Variable	Margin	P-value	[95% Conf. Interval]	
Birth Year				
2000	0.051	<0.001	0.030	0.072
2001	0.045	<0.001	0.027	0.064
2002	0.044	<0.001	0.026	0.062
2004	0.045	<0.001	0.026	0.063
2007	0.047	0.001	0.020	0.075
Race/Ethnicity				
Black	0.016	<0.001	0.009	0.023
Oxygen Status				
No Oxygen	0.046	<0.001	0.037	0.055
Received Oxygen	0.030	<0.001	0.021	0.038
Length of Stay				
Five or less Days	0.026	<0.001	0.019	0.034
Greater than 5 days	0.048	<0.001	0.039	0.056
Neonatal Infection Dx				
No Neonatal Infection	0.039	<0.001	0.034	0.044
Neonatal Infection	0.284	0.050	0.000	0.569

Likelihood of a Hearing Loss Diagnosis

Finally, 5011 infants with complete data were included in the analysis of risk factors associated with an eventual hearing loss diagnosis. The model, as described earlier, included demographic factors and clinical characteristics that have been shown in the literature to be associated with hearing loss or conditions/therapies associated with

hearing loss. One widely known risk factor, family history, was not measurable within this study and, therefore, is excluded from our analysis.

The overall incidence of hearing loss among the study population was 5.1 percent, which is higher than the reported incidence for the total population but not unlikely given the high risk of hearing loss among infant admitted to the NICU. Neither gender nor race were associated with a hearing loss diagnosis. Black infants had lower odds of hearing loss compared to white (OR=0.38, p-value<0.001), but there were no other differences by race/ethnicity. Among clinical indicators, Apgar scores, cytomegalovirus, hyperbilirubinemia, sepsis, and respiratory distress had no association with hearing loss.

Confirming the finding from other studies, length of stay greater than five days increased the odds of hearing loss (OR=1.68, p-value=0.002), as did assisted ventilation (OR=1.71, p-value=0.023). Receipt of oxygen decreased the odds of hearing loss (OR=0.59, p-value=0.005). Infants with a craniofacial anomaly had much greater odds of hearing loss (OR=12.89, p-value<0.001). Similarly, infants with a neonatal infection were also more likely to have hearing loss (OR=7.39, p-value=0.006). See Table 15 for complete results.

Table 15. Results of Logistic Regression Analysis, Likelihood an Infant Receives a Hearing Loss Diagnosis (n=4,855)

Variable	Odds Ratio	P>z	[95% Conf. Interval]	
Gender (referent is Female)				
Male	1.01	0.955	0.78	1.31
Birthweight (referent is >4,200g)				
2,500-4,199g	1.07	0.856	0.51	2.23
1,500-2,499g	0.75	0.075	0.55	1.03
1,000-1,499g	1.07	0.790	0.65	1.78
<1,000g	1.33	0.392	0.69	2.58
Race (referent is White)				
Black	0.38	<0.001	0.25	0.57
Hispanic	0.79	0.156	0.57	1.09
Other	1.35	0.435	0.64	2.85
Apgar (1 minute)	0.95	0.226	0.88	1.03
Apgar (5 minute)	1.04	0.646	0.88	1.22
Length of stay >5 days	1.68	0.002	1.20	2.34
Ventilation	1.71	0.023	1.08	2.72
Oxygen	0.59	0.005	0.40	0.85
Cytomegalovirus Dx	0.88	0.897	0.12	6.59
Craniofacial Anomoly Dx	12.89	<0.001	4.44	37.38
Neonatal Infection	7.39	0.006	1.79	30.53
Hyperbilirubinemia Dx	0.98	0.919	0.68	1.41
Sepsis Dx	0.92	0.776	0.52	1.62
Respiratory Distress Dx	0.79	0.295	0.52	1.22

The overall probability of hearing loss was 0.0506. Black infants had a two percent lower probability of hearing loss compared to the overall sample probability. Infants who received oxygen during their birth admission had a two and a half percent

lower probability of hearing loss compared to infants not receiving oxygen. Infants on ventilation had a three percent higher probability of hearing loss compared to infants with no ventilation. Infants with a length of stay greater than five days had a probability of hearing loss over two percent higher than those admitted for five or fewer days. The probability of hearing loss among infants with craniofacial anomalies was seven times the probability of those without craniofacial anomalies; and infants with a neonatal infection had a probability five times those without a neonatal infection (see Table 16).

Table 16. Average Marginal Effects for the Logistic Model of Diagnosis of Hearing Loss

Variable	Margin	P-value	[95% Conf. Interval]	
Race/Ethnicity				
Black	0.025	<0.001	0.016	0.034
Oxygen Status				
No Oxygen	0.061	<0.001	0.051	0.071
Received Oxygen	0.037	<0.001	0.028	0.047
Ventilation Status				
No Ventilation	0.046	<0.001	0.040	0.053
Received Ventilation	0.076	<0.001	0.049	0.104
Length of Stay				
Five or less Days	0.037	<0.001	0.028	0.046
Greater than 5 days	0.060	<0.001	0.051	0.069
Craniofacial Anomaly Dx				
No Craniofacial Anomaly	0.050	<0.001	0.044	0.056
Craniofacial Anomaly	0.384	0.002	0.146	0.622
Neonatal Infection Dx				
No Neonatal Infection	0.051	<0.001	0.045	0.057
Neonatal Infection	0.269	0.046	0.005	0.534

Specific Aim 3

In this final section of results, I present the findings from a survival analysis looking at the time-to-diagnosis of hearing loss. As summarized previously, earlier diagnosis of hearing loss can lead to better communication skills and school performance.^{7, 45} The outcome of interest is the length of time between discharge and diagnosis of hearing loss, measured in 30 day periods for easy translation into years. Of note, the hazard of interest here is diagnosis and, contrary to many survival studies where death or disease may be the hazard, the presence of a hearing loss diagnosis is positive if we presume that earlier diagnosis leads to earlier intervention. A hazard ratio greater than one indicates a higher likelihood of diagnosis, compared to the reference group, during the time period of the study. Important here, and what is different from the prior analyses of hearing loss using logistic regression, is that these models are adjusted for screening status (negative result, positive result, no screen) in an effort to understand timing of diagnosis related to the screening program. Of note, follow-up records are available through the year 2013, so we have a minimum of six years of potential follow-up data and a maximum of 17 years for infants born 1996 to 2007.

First, I present the mean time-to-diagnosis for each birth year included in the study. Then, the Kaplan-Meier survival curves for hearing screen result are reviewed to demonstrate the differences in time-to-diagnosis for the different groups. Finally, I present results of a stratified Cox proportional hazards regression model, and then the Kaplan-Meier survival curves for factors associated with earlier diagnosis. Hazard ratios

are not available for hearing screen status as this variable violated the proportional hazards assumption and therefore, the model was stratified by screen status.

Time-to-Diagnosis by Year

The median time-to-diagnosis decreased from 1996 to 2007. In 1996 the median time-to-diagnosis was approximately 5.9 years (range: 1.3-11.1) and decreased to 3.3 years by 2007 (range: 0.8-5.5) (see Table 17 for annual means and ranges). An independent t-test for the difference in mean time-to-diagnosis before and after full implementation of the newborn screening mandate in Texas (2001) indicates that the means are significantly different and that the difference is greater than 0 (p-value=0.004). Figure 8 visually depicts this downward trend in time-to-diagnosis. While providing evidence of a downward trend, these results do not take into account the fact that infants born in different years have different lengths of follow-up.

Table 17. Median Time to Hearing Loss Diagnosis, in Years

Birth Year	Median Time-to-Diagnosis, in years	Minimum	Maximum
1996	5.9	1.3	11.1
1997	5.5	0.1	16.1
1998	4.3	0.7	14.8
1999	5.3	0.2	13.0
2000	4.9	0.3	11.1
2001	4.1	0.1	10.9
2002	4.3	0.1	10.9
2003	5.7	0.3	10.0
2004	3.9	0.8	9.0
2005	4.3	0.3	6.4
2006	4.9	0.1	7.1
2007	3.3	0.8	5.5




Figure 8. Median Time-to-Diagnosis, NICU Graduates

Survival Estimates by Hearing Screen Status

The Kaplan-Meier survival curve for hearing screen result (shown in Figure 9) shows that the probability of a hearing loss diagnosis early in the study period was greater among infants that failed the newborn hearing screen, suggesting that the screening program is leading to earlier diagnosis in infants who do have hearing loss. A log-rank test for equality of survival curves confirms that these curves are significantly different ($\chi^2=181.51$, $p\text{-value}<0.0001$). The findings under Specific Aim 2 suggested that the false-negative rate among NICU infants is somewhat high, possibly due to delayed onset of hearing loss or other unmeasured factors. In Figure 9, we can see that the survival curve for infants who had a negative screen result are very close to the curve for infants that did not receive a screen at all.

While the Kaplan-Meier survival curve demonstrates that infants identified through screening receive earlier diagnosis, it is also influenced by the low incidence of hearing loss and sensitivity of the screening test (sensitivity = 0.2 in the overall sample and highly variable by year). So we do not see a steeper downward slope of the survival curve for infants who failed the screen as we would expect with a higher sensitivity. In this cohort, the sensitivity is low possibly due to delayed onset hearing loss and the inability to determine if diagnosis occurred outside of the health system.




Figure 9. Kaplan-Meier Survival Estimates, by Hearing Screen Status

Cox Proportional Hazards Regression

A total of 4,855 eligible NICU infants with complete information, including 255 with a confirmed diagnosis of hearing loss, were included in the survival study. Infants born in the year 2000, and each subsequent year through 2007, were more likely to receive a hearing loss diagnosis during the monitored time period, compared to infants born in 1996. For example, the hazard ratio for the year 2007 is 4.55 (p-value=0.001)

indicating that infants with hearing loss that were born in 2007 were 4.55 times as likely as those born in 1996 to receive a hearing loss diagnosis during the period in which they received services in the health care system. As a reminder, these results are adjusted for hearing screen result using stratification. The complete results are available in Table 18.

The remaining significant predictors of hearing loss diagnosis confirm the prior results presented in the logistic model predicting hearing loss, with one exception.

Infants with a length of stay greater than five days, those having received assisted ventilation during their admission, those with a craniofacial anomaly, and infants with neonatal infections were more likely to receive a hearing loss diagnosis during the study period, while black infants were less likely to receive a diagnosis (see Table 18).

However, this analysis finds that infants in the racial category of “other” were more likely to receive diagnosis when adjusted for screening status (hazard ratio = 2.26, p-value=0.026).

Table 18. Cox Proportional Hazards Model Results, Hearing Loss Diagnosis (n=4,855)

Variable	Hazard Ratio	P>z	[95% Conf. Interval]	
1997	2.07	0.085	0.90	4.74
1998	2.06	0.09	0.89	4.76
1999	1.73	0.229	0.71	4.24
2000	2.76	0.014	1.23	6.19
2001	3.02	0.007	1.35	6.76
2002	3.61	0.002	1.60	8.13
2003	2.49	0.033	1.07	5.77
2004	3.39	0.004	1.46	7.86
2005	3.20	0.008	1.36	7.55
2006	3.49	0.004	1.50	8.11
2007	4.55	0.001	1.81	11.48
Gender (referent is Female)				
Male	1.00	0.981	0.78	1.29
Birthweight (referent is 2,500-4,199g)				
>4,200g	1.06	0.862	0.52	2.19
1,500-2,499g	0.79	0.117	0.58	1.06
1,000-1,499g	1.16	0.534	0.72	1.86
<1,000g	1.40	0.283	0.76	2.59
Race (referent is White)				
Black	0.41	<0.001	0.28	0.62
Hispanic	0.77	0.111	0.56	1.06
Other	2.26	0.026	1.10	4.64
Length of stay >5 days	1.93	<0.001	1.40	2.66
Ventilation	1.60	0.041	1.02	2.52
Craniofacial Anomaly Dx	4.58	<0.001	1.96	10.69
Neonatal Infection	5.24	0.023	1.25	21.86

Survival Estimates for Significant Model Covariates

The Kaplan-Meier Survival Curves presented below are for each of the significant variable from the Cox Proportional hazards regression model. Figure 10

shows that the probability of diagnosis early in the study period for infants categorized as having a racial category of other was higher than for the other groups (log rank test for equality: $\chi^2=19.13$, $p\text{-value}=0.0003$).




Figure 10. Kaplan-Meier Survival Estimates, by Race/Ethnicity

Figure 11 demonstrates that infants with a longer length of stay in the NICU also have a higher probability of early diagnosis than those with a stay five or fewer days (log rank test for equality: $\chi^2=13.29$, $p\text{-value}=0.0003$). Infants with longer lengths of stay

are likely sicker and require more frequent follow-up after discharge from the NICU, which may be the reason early diagnosis of hearing loss is more likely in this group.




Figure 11. Kaplan-Meier Survival Estimates, by Length of Stay

Figure 12 shows that infants with diagnoses of craniofacial anomalies (log rank test for equality: $\chi^2=63.53$, $p\text{-value}<0.0001$) are more likely to receive earlier diagnosis of hearing loss. This diagnosis increases the likelihood of both hearing loss and of early diagnosis of hearing loss. Although neonatal infections increase the odds of

hearing loss (see Specific Aim 2), there is no difference in the survival functions for those infants with and without infections.




Figure 12. Kaplan-Meier Survival Estimates, by CFA Diagnosis

CHAPTER V

DISCUSSION AND CONCLUSIONS

Given the differing scope of methodologies used in Specific Aim 1 versus Specific Aims 2 and 3, the discussion below is separated into sections focusing first on the outcomes of the systematic review of neonatal databases and then on the findings from the portion of the study evaluating outcomes of newborn hearing screening.

Specific Aim 1

Although birth outcomes such as prematurity and LBW may be relatively rare, infants with these outcomes and related conditions are more likely now than ever to survive their birth admission and receive community-based care in infancy and childhood. Often this care requires treatment of morbidities or chronic conditions associated with birth status or treatment thereafter, which motivates researchers to study short- and long-term outcomes that inform the practice of neonatology and pediatrics.

Three large databases focusing on premature, LBW, and/or very acutely ill neonates are available to researchers seeking to understand and improve birth and long-term outcomes for those infants. To date, an increasing number of studies using the three neonatal research databases have been published in the literature, and these studies use both prospective and retrospective research designs.

The studies include research in clinical areas important to advancing neonatal and pediatric medicine. For example, ten studies included in this review are part of the body of research on antenatal steroid use in mothers at risk of preterm delivery, and have

contributed to the body of research demonstrating both the risks and benefits of antenatal steroid use. Further, over 20 studies focus on encephalopathy, a condition affecting moderately premature infants. This is an important enough issue in neonatal medicine that an entirely separate registry was developed by the Vermont Oxford Network to allow for quality improvement and research efforts specific to encephalopathy. The diversity of studies published using one of the three databases is extensive and demonstrates the versatility that such databases provide to clinical and health services researchers.

The databases included in the review under Specific Aim 1 offer several advantages for researchers. First, each of the databases includes a large number of infants allowing for larger sample sizes and improved statistical power, especially when studying rarer conditions such as heart defects. Second, the databases include infants born or treated at multiple centers from diverse geographies, improving the likelihood of obtaining generalizable results in epidemiologic studies. Finally, the databases each have significant administrative guidelines and support, which provides researchers with valid and reliable data.

While a large proportion of studies focus on outcomes, there are variations in how long these outcomes are monitored within each database. The length of follow-up within each database varies, with many studies following infants through discharge from the NICU or hospital, and others, especially those with prospective data collection, follow infants into childhood. Nevertheless, consistent durations of long-term follow-up is currently limited. Researchers seeking to study disease epidemiology and long-term

outcomes may find opportunities with single center databases with smaller sample sizes. Single-center retrospective databases may offer data that are easier to obtain administratively and may be available for many years on each infant.

Study Limitations

This review of studies utilizing data from existing neonatal databases expands on the work of Wright and Papile⁷⁴ and provides new information about how research on premature and LBW infants is evolving. The review is limited by a very focused search strategy that used the database names and abbreviations as the only search terms, which may have caused me to miss some studies that used the databases but did not reference the data source in the same way I searched. Even so, the search yielded 343 studies that were ultimately included in the review and I believe that this provides adequate power to show trends in this research area.

Implications for Research Practice

Research into treatment and outcomes of premature and LBW infants is expanding, partially due to the availability of large, multicenter databases. The consistency of clinical conditions and neonatal outcomes studied since 1990 demonstrates that there are dedicated research agendas and resources that allow for long-term, and potentially replicable, studies within this population. Alternatively, the diversity of research topics and outcomes establishes an environment in which researchers can study new and innovative interventions or even some of the more rare conditions for which premature and LBW infants are at risk. These trends in neonatal research, specifically research focused on premature and LBW infants, offer a strong

foundation for future research efforts to inform neonatology, pediatric and perhaps even adult medicine with the remarkable improvements in survivability and improved long-term outcomes for these medically fragile infants.

The choice of a single center database for this study of newborn hearing screening was intentional and based on the fact that the database had data on hearing screening results and an average of ten years of follow-up on infants admitted to the NICU. Additionally, the database allowed for examination of epidemiologic trends in the outcomes important to newborn hearing screening since the data were systematically collected over the course of many years. The comprehensiveness of the available data and the extent of follow-up available (78 percent with confirmed follow-up, mean of 10 years) provided me with confidence in the internal validity of and ability to make inferences within the study.

Specific Aims 2 and 3

Implementation of newborn hearing screening within this single integrated health care system has improved since 1996, the first year of screening. Since then the proportion of infants receiving a screen has improved to steady rates around 98 percent in the final years of study. Screening rates were already improving prior to the 1999 passage of HB 714 in Texas, which required screening for all but the smallest hospitals and mandated full implementation by 2001. Between 1999 and 2001, the health system saw a slight decrease in screening rates and the cause of this is unclear, although it could be due to reassessment of organizational protocol to meet the requirements of the new law. After 2001, screening rates continued to steadily increase and stabilize. Screening

clearly targeted infants admitted to the NICU, presumably due to their increased risk, in the early years of the program, although screening rates in the newborn nursery were virtually equivalent to those in the NICU by 2001.

The health system also experienced a decrease in loss to follow-up over the study period. The system maintains a high rate of follow-up among infants admitted to the NICU, and this results of this study demonstrate that a high proportion of those infants are likely to have the opportunity for a hearing loss diagnosis within the system if they do, in fact, have hearing loss. Despite low overall rates of loss to follow-up, black infants are more likely to be lost to follow-up compared to white infants, suggesting that discharge planning for high-risk black infants may be useful in ensuring follow-up services after a positive hearing screen.

Over time, the specificity of the screen has improved, leading to a decrease in the relative number of false-positive results. Even with the general decline in false-positives, the rate had a period of increase in the late 1990s. Clinicians from the health system have advised that this increase was recognized and an organizational policy around staff training for quality improvement was implemented around 2000 or 2001. The data show that, after 2001, the false-positive rate improved to what is expected in a universal newborn hearing screening program, suggesting that organizational quality improvement initiatives can impact screening outcomes. After adjusting for birth year and other covariates, infants with extremely LBW, black infants, those that received assisted ventilation, and infants that received a diagnosis of persistent pulmonary hypertension were more likely to receive a false-positive screen result. This supports other study

findings that rescreening prior to discharge may reduce the rate of false-positives⁴²² and may further suggest that targeted rescreening is useful.

The sensitivity of the hearing screen, and associated false-negative rate, had less improvement over time and demonstrated less consistency across any given year. There is no single year where we observe a sustainable positive shift in the false-negative rate so this issue remains a prominent challenge, at least as of 2007. Infants with a longer length of stay and those with neonatal infections had an increased likelihood of a false-negative result, which indicates that targeted follow-up among these infants is important to ensure the earliest diagnosis possible. This assessment of false-negative rates may be biased due to the way in which I coded for hearing loss. All types of hearing loss are included and there is no differentiation between conductive, sensorineural, or delayed onset. The findings related to the high false-negative rate may be unusually high given the increased risk of delayed onset among NICU infants.²³ Further, it is not possible through the database to determine if there were post-discharge factors, such as head trauma, that led to hearing loss. In either case, the infants would not have had hearing loss during their birth admission and, therefore, a negative screen result at that time was probably accurate. As such, these results should be interpreted with some caution until future research determines the types of hearing loss actually diagnosed.

In this study, infants with a higher likelihood of hearing loss include those with craniofacial anomalies, neonatal infection, a length of stay greater than five days, and those receiving ventilation, confirming several risk factors cited by the JCIH, USPSTF, and other studies.^{1, 10, 15-19} However, there was no difference in likelihood for infants

with hyperbilirubinemia or for those with LBW. Black infants had a lower probability of hearing loss in contrast to findings of other studies,²² but they were also at higher risk of being lost to follow-up so diagnostic information may be missing. Receipt of oxygen is paradoxically associated with less likelihood of hearing loss, but there is no evidence from the literature that oxygen treatment is protective and there may be unmeasured clinical factors associated with these decreased odds. When adjusting for screening status in the Cox proportional hazards model, these results are mostly confirmed. However oxygen status no longer has an association with hearing loss while infants categorized as having “other race/ethnicity” have an increased likelihood of being diagnosed with hearing loss. Again, this may be due to unmeasured confounders since screening status is unlikely to have a causal relationship with hearing status.

Over the study period, the mean time-to-diagnosis has decreased and the difference prior to and after full implementation of HB 714 is statistically significant, although it was already declining. Infants that receive a positive hearing screen have a higher probability of early diagnosis, suggesting that the underlying motivations for universal newborn hearing screening are justified. Black infants have a slightly higher probability of later diagnosis, while infants categorized as “other race/ethnicity” have the highest probability of early diagnosis. Time-to-diagnosis for infants with certain risk factors for hearing loss (craniofacial anomalies, longer length of stay) are more likely to receive early diagnosis. Infants with a false-negative screen result had a probability of early diagnosis close to that for infants that had no screening at all. This may indicate

that targeted follow-up of high risk infants that did not fail the newborn hearing screen is a means to improving time-to-diagnosis.

Study Limitations

This study includes several limitations. First, I was unable to include family history in the models due to unavailable data. This means the models are missing a well-documented risk factor for hearing loss, and a potential predictor of other outcomes such as loss to follow-up (presuming that families with a history of hearing loss are more aware of the need for early diagnosis and, therefore, are more likely to follow through with diagnostic assessment). Second, the study does not discern between types of hearing loss, which may impact interpretation of false-negative screen results. Infants documented in the study may actually have delayed onset hearing loss or other causes not related to the birth encounter, meaning that they were not likely to be identified through screening in the first place. Third, the data used in analysis are from the time period 1996 to 2007 and there could have been significant changes in program implementation and outcomes since that time. The 2007 JCIH statement includes a recommendation for routine follow-up and monitoring of high-risk infants, which may lead to earlier diagnosis among infants not identified through newborn screening after 2007, but was not measurable in the study.

Finally, this study focuses on implementation of screening within a single health system, potentially limiting the external validity or generalizability of the results to other centers or populations. Further, the health system began screening earlier than was mandated by law suggesting high levels of clinical and organizational motivation for

change possibly not true of all systems; and the center maintains a rate of follow-up that may not exist in other systems. This may limit the application of our results to other organizational or clinical settings. Even with these limitations, there are policy and clinical implications that arise.

Policy Implications

The findings from this study provide further evidence in support of universal newborn hearing screening, namely the findings that hospital-based implementation is successful and that screening leads to earlier diagnosis for infants with hearing loss. Nevertheless, identification of hearing loss among high risk infants admitted to the NICU remains challenging. The high rate of false-negative screen results suggests that the JCIH recommendation for targeted follow-up and monitoring of high risk infants is justified. Coordination of efforts to ensure follow-up of these infants should be undertaken at both the state and organizational level.

Statewide rates of loss to follow up are high (approximately 40% in Texas in 2011), making the study of screening program outcomes difficult. However, studies within integrated health systems providing continuous care to infants after hospital discharge may provide insights into program success and opportunities for improvement.

As state newborn screening programs expand to include other point-of-care screening programs such as that for critical congenital heart disease, there is much to be learned from the history of newborn hearing screening. Facilitating quality improvement efforts, such as staff training programs, at local hospitals may be a particularly important component of any state law requiring universal screening at the bedside. Contrary to

traditional blood spot screening where state employees analyze, interpret, and follow-up on the screen, point-of-care screening shifts the burden of interpretation, parental notification, and referral to hospital staff.

Clinical Implications

Clinicians and health systems can use the results of this study, and others, to identify opportunities to improve screening and follow-up. For example, infants with persistent pulmonary hypertension had a high probability of false-positive results so NICUs can consider rescreening prior to discharge to avoid time consuming and costly diagnostic testing. Similarly, targeted follow-up of infants with a length of stay longer than five days and those with neonatal infections may lead to earlier identification of hearing loss and earlier intervention. NICU follow-up clinics should continue to emphasize developmental screening, including that focused on assessing potential hearing loss.

Physicians can use the results of this study to identify infants at risk for any of the outcomes studied. Discharge planning should take into account the risk for false-positive and false-negative results into account. For example, the study finds that the probability of false-negative results were seven times higher for infants with neonatal infections compared to those without. This information may alert providers to the need for referral for follow-up despite the screening result, and in addition to the usual referral for general follow-up after NICU discharge. Similarly, community-based pediatricians caring for these infants after discharge and throughout childhood should be aware of infant and clinical risk factors that increase the risk of hearing loss, especially among

populations of infants with a high probability of false-negative screen results. The average marginal effects associated with the logistic models presented in this study may be particularly useful in clinical education and training, as they are easily interpretable and applicable to individual patients.

Future Research

This study of hospital-based implementation of newborn hearing screening provides evidence for continuing universal newborn hearing screening, and makes recommendations for policy and practice. There are several opportunities for future research. First, this study should be expanded to include an analysis of the different types of hearing loss, specifically sensorineural hearing loss. NICU infants are at high risk of sensorineural hearing loss, which may have delayed onset. Analyses focused on the type of hearing loss may provide further explanation of the findings related to false-negative screen results and delayed time-to-diagnosis for infants with a false-negative.

Second, current procedural terminology (CPT) codes could be used to assess whether infants were receiving the intervention services as recommended by the JCIH. CPT codes would allow researchers to document services such as hearing and developmental assessments and receipt of amplification devices, potentially strengthening the general knowledge about factors associated with specific follow-up services, not just diagnosis.

Third, the study should be extended to the period after 2007 to identify progress in implementing Texas HB411, which provided follow-up guidelines and reporting requirements for hospitals and community-based practitioners. Finally, cost-

effectiveness studies could utilize the findings from this study, especially the marginal effects identified, to determine the marginal costs associated with outcomes such as false-positive and false-negative results among NICU populations.

REFERENCES

1. US Preventive Services Task Force. Universal screening for hearing loss in newborns: US Preventive Services Task Force recommendation statement. *Pediatrics*. 2008;122(1):143-148.
2. Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. *Pediatrics*. 1998;102(5):1161-1171.
3. Kennedy CR, McCann DC, Campbell MJ, Law CM, Mullee M, Petrou S, et al. Language ability after early detection of permanent childhood hearing impairment. *New England Journal of Medicine*. 2006;354(20):2131-2141.
4. Tomblin JB, Oleson JJ, Ambrose SE, Walker E, Moeller MP. The influence of hearing aids on the speech and language development of children with hearing loss. *JAMA Otolaryngology--Head & Neck Surgery*. 2014;140(5):403-409.
5. Lieu JE. Unilateral hearing loss in children: speech-language and school performance. *B-ENT*. 2013;Suppl 21:107-115.
6. Lieu JEC, Tye-Murray N, Karzon RK, Piccirillo JF. Unilateral hearing loss is associated with worse speech-language scores in children. *Pediatrics*. 2010;125(6):e1348-e1355.
7. Culbertson JL, Gilbert LE. Children with unilateral sensorineural hearing loss: cognitive, academic, and social development. *Ear and Hearing*. 1986;7(1):38-42.
8. Cristobal R, Oghalai JS. Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2008;93(6):F462-F468.
9. Grindle CR. Pediatric hearing loss. *Pediatrics in Review*. 2014;35(11):456-463; quiz 464.
10. Joint Committee on Infant Hearing. Year 2007 position statement: principles and guidelines for early hearing detection and intervention programs. *Pediatrics*. 2007;120(4):898-921.
11. Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR, American College of Medical Genetics Newborn Screening Expert Group. Newborn Screening: Toward a Uniform Screening Panel and System—Executive Summary. *Pediatrics*. 2006;117(Supplement 3):S296-S307.

12. TEX. HEALTH AND SAFETY CODE. §§ 47.001 *et seq* 1999.
<http://www.statutes.legis.state.tx.us/Docs/HS/htm/HS.47.htm>.
13. TEX. HEALTH AND SAFETY CODE. §§ 47.001 *et seq* 2011.
<http://www.statutes.legis.state.tx.us/Docs/HS/htm/HS.47.htm>.
14. Texas Department of State Health Services. Texas early hearing detection and intervention program annual report.
<http://www.dshs.state.tx.us/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=8589977959>. Published 2011.
15. Yelverton JC, Dominguez LM, Chapman DA, Wang S, Pandya A, Dodson KM. Risk factors associated with unilateral hearing loss. *JAMA Otolaryngology--Head & Neck Surgery*. 2013;139(1):59-63.
16. Beswick R, Driscoll C, Kei J, Khan A, Glennon S. Which risk factors predict postnatal hearing loss in children? *Journal of the American Academy of Audiology*. 2013;24(3):205-213.
17. Bielecki I, Horbulewicz A, Wolan T. Risk factors associated with hearing loss in infants: an analysis of 5282 referred neonates. *International Journal of Pediatric Otorhinolaryngology*. 2011;75(7):925-930.
18. Abu-Shaheen A, Al-Masri M, El-Bakri N, Batieha A, Nofal A, Abdelmoety D. Prevalence and risk factors of hearing loss among infants in Jordan: Initial results from universal neonatal screening. *International Journal of Audiology*. 2014:1-6.
19. Karaca CT, Oysu C, Toros SZ, Naiboglu B, Verim A. Is hearing loss in infants associated with risk factors? Evaluation of the frequency of risk factors. *Clinical and Experimental Otorhinolaryngology*. 2014;7(4):260-263.
20. Nance WE. The genetics of deafness. *Mental Retardation and Developmental Disabilities Research Reviews*. 2003;9(2):109-119.
21. Mehra S, Eavey RD, Keamy DG, Jr. The epidemiology of hearing impairment in the United States: newborns, children, and adolescents. *Otolaryngology--Head and Neck Surgery*. 2009;140(4):461-472.
22. Van Naarden K, Decoufle P. Relative and attributable risks for moderate to profound bilateral sensorineural hearing impairment associated with lower birth weight in children 3 to 10 years old. *Pediatrics*. 1999;104(4 Pt 1):905-910.
23. Yoon PJ, Price M, Gallagher K, Fleisher BE, Messner AH. The need for long-term audiologic follow-up of neonatal intensive care unit (NICU) graduates. *International Journal of Pediatric Otorhinolaryngology*. 2003;67(4):353-357.

24. Roizen NJ. Nongenetic causes of hearing loss. *Mental Retardation and Developmental Disabilities Research Reviews*. 2003;9(2):120-127.
25. Kumar A, Bhat BV. Epidemiology of respiratory distress of newborns. *Indian Journal of Pediatrics*. 1996;63(1):93-98.
26. Hermansen CL, Lorah KN. Respiratory distress in the newborn. *American Family Physician*. 2007;76(7):987-994.
27. St John EB, Carlo WA. Respiratory distress syndrome in VLBW infants: changes in management and outcomes observed by the NICHD Neonatal Research Network. *Seminars in Perinatology*. 2003;27(4):288-292.
28. Claure N, Bancalari E. New modes of mechanical ventilation in the preterm newborn: evidence of benefit. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2007;92(6):F508-512.
29. Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, Olsen MA, Fraser VJ. Ventilator-associated pneumonia in extremely preterm neonates in a neonatal intensive care unit: characteristics, risk factors, and outcomes. *Pediatrics*. 2003;112(6):1283-1289.
30. Greenough A, Dimitriou G, Prendergast M, Milner AD. Synchronized mechanical ventilation for respiratory support in newborn infants. *The Cochrane Database of Systematic Reviews*. 2008;1.
31. Fanaroff AA, Hack M, Walsh MC. The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. *Seminars in Perinatology*. 2003;27(4):281-287.
32. Wilson MG, Riley P, Hurteau AM, Baird R, Puligandla PS. Hearing loss in congenital diaphragmatic hernia (CDH) survivors: is it as prevalent as we think? *Journal of Pediatric Surgery*. 2013;48(5):942-945.
33. Robertson CM, Tyebkhan JM, Hagler ME, Cheung PY, Peliowski A, Etches PC. Late-onset, progressive sensorineural hearing loss after severe neonatal respiratory failure. *Otology & Neurotology*. 2002;23(3):353-356.
34. Morando C, Midrio P, Gamba P, Filippone M, Sgro A, Orzan E. Hearing assessment in high-risk congenital diaphragmatic hernia survivors. *International Journal of Pediatric Otorhinolaryngology*. 2010;74(10):1176-1179.
35. Hille ETM, van Straaten HI, Verkerk PH. Prevalence and independent risk factors for hearing loss in NICU infants. *Acta Paediatrica*. 2007;96(8):1155-1158.

36. Lu J, Huang Z, Yang T, Li Y, Mei L, Xiang M, et al. Screening for delayed-onset hearing loss in preschool children who previously passed the newborn hearing screening. *International Journal of Pediatric Otorhinolaryngology*. 2011;75(8):1045-1049.
37. Bahrami KR, Van Meurs KP. ECMO for neonatal respiratory failure. *Seminars in Perinatology*. 2005;29(1):15-23.
38. U.S. National Library of Medicine. Extracorporeal membrane oxygenation. <http://www.nlm.nih.gov/medlineplus/ency/article/007234.htm>. Published 2014.
39. Graziani LJ, Gringlas M, Baumgart S. Cerebrovascular complications and neurodevelopmental sequelae of neonatal ECMO. *Clinics in Perinatology*. 1997;24(3):655-675.
40. Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. *The Cochrane Database of Systematic Reviews*. 2008(3):CD001340.
41. Petrou S, Bischof M, Bennett C, Elbourne D, Field D, McNally H. Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial. *Pediatrics*. 2006;117(5):1640-1649.
42. Fligor BJ, Neault MW, Mullen CH, Feldman HA, Jones DT. Factors associated with sensorineural hearing loss among survivors of extracorporeal membrane oxygenation therapy. *Pediatrics*. 2005;115(6):1519-1528.
43. Ijsselstijn H, van Heijst AF. Long-term outcome of children treated with neonatal extracorporeal membrane oxygenation: increasing problems with increasing age. *Seminars in Perinatology*. 2014;38(2):114-121.
44. Murray M, Nield T, Larson-Tuttle C, Seri I, Friedlich P. Sensorineural hearing loss at 9–13 years of age in children with a history of neonatal extracorporeal membrane oxygenation. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2011;96(2):F128-F132.
45. Khairi Md Daud M, Noor RM, Rahman NA, Sidek DS, Mohamad A. The effect of mild hearing loss on academic performance in primary school children. *International Journal of Pediatric Otorhinolaryngology*. 2010;74(1):67-70.
46. Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR, American College of Medical Genetics Newborn Screening Expert Group. Newborn Screening: Toward a Uniform Screening Panel and System—Executive Summary. *Pediatrics*. 2006;117(Supplement 3):S296-S307.

47. Joint Committee on Infant Hearing. American Academy of Pediatrics Joint Committee on Infant Hearing, 1994 position statement. *Pediatrics*. 1995;95(1):152-156.
48. Centers for Disease Control and Prevention. Documented Status of Infants Not Passing Hearing Screening, United States, 2009–2012. http://www.cdc.gov/ncbddd/hearingloss/2012-data/ehdi_lfu_2009_2012.pdf. Published 2014.
49. Gaffney M, Green DR, Gaffney C. Newborn hearing screening and follow-up: are children receiving recommended services? *Public Health Reports*. 2010;125(2):199-207.
50. Alam S, Gaffney M, Eichwald J. Improved newborn hearing screening follow-up results in more infants identified. *Journal of Public Health Management and Practice*. 2014;20(2):220-223.
51. American Speech-Language-Hearing Association Working Group on Loss to Follow-Up. Loss to follow-up in early hearing detection and intervention. <http://www.asha.org/policy/tr2008-00302/#sec1.4>. Published 2008.
52. Oghalai JS, Chen L, Brennan ML, Tonini R, Manolidis S. Neonatal hearing loss in the indigent. *The Laryngoscope*. 2002;112(2):281-286.
53. Centers for Disease Control and Prevention. 2012 Diagnostic Demographic Summary. http://www.cdc.gov/ncbddd/hearingloss/2012-data/2012-diagnosis_ehdi.pdf. Published 2012.
54. Centers for Disease Control and Prevention. 2012 Early Intervention Demographic Summary. http://www.cdc.gov/ncbddd/hearingloss/2012-data/2012-intervention_ehdi.pdf. Published 2012.
55. Liu CL, Farrell J, MacNeil JR, Stone S, Barfield W. Evaluating loss to follow-up in newborn hearing screening in Massachusetts. *Pediatrics*. 2008;121(2):e335-343.
56. Spivak L, Sokol H, Auerbach C, Gershkovich S. Newborn hearing screening follow-up: factors affecting hearing aid fitting by 6 months of age. *American Journal of Audiology*. 2009;18(1):24-33.
57. Folsom RC, Widen JE, Vohr BR, Cone-Wesson B, Gorga MP, Sininger YS, et al. Identification of neonatal hearing impairment: recruitment and follow-up. *Ear and Hearing*. 2000;21(5):462-470.

58. Lieu JE, Karzon RK, Mange CC. Hearing screening in the neonatal intensive care unit: follow-up of referrals. *American Journal of Audiology*. 2006;15(1):66-74.
59. Healthy People 2020. Hearing and Other Sensory or Communication Disorders, Objectives. <https://www.healthypeople.gov/2020/topics-objectives/topic/hearing-and-other-sensory-or-communication-disorders>.
60. Sininger YS, Martinez A, Eisenberg L, Christensen E, Grimes A, Hu J. Newborn hearing screening speeds diagnosis and access to intervention by 20-25 months. *Journal of the American Academy of Audiology*. 2009;20(1):49-57.
61. U.S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020. <http://www.healthypeople.gov/2020/topics-objectives/topic/maternal-infant-and-child-health/objectives>.
62. MacDorman MF, Hoyert DL, Mathews TJ. Recent declines in infant mortality in the United States, 2005-2011. *NCHS Data Brief*. 2013(120):1-8.
63. MacDorman MF, Matthews T, Mohangoo AD, Zeitlin J. International comparisons of infant mortality and related factors: United States and Europe, 2010. *National Vital Statistics Reports*. 2014;63(5):1-7.
64. Matthews TJ, MacDorman MF. Infant mortality statistics from the 2010 period linked birth/infant death data set. *National Vital Statistics Reports*. 2013;62(8):1-26.
65. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale, EC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. *Pediatrics*. 2010;126(3):443-456.
66. Hintz SR, Kendrick DE, Wilson-Costello DE, Das A, Bell EF, Vohr BR, et al. Early-childhood neurodevelopmental outcomes are not improving for infants born at <25 weeks' gestational age. *Pediatrics*. 2011;127(1):62-70.
67. Gargus RA, Vohr BR, Tyson JE, High P, Higgins RD, Wragge LA, et al. Unimpaired outcomes for extremely low birth weight infants at 18 to 22 months. *Pediatrics*. 2009;124(1):112-121.
68. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. *American Journal of Obstetrics & Gynecology*. 2007;196(2):147.e141-148.

69. Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevelopmental outcomes of extremely low birth weight infants <32 weeks' gestation between 1993 and 1998. *Pediatrics*. 2005;116(3):635-643.
70. Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. *JAMA*. 2003;289(9):1124-1129.
71. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. *Pediatrics*. 2001;107(1):E1.
72. Stevenson DK, Wright LL, Lemons JA, Oh W, Korones SB, Papile LA, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. *American Journal of Obstetrics & Gynecology*. 1998;179(6 Pt 1):1632-1639.
73. Bergman I, Hirsch RP, Fria TJ, Shapiro SM, Holzman I, Painter MJ. Cause of hearing loss in the high-risk premature infant. *The Journal of Pediatrics*. 106(1):95-101.
74. Wright LL, Papile L-A. US neonatal databases: methods and uses. *Seminars in Neonatology*. 1997;2(3):159-169.
75. Escobar GJ, Fischer A, Kremers R, Usatin MS, Macedo AM, Gardner MN. Rapid retrieval of neonatal outcomes data: the Kaiser Permanente Neonatal Minimum Data Set. *Quality Management in Health Care*. 1997;5(4):19-33.
76. Vermont Oxford Network. About Us. <https://public.vtoxford.org/about-us/>. Published 2014. Accessed October 12, 2014.
77. Vermont Oxford Network. Network Databases. <https://public.vtoxford.org/databases/very-low-birth-weight/>. Published 2014. Accessed October 12, 2014.
78. Vermont Oxford Network. Policy on Data Use. https://public.vtoxford.org/wp-content/uploads/2014/03/datause_policy.pdf . Published 2012. Accessed October 12, 2014.
79. NICHD Neonatal Research Network. NICHD Neonatal Research Network background and overview. <https://neonatal.rti.org/about/network.cfm>. Published 2014. Accessed October 12, 2014.

80. NICHD Neonatal Research Network. Participating Neonatal Research Network centers. <https://neonatal.rti.org/about/map.cfm>. Published 2014. Accessed August 1, 2014.
81. National Center for Medical Home Implementation. Hearing screening: coding fact sheet for primary care pediatricians. http://www.medicalhomeinfo.org/downloads/pdfs/edhi_coding_fact_sheet_final.pdf. Accessed July 12, 2014.
82. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013.
83. Onukwugha E, Bergtold J, Jain R. A primer on marginal effects—part I: theory and formulae. *PharmacoEconomics*. 2015;33(1):25-30.
84. Onukwugha E, Bergtold J, Jain R. A primer on marginal effects—part II: health services research applications. *PharmacoEconomics*. 2014;33(2):97-103.
85. Kleinbaum DG, Klein M. *Survival analysis: a self-learning text*. Third ed: Springer; 2012.
86. Kane R. *Understanding health care outcomes research*: Jones & Bartlett Learning; 2006.
87. Pietz J, Achanti B, Lilien L, Stepka EC, Mehta SK. Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience. *Pediatrics*. 2007;119(1):e164-170.
88. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. *The Journal of Pediatrics*. 2005;146(4):469-473.
89. Mercier CE, Dunn MS, Ferrelli KR, Howard DB, Soll RF. Neurodevelopmental outcome of extremely low birth weight infants from the Vermont Oxford Network: 1998-2003. *Neonatology*. 2010;97(4):329-338.
90. Lorch SA, Srinivasan L, Escobar GJ. Epidemiology of apnea and bradycardia resolution in premature infants. *Pediatrics*. 2011;128(2):e366-e373.
91. Escobar GJ, Gebretsadik T, Carroll K, Li SX, Walsh EM, Wu P, et al. Adherence to immunoprophylaxis regimens for respiratory syncytial virus infection in insured and Medicaid populations. *Journal of the Pediatric Infectious Diseases Society*. 2013;2(3):205-214.

92. Kuzniewicz M, Draper D, Escobar GJ. Incorporation of physiological trend and interaction effects in neonatal severity of illness scores: an experiment using a variant of the Richardson score. *Intensive Care Medicine*. 2007;33(9):1602-1608.
93. Wilson A, Gardner MN, Armstrong MA, Folck BF, Escobar GJ. Neonatal assisted ventilation: predictors, frequency, and duration in a mature managed care organization. *Pediatrics*. 2000;105(4):822-830.
94. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, et al. Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. *The Journal of Pediatrics*. 2004;144(6):799-803.
95. Escobar GJ, Ragins A, Li SX, Prager L, Masaquel AS, Kipnis P. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life. *Archives of Pediatrics & Adolescent Medicine*. 2010;164(10):915-922.
96. Escobar GJ, Shaheen SM, Breed EM, Botas C, Greene JD, Yoshida CK, et al. Richardson score predicts short-term adverse respiratory outcomes in newborns \geq 34 weeks gestation. *The Journal of Pediatrics*. 2004;145(6):754-760.
97. Lorch SA, Wade KC, Bakewell-Sachs S, Medoff-Cooper B, Escobar GJ, Silber JH. Racial differences in the use of respiratory medications in premature infants after discharge from the neonatal intensive care unit. *The Journal of Pediatrics*. 2007;151(6):604-610. e601.
98. Anadkat J, Kuzniewicz M, Chaudhari B, Cole F, Hamvas A. Increased risk for respiratory distress among white, male, late preterm and term infants. *Journal of Perinatology*. 2012;32(10):780-785.
99. Ambalavanan N, Carlo WA, D'Angio CT, McDonald SA, Das A, Schendel D, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. *Pediatrics*. 2009;123(4):1132-1141.
100. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. *Pediatrics*. 2005;116(6):1353-1360.
101. Kennedy KA, Stoll BJ, Ehrenkranz RA, Oh W, Wright LL, Stevenson DK, et al. Vitamin A to prevent bronchopulmonary dysplasia in very-low-birth-weight infants: has the dose been too low? The NICHD Neonatal Research Network. *Early Human Development*. 1997;49(1):19-31.

102. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. *American Journal of Respiratory and Critical Care Medicine*. 2011;183(12):1715-1722.
103. Natarajan G, Pappas A, Shankaran S, Kendrick DE, Das A, Higgins RD, et al. Outcomes of extremely low birth weight infants with bronchopulmonary dysplasia: impact of the physiologic definition. *Early Human Development*. 2012;88(7):509-515.
104. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. *The Journal of Pediatrics*. 2005;147(6):786-790.
105. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. *Pediatrics*. 2004;114(5):1305-1311.
106. Ambalavanan N, Walsh M, Bobashev G, Das A, Levine B, Carlo WA, et al. Intercenter differences in bronchopulmonary dysplasia or death among very low birth weight infants. *Pediatrics*. 2011;127(1):e106-116.
107. Fernandez E, Watterberg KL, Faix RG, Yoder BA, Walsh MC, Lacy CB, et al. Incidence, Management, and Outcomes of Cardiovascular Insufficiency in Critically Ill Term and Late Preterm Newborn Infants. *American Journal of Perinatology*. 2014.
108. Leitch CA, Ahlrichs J, Karn C, Denne SC. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. *Pediatr Research*. 1999;46(1):109-113.
109. Finer NN, Carlo WA, Duara S, Fanaroff AA, Donovan EF, Wright LL, et al. Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial. *Pediatrics*. 2004;114(3):651-657.
110. Vaucher YE, Peralta-Carcelen M, Finer NN, Carlo WA, Gantz MG, Walsh MC, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. *New England Journal of Medicine*. 2012;367(26):2495-2504.
111. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. *New England Journal of Medicine*. 1998;338(16):1112-1118.

112. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. *New England Journal of Medicine*. 2001;344(2):95-101.
113. Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, et al. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. *The Journal of Pediatrics*. 2014;164(1):34-39.e32.
114. LeVan JM, Wyckoff MH, Ahn C, Heyne R, Sanchez PJ, Chalak L, et al. Change in care among nonenrolled patients during and after a randomized trial. *Pediatrics*. 2013;132(4):e960-970.
115. Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, et al. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. *Pediatrics*. 2004;113(3 Pt 1):559-564.
116. Konduri GG, Vohr B, Robertson C, Sokol GM, Solimano A, Singer J, et al. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. *The Journal of Pediatrics*. 2007;150(3):235-240, 240.e231.
117. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. *New England Journal of Medicine*. 1997;336(9):597-604.
118. Sokol GM, Fineberg NS, Wright LL, Ehrenkranz RA. Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. *Pediatric Pulmonology*. 2001;32(1):14-19.
119. Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, et al. Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. *Journal of Perinatology*. 2007;27(6):347-352.
120. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. *New England Journal of Medicine*. 2005;353(1):13-22.
121. Konduri GG, Sokol GM, Van Meurs KP, Singer J, Ambalavanan N, Lee T, et al. Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure. *Journal of Perinatology*. 2013;33(12):944-949.

122. Laptook AR, Salhab W, Allen J, Saha S, Walsh M. Pulse oximetry in very low birth weight infants: can oxygen saturation be maintained in the desired range? *Journal of Perinatology*. 2006;26(6):337-341.
123. Truog WE, Nelin LD, Das A, Kendrick DE, Bell EF, Carlo WA, et al. Inhaled nitric oxide usage in preterm infants in the NICHD neonatal research network: inter-site variation and propensity evaluation. *Journal of Perinatology*. 2014.
124. Walsh MC, Morris BH, Wrage LA, Vohr BR, Poole WK, Tyson JE, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. *The Journal of Pediatrics*. 2005;146(6):798-804.
125. Wang K, Difiore JM, Martin RJ, Rosen CL, Hibbs AM. Markers for severity of illness associated with decreased snoring in toddlers born ELGA. *Acta Paediatrica*. 2013;102(1):e39-43.
126. Chock VY, Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Kendrick DE, et al. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. *American Journal of Perinatology*. 2009;26(4):317-322.
127. Walsh M, Laptook A, Kazzi SN, Engle WA, Yao Q, Rasmussen M, et al. A cluster-randomized trial of benchmarking and multimodal quality improvement to improve rates of survival free of bronchopulmonary dysplasia for infants with birth weights of less than 1250 grams. *Pediatrics*. 2007;119(5):876-890.
128. Thomas CW, Meinzen-Derr J, Hoath SB, Narendran V. Neurodevelopmental outcomes of extremely low birth weight infants ventilated with continuous positive airway pressure vs. mechanical ventilation. *Indian Journal of Pediatrics*. 2012;79(2):218-223.
129. Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Early CPAP versus surfactant in extremely preterm infants. *New England Journal of Medicine*. 2010;362(21):1970-1979.
130. Di Fiore JM, Walsh M, Wrage L, Rich W, Finer N, Carlo WA, et al. Low oxygen saturation target range is associated with increased incidence of intermittent hypoxemia. *The Journal of Pediatrics*. 2012;161(6):1047-1052.
131. Ambalavanan N, Van Meurs KP, Perritt R, Carlo WA, Ehrenkranz RA, Stevenson DK, et al. Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. *Journal of Perinatology*. 2008;28(6):420-426.

132. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. The Members of the National Institute of Child Health and Human Development Neonatal Research Network. *Pediatrics*. 1993;92(2):191-196.
133. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. *The Journal of Pediatrics*. 1993;123(5):757-766.
134. DeMauro SB, D'Agostino JA, Bann C, Bernbaum J, Gerdes M, Bell EF, et al. Developmental outcomes of very preterm infants with tracheostomies. *The Journal of Pediatrics*. 2014;164(6):1303-1310.e1302.
135. Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, et al. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. *The Journal of Pediatrics*. 2002;141(3):370-374.
136. Bhandari V, Finer NN, Ehrenkranz RA, Saha S, Das A, Walsh MC, et al. Synchronized nasal intermittent positive-pressure ventilation and neonatal outcomes. *Pediatrics*. 2009;124(2):517-526.
137. Dunn MS, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D, et al. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. *Pediatrics*. 2011;128(5):e1069-1076.
138. Hentschel J, Berger TM, Tschopp A, Muller M, Adams M, Bucher HU. Population-based study of bronchopulmonary dysplasia in very low birth weight infants in Switzerland. *European Journal of Pediatrics*. 2005;164(5):292-297.
139. Mandy G, Malkar M, Welty SE, Brown R, Shepherd E, Gardner W, et al. Tracheostomy placement in infants with bronchopulmonary dysplasia: safety and outcomes. *Pediatric Pulmonology*. 2013;48(3):245-249.
140. Payne NR, LaCorte M, Karna P, Chen S, Finkelstein M, Goldsmith JP, et al. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. *Pediatrics*. 2006;118 Suppl 2:S73-77.
141. Pinheiro JM, Boynton S, Furdon SA, Dugan R, Reu-Donlon C. Use of chemical warming packs during delivery room resuscitation is associated with decreased rates of hypothermia in very low-birth-weight neonates. *Advances in Neonatal Care*. 2011;11(5):357-362.

142. Group TVONSS. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. *Pediatrics*. 2001;108(3):741-748.
143. Kirchner L, Weninger M, Unterasinger L, Birnbacher R, Hayde M, Krepler R, et al. Is the use of early nasal CPAP associated with lower rates of chronic lung disease and retinopathy of prematurity? Nine years of experience with the Vermont Oxford Neonatal Network. *Journal of perinatal medicine*. 2005;33(1):60-66.
144. Rudiger M, Ifflander S, Reichert J, Batzel C, Reiter G, Wauer RR. Which information will be given to parents of preterm infants--a comparison of estimates and local data. *Journal of Perinatal Medicine*. 2007;35(5):436-442.
145. Klebermass-Schrehof K, Wald M, Schwindt J, Grill A, Prusa AR, Haiden N, et al. Less invasive surfactant administration in extremely preterm infants: impact on mortality and morbidity. *Neonatology*. 2013;103(4):252-258.
146. Payne NR, Finkelstein MJ, Liu M, Kaempf JW, Sharek PJ, Olsen S. NICU practices and outcomes associated with 9 years of quality improvement collaboratives. *Pediatrics*. 2010;125(3):437-446.
147. Horbar JD, Carpenter JH, Buzas J, Soll RF, Suresh G, Bracken MB, et al. Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trial. *BMJ (Clinical research ed)*. 2004;329(7473):1004.
148. Horbar JD, Carpenter JH, Buzas J, Soll RF, Suresh G, Bracken MB, et al. Timing of initial surfactant treatment for infants 23 to 29 weeks' gestation: is routine practice evidence based? *Pediatrics*. 2004;113(6):1593-1602.
149. Malkar MB, Gardner WP, Mandy GT, Stenger MR, Nelin LD, Shepherd EG, et al. Respiratory severity score on day of life 30 is predictive of mortality and the length of mechanical ventilation in premature infants with protracted ventilation. *Pediatric Pulmonology*. 2014.
150. Vermont-Oxford Neonatal Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. *Pediatrics*. 1996;97(1):1-6.
151. Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. *Pediatrics*. 2006;118(5):e1328-1335.
152. Wilson-Costello D, Walsh MC, Langer JC, Guillet R, Laptook AR, Stoll BJ, et al. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22

- months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. *Pediatrics*. 2009;123(3):e430-437.
153. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. *The Journal of Pediatrics*. 2011;159(5):720-725.
 154. Oh W, Stevenson DK, Tyson JE, Morris BH, Ahlfors CE, Bender GJ, et al. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. *Acta Paediatrica*. 2010;99(5):673-678.
 155. Oh W, Tyson JE, Fanaroff AA, Vohr BR, Perritt R, Stoll BJ, et al. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. *Pediatrics*. 2003;112(4):773-779.
 156. Carlo WA, McDonald SA, Tyson JE, Stoll BJ, Ehrenkranz RA, Shankaran S, et al. Cytokines and neurodevelopmental outcomes in extremely low birth weight infants. *The Journal of Pediatrics*. 2011;159(6):919-925.e913.
 157. Duncan AF, Watterberg KL, Nolen TL, Vohr BR, Adams-Chapman I, Das A, et al. Effect of ethnicity and race on cognitive and language testing at age 18-22 months in extremely preterm infants. *The Journal of Pediatrics*. 2012;160(6):966-971.e962.
 158. Walden RV, Taylor SC, Hansen NI, Poole WK, Stoll BJ, Abuelo D, et al. Major congenital anomalies place extremely low birth weight infants at higher risk for poor growth and developmental outcomes. *Pediatrics*. 2007;120(6):e1512-1519.
 159. Lowe J, Woodward B, Papile LA. Emotional regulation and its impact on development in extremely low birth weight infants. *Journal of Developmental and Behavioral Pediatrics*. 2005;26(3):209-213.
 160. Lowe JR, Duncan AF, Bann CM, Fuller J, Hintz SR, Das A, et al. Early working memory as a racially and ethnically neutral measure of outcome in extremely preterm children at 18-22 months. *Early Human Development*. 2013;89(12):1055-1061.
 161. Lowe JR, Nolen TL, Vohr B, Adams-Chapman I, Duncan AF, Watterberg K. Effect of primary language on developmental testing in children born extremely preterm. *Acta Paediatrica*. 2013;102(9):896-900.
 162. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in

extremely low birth weight infants treated with early erythropoietin and iron. *Pediatrics*. 2004;114(5):1287-1291.

163. Adams-Chapman I, Bann CM, Vaucher YE, Stoll BJ. Association between feeding difficulties and language delay in preterm infants using Bayley Scales of Infant Development-Third Edition. *The Journal of Pediatrics*. 2013;163(3):680-685.e681-683.
164. Ehrenkranz RA, Younes N, Lemons JA, Fanaroff AA, Donovan EF, Wright LL, et al. Longitudinal growth of hospitalized very low birth weight infants. *Pediatrics*. 1999;104(2 Pt 1):280-289.
165. Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole WK. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. *Pediatrics*. 2006;117(4):1253-1261.
166. Wadhawan R, Oh W, Hintz SR, Blakely ML, Das A, Bell EF, et al. Neurodevelopmental outcomes of extremely low birth weight infants with spontaneous intestinal perforation or surgical necrotizing enterocolitis. *Journal of Perinatology*. 2014;34(1):64-70.
167. Tsai AJ, Lasky RE, John SD, Evans PW, Kennedy KA. Predictors of neurodevelopmental outcomes in preterm infants with intraparenchymal hemorrhage. *Journal of Perinatology*. 2014;34(5):399-404.
168. Merhar SL, Tabangin ME, Meinzen-Derr J, Schibler KR. Grade and laterality of intraventricular haemorrhage to predict 18-22 month neurodevelopmental outcomes in extremely low birthweight infants. *Acta Paediatrica*. 2012;101(4):414-418.
169. Payne AH, Hintz SR, Hibbs AM, Walsh MC, Vohr BR, Bann CM, et al. Neurodevelopmental outcomes of extremely low-gestational-age neonates with low-grade periventricular-intraventricular hemorrhage. *JAMA Pediatrics*. 2013;167(5):451-459.
170. Hintz SR, Kendrick DE, Stoll BJ, Vohr BR, Fanaroff AA, Donovan EF, et al. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. *Pediatrics*. 2005;115(3):696-703.
171. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. *JAMA*. 2004;292(19):2357-2365.

172. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. *Pediatrics*. 2000;105(6):1216-1226.
173. Lainwala S, Perritt R, Poole K, Vohr B. Neurodevelopmental and growth outcomes of extremely low birth weight infants who are transferred from neonatal intensive care units to level I or II nurseries. *Pediatrics*. 2007;119(5):e1079-1087.
174. Castro L, Yolton K, Haberman B, Roberto N, Hansen NI, Ambalavanan N, et al. Bias in reported neurodevelopmental outcomes among extremely low birth weight survivors. *Pediatrics*. 2004;114(2):404-410.
175. Hintz SR, Kendrick DE, Vohr BR, Kenneth Poole W, Higgins RD. Gender differences in neurodevelopmental outcomes among extremely preterm, extremely-low-birthweight infants. *Acta Paediatrica*. 2006;95(10):1239-1248.
176. Hintz SR, Kendrick DE, Vohr BR, Poole WK, Higgins RD. Changes in neurodevelopmental outcomes at 18 to 22 months' corrected age among infants of less than 25 weeks' gestational age born in 1993-1999. *Pediatrics*. 2005;115(6):1645-1651.
177. Laptook AR, O'Shea TM, Shankaran S, Bhaskar B. Adverse neurodevelopmental outcomes among extremely low birth weight infants with a normal head ultrasound: prevalence and antecedents. *Pediatrics*. 2005;115(3):673-680.
178. Messinger D, Lambert B, Bauer CR, Bann CM, Hamlin-Smith K, Das A. The relationship between behavior ratings and concurrent and subsequent mental and motor performance in toddlers born at extremely low birth weight. *Journal of Early Intervention*. 2010;32(3):214-233.
179. Shankaran S, Johnson Y, Langer JC, Vohr BR, Fanaroff AA, Wright LL, et al. Outcome of extremely-low-birth-weight infants at highest risk: gestational age < or =24 weeks, birth weight < or =750 g, and 1-minute Apgar < or =3. *American Journal of Obstetrics & Gynecology*. 2004;191(4):1084-1091.
180. Vohr BR, Stephens BE, Higgins RD, Bann CM, Hintz SR, Das A, et al. Are outcomes of extremely preterm infants improving? Impact of Bayley assessment on outcomes. *The Journal of Pediatrics*. 2012;161(2):222-228.e223.
181. Vohr BR, Tyson JE, Wright LL, Perritt RL, Li L, Poole WK. Maternal age, multiple birth, and extremely low birth weight infants. *The Journal of Pediatrics*. 2009;154(4):498-503.e492.

182. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). *The Journal of Pediatrics*. 2000;136(5):611-617.
183. Morriss FH, Jr., Saha S, Bell EF, Colaizy TT, Stoll BJ, Hintz SR, et al. Surgery and neurodevelopmental outcome of very low-birth-weight infants. *JAMA Pediatrics*. 2014;168(8):746-754.
184. Wadhawan R, Oh W, Vohr BR, Wrage L, Das A, Bell EF, et al. Neurodevelopmental outcomes of triplets or higher-order extremely low birth weight infants. *Pediatrics*. 2011;127(3):e654-660.
185. Adams-Chapman I, Hansen NI, Stoll BJ, Higgins R. Neurodevelopmental outcome of extremely low birth weight infants with posthemorrhagic hydrocephalus requiring shunt insertion. *Pediatrics*. 2008;121(5):e1167-1177.
186. Dusick AM, Poindexter BB, Ehrenkranz RA, Lemons JA. Growth failure in the preterm infant: can we catch up? *Seminars in Perinatology*. 2003;27(4):302-310.
187. Broitman E, Ambalavanan N, Higgins RD, Vohr BR, Das A, Bhaskar B, et al. Clinical data predict neurodevelopmental outcome better than head ultrasound in extremely low birth weight infants. *The Journal of Pediatrics*. 2007;151(5):500-505, 505.e501-502.
188. Hintz SR, Van Meurs KP, Perritt R, Poole WK, Das A, Stevenson DK, et al. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. *The Journal of Pediatrics*. 2007;151(1):16-22, 22.e11-13.
189. Davis AS, Hintz SR, Van Meurs KP, Li L, Das A, Stoll BJ, et al. Seizures in extremely low birth weight infants are associated with adverse outcome. *The Journal of Pediatrics*. 2010;157(5):720-725.e721-722.
190. Goldstein RF, Cotten CM, Shankaran S, Gantz MG, Poole WK. Influence of gestational age on death and neurodevelopmental outcome in premature infants with severe intracranial hemorrhage. *Journal of Perinatology*. 2013;33(1):25-32.
191. Wadhawan R, Oh W, Vohr BR, Saha S, Das A, Bell EF, et al. Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2013;98(2):F127-132.

192. Wadhawan R, Oh W, Perritt RL, McDonald SA, Das A, Poole WK, et al. Twin gestation and neurodevelopmental outcome in extremely low birth weight infants. *Pediatrics*. 2009;123(2):e220-227.
193. Petrini JR, Dias T, McCormick MC, Massolo ML, Green NS, Escobar GJ. Increased risk of adverse neurological development for late preterm infants. *The Journal of Pediatrics*. 2009;154(2):169-176. e163.
194. Peralta-Carcelen M, Moses M, Adams-Chapman I, Gantz M, Vohr BR. Stability of neuromotor outcomes at 18 and 30 months of age after extremely low birth weight status. *Pediatrics*. 2009;123(5):e887-895.
195. Vohr BR, Msall ME, Wilson D, Wright LL, McDonald S, Poole WK. Spectrum of gross motor function in extremely low birth weight children with cerebral palsy at 18 months of age. *Pediatrics*. 2005;116(1):123-129.
196. Hack M, Horbar JD, Malloy MH, Tyson JE, Wright E, Wright L. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. *Pediatrics*. 1991;87(5):587-597.
197. Horbar JD, Onstad L, Wright E. Predicting mortality risk for infants weighing 501 to 1500 grams at birth: a National Institutes of Health Neonatal Research Network report. *Critical Care Medicine*. 1993;21(1):12-18.
198. Fanaroff AA, Wright LL, Stevenson DK, Shankaran S, Donovan EF, Ehrenkranz RA, et al. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, May 1991 through December 1992. *American Journal of Obstetrics & Gynecology*. 1995;173(5):1423-1431.
199. Hack M, Wright LL, Shankaran S, Tyson JE, Horbar JD, Bauer CR, et al. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Network, November 1989 to October 1990. *American Journal of Obstetrics & Gynecology*. 1995;172(2 Pt 1):457-464.
200. Tyson JE, Younes N, Verter J, Wright LL. Viability, morbidity, and resource use among newborns of 501- to 800-g birth weight. National Institute of Child Health and Human Development Neonatal Research Network. *JAMA*. 1996;276(20):1645-1651.
201. Horbar JD, Badger GJ, Lewit EM, Rogowski J, Shiono PH. Hospital and patient characteristics associated with variation in 28-day mortality rates for very low birth weight infants. Vermont Oxford Network. *Pediatrics*. 1997;99(2):149-156.

202. Donovan EF, Ehrenkranz RA, Shankaran S, Stevenson DK, Wright LL, Younes N, et al. Outcomes of very low birth weight twins cared for in the National Institute of Child Health and Human Development Neonatal Research Network's intensive care units. *American Journal of Obstetrics & Gynecology*. 1998;179(3 Pt 1):742-749.
203. Stevenson DK, Verter J, Fanaroff AA, Oh W, Ehrenkranz RA, Shankaran S, et al. Sex differences in outcomes of very low birthweight infants: the newborn male disadvantage. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2000;83(3):F182-185.
204. Horbar JD, Badger GJ, Carpenter JH, Fanaroff AA, Kilpatrick S, LaCorte M, et al. Trends in mortality and morbidity for very low birth weight infants, 1991-1999. *Pediatrics*. 2002;110(1 Pt 1):143-151.
205. Shankaran S, Fanaroff AA, Wright LL, Stevenson DK, Donovan EF, Ehrenkranz RA, et al. Risk factors for early death among extremely low-birth-weight infants. *American Journal of Obstetrics & Gynecology*. 2002;186(4):796-802.
206. Vohr BR, Wright LL, Dusick AM, Perritt R, Poole WK, Tyson JE, et al. Center differences and outcomes of extremely low birth weight infants. *Pediatrics*. 2004;113(4):781-789.
207. Rogowski JA, Horbar JD, Staiger DO, Kenny M, Carpenter J, Geppert J. Indirect vs direct hospital quality indicators for very low-birth-weight infants. *JAMA*. 2004;291(2):202-209.
208. Lucey JF, Rowan CA, Shiono P, Wilkinson AR, Kilpatrick S, Payne NR, et al. Fetal infants: the fate of 4172 infants with birth weights of 401 to 500 grams--the Vermont Oxford Network experience (1996-2000). *Pediatrics*. 2004;113(6):1559-1566.
209. Hintz SR, Poole WK, Wright LL, Fanaroff AA, Kendrick DE, Laptook AR, et al. Changes in mortality and morbidities among infants born at less than 25 weeks during the post-surfactant era. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2005;90(2):F128-133.
210. Ambalavanan N, Carlo WA, Bobashev G, Mathias E, Liu B, Poole K, et al. Prediction of death for extremely low birth weight neonates. *Pediatrics*. 2005;116(6):1367-1373.
211. Morales LS, Staiger D, Horbar JD, Carpenter J, Kenny M, Geppert J, et al. Mortality among very low-birthweight infants in hospitals serving minority populations. *American Journal of Public Health*. 2005;95(12):2206-2212.

212. Ambalavanan N, Baibergenova A, Carlo WA, Saigal S, Schmidt B, Thorpe KE. Early prediction of poor outcome in extremely low birth weight infants by classification tree analysis. *The Journal of Pediatrics*. 2006;148(4):438-444.
213. Wadhawan R, Oh W, Perritt R, Laptook AR, Poole K, Wright LL, et al. Association between early postnatal weight loss and death or BPD in small and appropriate for gestational age extremely low-birth-weight infants. *Journal of Perinatology*. 2007;27(6):359-364.
214. Bakewell-Sachs S, Medoff-Cooper B, Escobar GJ, Silber JH, Lorch SA. Infant functional status: the timing of physiologic maturation of premature infants. *Pediatrics*. 2009;123(5):e878-e886.
215. Chedid F, Shanteer S, Haddad H, Musharraf I, Shihab Z, Imran A, et al. Short-term outcome of very low birth weight infants in a developing country: comparison with the Vermont Oxford Network. *Journal of tropical pediatrics*. 2009;55(1):15-19.
216. De Nisi G, Berti M, Malossi R, Pederzini F, Pedrotti A, Valente A. Comparison of neonatal intensive care: Trento area versus Vermont Oxford Network. *Italian Journal of Pediatrics*. 2009;35(1):5.
217. Bell EF, Hansen NI, Morriss FH, Jr., Stoll BJ, Ambalavanan N, Gould JB, et al. Impact of timing of birth and resident duty-hour restrictions on outcomes for small preterm infants. *Pediatrics*. 2010;126(2):222-231.
218. Murphy BP, Armstrong K, Ryan CA, Jenkins JG. Benchmarking care for very low birthweight infants in Ireland and Northern Ireland. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2010;95(1):F30-35.
219. Morrow AL, Meinzen-Derr J, Huang P, Schibler KR, Cahill T, Keddache M, et al. Fucosyltransferase 2 non-secretor and low secretor status predicts severe outcomes in premature infants. *The Journal of Pediatrics*. 2011;158(5):745-751.
220. Rahman S, Salameh K, Al-Rifai H, Masoud A, Lutfi S, Salama H, et al. Gestational age specific neonatal survival in the State of Qatar (2003-2008) - a comparative study with international benchmarks. *Journal of the College of Physicians and Surgeons--Pakistan*. 2011;21(9):542-547.
221. De Jesus LC, Pappas A, Shankaran S, Kendrick D, Das A, Higgins RD, et al. Risk factors for post-neonatal intensive care unit discharge mortality among extremely low birth weight infants. *The Journal of Pediatrics*. 2012;161(1):70-74.e71-72.

222. Ambalavanan N, Carlo WA, Tyson JE, Langer JC, Walsh MC, Parikh NA, et al. Outcome trajectories in extremely preterm infants. *Pediatrics*. 2012;130(1):e115-125.
223. Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. *Pediatrics*. 2012;129(6):1019-1026.
224. Alleman BW, Bell EF, Li L, Dagle JM, Smith PB, Ambalavanan N, et al. Individual and center-level factors affecting mortality among extremely low birth weight infants. *Pediatrics*. 2013;132(1):e175-184.
225. Kumar P, Shankaran S, Ambalavanan N, Kendrick DE, Pappas A, Vohr BR, et al. Characteristics of extremely low-birth-weight infant survivors with unimpaired outcomes at 30 months of age. *Journal of Perinatology*. 2013;33(10):800-805.
226. Randolph DA, Nolen TL, Ambalavanan N, Carlo WA, Peralta-Carcelen M, Das A, et al. Outcomes of extremely low birthweight infants with acidosis at birth. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2014;99(4):F263-268.
227. Davis AS, Hintz SR, Goldstein RF, Ambalavanan N, Bann CM, Stoll BJ, et al. Outcomes of extremely preterm infants following severe intracranial hemorrhage. *Journal of Perinatology*. 2014;34(3):203-208.
228. Peralta-Carcelen M, Bailey K, Rector R, Gantz M. Behavioral and socioemotional competence problems of extremely low birth weight children. *Journal of Perinatology*. 2013;33(11):887-892.
229. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. *American Journal of Obstetrics & Gynecology*. 2000;182(1 Pt 1):198-206.
230. Shankaran S, Laptook A, Wright LL, Ehrenkranz RA, Donovan EF, Fanaroff AA, et al. Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants. *Pediatrics*. 2002;110(2 Pt 1):377-385.
231. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. *New England Journal of Medicine*. 2005;353(15):1574-1584.

232. Ambalavanan N, Carlo WA, Shankaran S, Bann CM, Emrich SL, Higgins RD, et al. Predicting outcomes of neonates diagnosed with hypoxemic-ischemic encephalopathy. *Pediatrics*. 2006;118(5):2084-2093.
233. Laptook A, Tyson J, Shankaran S, McDonald S, Ehrenkranz R, Fanaroff A, et al. Elevated temperature after hypoxic-ischemic encephalopathy: risk factor for adverse outcomes. *Pediatrics*. 2008;122(3):491-499.
234. Oh W, Perritt R, Shankaran S, Merritts M, Donovan EF, Ehrenkranz RA, et al. Association between urinary lactate to creatinine ratio and neurodevelopmental outcome in term infants with hypoxic-ischemic encephalopathy. *The Journal of Pediatrics*. 2008;153(3):375-378.
235. Shankaran S, Pappas A, Laptook AR, McDonald SA, Ehrenkranz RA, Tyson JE, et al. Outcomes of safety and effectiveness in a multicenter randomized, controlled trial of whole-body hypothermia for neonatal hypoxic-ischemic encephalopathy. *Pediatrics*. 2008;122(4):e791-798.
236. Mietzsch U, Parikh NA, Williams AL, Shankaran S, Lasky RE. Effects of hypoxic-ischemic encephalopathy and whole-body hypothermia on neonatal auditory function: a pilot study. *American Journal of Perinatology*. 2008;25(7):435-441.
237. Laptook AR, Shankaran S, Ambalavanan N, Carlo WA, McDonald SA, Higgins RD, et al. Outcome of term infants using apgar scores at 10 minutes following hypoxic-ischemic encephalopathy. *Pediatrics*. 2009;124(6):1619-1626.
238. Lasky RE, Parikh NA, Williams AL, Padhye NS, Shankaran S. Changes in the PQRST intervals and heart rate variability associated with rewarming in two newborns undergoing hypothermia therapy. *Neonatology*. 2009;96(2):93-95.
239. Parikh NA, Lasky RE, Garza CN, Bonfante-Mejia E, Shankaran S, Tyson JE. Volumetric and anatomical MRI for hypoxic-ischemic encephalopathy: relationship to hypothermia therapy and neurosensory impairments. *Journal of Perinatology*. 2009;29(2):143-149.
240. Kwon JM, Guillet R, Shankaran S, Laptook AR, McDonald SA, Ehrenkranz RA, et al. Clinical seizures in neonatal hypoxic-ischemic encephalopathy have no independent impact on neurodevelopmental outcome: secondary analyses of data from the neonatal research network hypothermia trial. *Journal of Child Neurology*. 2011;26(3):322-328.
241. Pappas A, Shankaran S, Laptook AR, Langer JC, Bara R, Ehrenkranz RA, et al. Hypocarbica and adverse outcome in neonatal hypoxic-ischemic encephalopathy. *The Journal of Pediatrics*. 2011;158(5):752-758.e751.

242. Shankaran S, Pappas A, McDonald SA, Laptook AR, Bara R, Ehrenkranz RA, et al. Predictive value of an early amplitude integrated electroencephalogram and neurologic examination. *Pediatrics*. 2011;128(1):e112-120.
243. Natarajan G, Pappas A, Shankaran S, Laptook AR, Walsh M, McDonald SA, et al. Effect of inborn vs. outborn delivery on neurodevelopmental outcomes in infants with hypoxic-ischemic encephalopathy: secondary analyses of the NICHD whole-body cooling trial. *Pediatric Research*. 2012;72(4):414-419.
244. Sant'Anna G, Laptook AR, Shankaran S, Bara R, McDonald SA, Higgins RD, et al. Phenobarbital and temperature profile during hypothermia for hypoxic-ischemic encephalopathy. *Journal of Child Neurology*. 2012;27(4):451-457.
245. Shankaran S, Barnes PD, Hintz SR, Laptook AR, Zaterka-Baxter KM, McDonald SA, et al. Brain injury following trial of hypothermia for neonatal hypoxic-ischaemic encephalopathy. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2012;97(6):F398-404.
246. Shankaran S, Laptook AR, McDonald SA, Higgins RD, Tyson JE, Ehrenkranz RA, et al. Temperature profile and outcomes of neonates undergoing whole body hypothermia for neonatal hypoxic-ischemic encephalopathy. *Pediatric Critical Care Medicine*. 2012;13(1):53-59.
247. Shankaran S, Laptook AR, Tyson JE, Ehrenkranz RA, Bann CM, Das A, et al. Evolution of encephalopathy during whole body hypothermia for neonatal hypoxic-ischemic encephalopathy. *The Journal of Pediatrics*. 2012;160(4):567-572.e563.
248. Shankaran S, Pappas A, McDonald SA, Vohr BR, Hintz SR, Yolton K, et al. Childhood outcomes after hypothermia for neonatal encephalopathy. *New England Journal of Medicine*. 2012;366(22):2085-2092.
249. Natarajan G, Shankaran S, Laptook AR, Pappas A, Bann CM, McDonald SA, et al. Apgar scores at 10 min and outcomes at 6-7 years following hypoxic-ischaemic encephalopathy. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2013;98(6):F473-479.
250. Vohr BR, Stephens BE, McDonald SA, Ehrenkranz RA, Laptook AR, Pappas A, et al. Cerebral palsy and growth failure at 6 to 7 years. *Pediatrics*. 2013;132(4):e905-914.
251. Laptook AR, McDonald SA, Shankaran S, Stephens BE, Vohr BR, Guillet R, et al. Elevated temperature and 6- to 7-year outcome of neonatal encephalopathy. *Annals of Neurology*. 2013;73(4):520-528.

252. Cotten CM, Goldstein RF, McDonald SA, Goldberg RN, Salhab WA, Carlo WA, et al. Apolipoprotein E genotype and outcome in infants with hypoxic-ischemic encephalopathy. *Pediatric Research*. 2014;75(3):424-430.
253. Natarajan G, Shankaran S, Pappas A, Bann C, Tyson JE, McDonald S, et al. Functional status at 18 months of age as a predictor of childhood disability after neonatal hypoxic-ischemic encephalopathy. *Developmental Medicine and Child Neurology*. 2014.
254. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. *New England Journal of Medicine*. 1994;330(16):1107-1113.
255. Stoll BJ, Hansen N, Fanaroff AA, Lemons JA. Enterobacter sakazakii is a rare cause of neonatal septicemia or meningitis in VLBW infants. *The Journal of Pediatrics*. 2004;144(6):821-823.
256. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. *Pediatrics*. 2004;113(5):1181-1186.
257. Payne NR, Carpenter JH, Badger GJ, Horbar JD, Rogowski J. Marginal increase in cost and excess length of stay associated with nosocomial bloodstream infections in surviving very low birth weight infants. *Pediatrics*. 2004;114(2):348-355.
258. Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK, Jr. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. *Pediatrics*. 2006;118(2):717-722.
259. Benjamin DK, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. *Pediatrics*. 2006;117(1):84-92.
260. Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, et al. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. *Pediatrics*. 2009;123(1):313-318.
261. Benjamin DK, Jr., Stoll BJ, Gantz MG, Walsh MC, Sanchez PJ, Das A, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. *Pediatrics*. 2010;126(4):e865-873.

262. Ang JY, Lua JL, Asmar BI, Shankaran S, Heyne RJ, Schelonka RL, et al. Nasopharyngeal carriage of *Streptococcus pneumoniae* in very low-birth-weight infants after administration of heptavalent pneumococcal conjugate vaccine. *Archives of Pediatric and Adolescent Medicine*. 2010;164(12):1173-1175.
263. Schelonka RL, Maheshwari A, Carlo WA, Taylor S, Hansen NI, Schendel DE, et al. T cell cytokines and the risk of blood stream infection in extremely low birth weight infants. *Cytokine*. 2011;53(2):249-255.
264. Greenberg RG, Benjamin DK, Jr., Gantz MG, Cotten CM, Stoll BJ, Walsh MC, et al. Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. *The Journal of Pediatrics*. 2012;161(2):264-269.e262.
265. Wynn JL, Tan S, Gantz MG, Das A, Goldberg RN, Adams-Chapman I, et al. Outcomes following candiduria in extremely low birth weight infants. *Clinical Infectious Diseases*. 2012;54(3):331-339.
266. Shane AL, Hansen NI, Stoll BJ, Bell EF, Sanchez PJ, Shankaran S, et al. Methicillin-resistant and susceptible *Staphylococcus aureus* bacteremia and meningitis in preterm infants. *Pediatrics*. 2012;129(4):e914-922.
267. Bliss JM, Wong AY, Bhak G, Laforce-Nesbitt SS, Taylor S, Tan S, et al. *Candida* virulence properties and adverse clinical outcomes in neonatal candidiasis. *The Journal of Pediatrics*. 2012;161(3):441-447.e442.
268. Adams-Chapman I, Bann CM, Das A, Goldberg RN, Stoll BJ, Walsh MC, et al. Neurodevelopmental outcome of extremely low birth weight infants with *Candida* infection. *The Journal of Pediatrics*. 2013;163(4):961-967.e963.
269. Fairlie T, Zell ER, Schrag S. Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease. *Obstetrics and Gynecology*. 2013;121(3):570-577.
270. Donovan EF, Sparling K, Lake MR, Narendran V, Schibler K, Haberman B, et al. The investment case for preventing NICU-associated infections. *American Journal of Perinatology*. 2013;30(3):179-184.
271. Rogowski JA, Staiger D, Patrick T, Horbar J, Kenny M, Lake ET. Nurse staffing and NICU infection rates. *JAMA Pediatrics*. 2013;167(5):444-450.
272. Uauy RD, Fanaroff AA, Korones SB, Phillips EA, Phillips JB, Wright LL. Necrotizing enterocolitis in very low birth weight infants: biodemographic and clinical correlates. National Institute of Child Health and Human Development Neonatal Research Network. *The Journal of Pediatrics*. 1991;119(4):630-638.

273. Blakely ML, Lally KP, McDonald S, Brown RL, Barnhart DC, Ricketts RR, et al. Postoperative outcomes of extremely low birth-weight infants with necrotizing enterocolitis or isolated intestinal perforation: a prospective cohort study by the NICHD Neonatal Research Network. *Annals of Surgery*. 2005;241(6):984-989; discussion 989-994.
274. Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. *Pediatrics*. 2006;117(2):e137-142.
275. Blakely ML, Tyson JE, Lally KP, McDonald S, Stoll BJ, Stevenson DK, et al. Laparotomy versus peritoneal drainage for necrotizing enterocolitis or isolated intestinal perforation in extremely low birth weight infants: outcomes through 18 months adjusted age. *Pediatrics*. 2006;117(4):e680-687.
276. Cole CR, Hansen NI, Higgins RD, Ziegler TR, Stoll BJ. Very low birth weight preterm infants with surgical short bowel syndrome: incidence, morbidity and mortality, and growth outcomes at 18 to 22 months. *Pediatrics*. 2008;122(3):e573-582.
277. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sanchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. *Pediatrics*. 2009;123(1):58-66.
278. Meinzen-Derr J, Morrow AL, Hornung RW, Donovan EF, Dietrich KN, Succop PA. Epidemiology of necrotizing enterocolitis temporal clustering in two neonatology practices. *The Journal of Pediatrics*. 2009;154(5):656-661.
279. Fitzgibbons SC, Ching Y, Yu D, Carpenter J, Kenny M, Weldon C, et al. Mortality of necrotizing enterocolitis expressed by birth weight categories. *Journal of Pediatric Surgery*. 2009;44(6):1072-1075; discussion 1075-1076.
280. Singh R, Visintainer PF, Frantz ID, 3rd, Shah BL, Meyer KM, Favila SA, et al. Association of necrotizing enterocolitis with anemia and packed red blood cell transfusions in preterm infants. *Journal of Perinatology*. 2011;31(3):176-182.
281. Cole CR, Hansen NI, Higgins RD, Bell EF, Shankaran S, Laptook AR, et al. Bloodstream infections in very low birth weight infants with intestinal failure. *The Journal of Pediatrics*. 2012;160(1):54-59.e52.
282. Shah TA, Meinzen-Derr J, Gratton T, Steichen J, Donovan EF, Yolton K, et al. Hospital and neurodevelopmental outcomes of extremely low-birth-weight infants with necrotizing enterocolitis and spontaneous intestinal perforation. *Journal of Perinatology*. 2012;32(7):552-558.

283. Hull MA, Fisher JG, Gutierrez IM, Jones BA, Kang KH, Kenny M, et al. Mortality and Management of Surgical Necrotizing Enterocolitis in Very Low Birth Weight Neonates: A Prospective Cohort Study. *Journal of the American College of Surgeons*. 2013.
284. Maheshwari A, Schelonka RL, Dimmitt RA, Carlo WA, Munoz-Hernandez B, Das A, et al. Cytokines associated with necrotizing enterocolitis in extremely-low-birth-weight infants. *Pediatric Research*. 2014;76(1):100-108.
285. Fisher JG, Jones BA, Gutierrez IM, Hull MA, Kang KH, Kenny M, et al. Mortality associated with laparotomy-confirmed neonatal spontaneous intestinal perforation: A prospective 5-year multicenter analysis. *Journal of Pediatric Surgery*. 2014;49(8):1215-1219.
286. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. *The Journal of Pediatrics*. 1996;129(1):72-80.
287. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. *The Journal of Pediatrics*. 1996;129(1):63-71.
288. Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. *Pediatric Infectious Disease Journal*. 1998;17(7):593-598.
289. Escobar GJ, Li D-k, Armstrong MA, Gardner MN, Folck BF, Verdi JE, et al. Neonatal sepsis workups in infants \geq 2000 grams at birth: a population-based study. *Pediatrics*. 2000;106(2):256-263.
290. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. *New England Journal of Medicine*. 2002;347(4):240-247.
291. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. *Pediatrics*. 2002;110(2 Pt 1):285-291.
292. Edwards WH, Conner JM, Soll RF. The effect of prophylactic ointment therapy on nosocomial sepsis rates and skin integrity in infants with birth weights of 501 to 1000 g. *Pediatrics*. 2004;113(5):1195-1203.

293. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. *Pediatric Infectious Disease Journal*. 2005;24(7):635-639.
294. Stoll BJ, Hansen NI, Sanchez PJ, Faix RG, Poindexter BB, Van Meurs KP, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. *Pediatrics*. 2011;127(5):817-826.
295. Weston EJ, Pondo T, Lewis MM, Martell-Cleary P, Morin C, Jewell B, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. *Pediatric Infectious Disease Journal*. 2011;30(11):937-941.
296. Sood BG, Shankaran S, Schelonka RL, Saha S, Benjamin DK, Jr., Sanchez PJ, et al. Cytokine profiles of preterm neonates with fungal and bacterial sepsis. *Pediatric Research*. 2012;72(2):212-220.
297. Boghossian NS, Page GP, Bell EF, Stoll BJ, Murray JC, Cotten CM, et al. Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births. *The Journal of Pediatrics*. 2013;162(6):1120-1124, 1124.e1121.
298. Wynn JL, Hansen NI, Das A, Cotten CM, Goldberg RN, Sanchez PJ, et al. Early sepsis does not increase the risk of late sepsis in very low birth weight neonates. *The Journal of Pediatrics*. 2013;162(5):942-948.e941-943.
299. Escobar GJ, Puopolo KM, Wi S, Turk BJ, Kuzniewicz MW, Walsh EM, et al. Stratification of risk of early-onset sepsis in newborns \geq 34 weeks' gestation. *Pediatrics*. 2014;133(1):30-36.
300. Wright LL, Verter J, Younes N, Stevenson D, Fanaroff AA, Shankaran S, et al. Antenatal corticosteroid administration and neonatal outcome in very low birth weight infants: the NICHD Neonatal Research Network. *American Journal of Obstetrics & Gynecology*. 1995;173(1):269-274.
301. Shankaran S, Bauer CR, Bain R, Wright LL, Zachary J. Relationship between antenatal steroid administration and grades III and IV intracranial hemorrhage in low birth weight infants. The NICHD Neonatal Research Network. *American Journal of Obstetrics & Gynecology*. 1995;173(1):305-312.
302. Horbar JD. Antenatal corticosteroid treatment and neonatal outcomes for infants 501 to 1500 gm in the Vermont-Oxford Trials Network. *American Journal of Obstetrics & Gynecology*. 1995;173(1):275-281.

303. Wright LL, Horbar JD, Gunkel H, Verter J, Younes N, Andrews EB, et al. Evidence from multicenter networks on the current use and effectiveness of antenatal corticosteroids in low birth weight infants. *American Journal of Obstetrics & Gynecology*. 1995;173(1):263-269.
304. Gardner MO, Papile LA, Wright LL. Antenatal corticosteroids in pregnancies complicated by preterm premature rupture of membranes. *Obstetrics and Gynecology*. 1997;90(5):851-853.
305. Horbar JD. Increasing use of antenatal corticosteroid therapy between 1990 and 1993 in Vermont Oxford Network. *Journal of Perinatology*. 1997;17(4):309-313.
306. Demarini S, Dollberg S, Hoath SB, Ho M, Donovan EF. Effects of antenatal corticosteroids on blood pressure in very low birth weight infants during the first 24 hours of life. *Journal of Perinatology*. 1999;19(6 Pt 1):419-425.
307. Lee BH, Stoll BJ, McDonald SA, Higgins RD. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. *Pediatrics*. 2006;117(5):1503-1510.
308. Lee BH, Stoll BJ, McDonald SA, Higgins RD. Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone. *Pediatrics*. 2008;121(2):289-296.
309. Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. *JAMA*. 2011;306(21):2348-2358.
310. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. *Pediatrics*. 2000;105(2):295-310.
311. Blair BM, O'Halloran H S, Pauly TH, Stevens JL. Decreased incidence of retinopathy of prematurity, 1995-1997. *Journal of the American Association for Pediatric Ophthalmology and Strabismus*. 2001;5(2):118-122.
312. Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? *Pediatrics*. 2003;111(2):339-345.
313. Bhola R, Purkiss T, Hunter S, Stewart D, Rychwalski PJ. Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity. *Journal of the American Association for Pediatric Ophthalmology and Strabismus*. 2009;13(5):450-453.

314. Sood BG, Madan A, Saha S, Schendel D, Thorsen P, Skogstrand K, et al. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. *Pediatric Research*. 2010;67(4):394-400.
315. Carlo WA, Higgins RD. Optimum oxygen therapy to prevent retinopathy of prematurity. *Expert Review of Ophthalmology*. 2010;5(5):583-585.
316. Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Target ranges of oxygen saturation in extremely preterm infants. *New England Journal of Medicine*. 2010;362(21):1959-1969.
317. Kennedy KA, Wrage LA, Higgins RD, Finer NN, Carlo WA, Walsh MC, et al. Evaluating retinopathy of prematurity screening guidelines for 24- to 27-week gestational age infants. *Journal of Perinatology*. 2014;34(4):311-318.
318. Atkinson LR, Escobar GJ, Takayama JI, Newman TB. Phototherapy use in jaundiced newborns in a large managed care organization: do clinicians adhere to the guideline? *Pediatrics*. 2003;111(5):e555-e561.
319. Bender GJ, Cashore WJ, Oh W. Ontogeny of bilirubin-binding capacity and the effect of clinical status in premature infants born at less than 1300 grams. *Pediatrics*. 2007;120(5):1067-1073.
320. Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. *Pediatrics*. 2009;124(4):1031-1039.
321. Hintz SR, Stevenson DK, Yao Q, Wong RJ, Das A, Van Meurs KP, et al. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants? *Acta Paediatrica*. 2011;100(7):960-965.
322. Morris BH, Oh W, Tyson JE, Stevenson DK, Phelps DL, O'Shea TM, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. *New England Journal of Medicine*. 2008;359(18):1885-1896.
323. Tyson JE, Pedroza C, Langer J, Green C, Morris B, Stevenson D, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? *Journal of Perinatology*. 2012;32(9):677-684.
324. Lasky RE, Church MW, Orlando MS, Morris BH, Parikh NA, Tyson JE, et al. The effects of aggressive vs. conservative phototherapy on the brainstem auditory evoked responses of extremely-low-birth-weight infants. *Pediatric Research*. 2012;71(1):77-84.

325. Morris BH, Tyson JE, Stevenson DK, Oh W, Phelps DL, O'Shea TM, et al. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study. *Journal of Perinatology*. 2013;33(2):126-133.
326. Clyman RI, Saha S, Jobe A, Oh W. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. *The Journal of Pediatrics*. 2007;150(1):46-50.e42.
327. Alfaleh K, Smyth JA, Roberts RS, Solimano A, Asztalos EV, Schmidt B. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. *Pediatrics*. 2008;121(2):e233-238.
328. Laptook AR, Salhab W, Bhaskar B. Admission temperature of low birth weight infants: predictors and associated morbidities. *Pediatrics*. 2007;119(3):e643-649.
329. Stephens BE, Bann CM, Watson VE, Sheinkopf SJ, Peralta-Carcelen M, Bodnar A, et al. Screening for autism spectrum disorders in extremely preterm infants. *Journal of Developmental and Behavioral Pediatrics*. 2012;33(7):535-541.
330. Kuzniewicz MW, Wi S, Qian Y, Walsh EM, Armstrong MA, Croen LA. Prevalence and neonatal factors associated with autism spectrum disorders in preterm infants. *The Journal of Pediatrics*. 2014;164(1):20-25.
331. Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, et al. The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants. *New England Journal of Medicine*. 1997;337(7):466-471.
332. McCain GC, Donovan EF, Gartside P. Preterm infant behavioral and heart rate responses to antenatal phenobarbital. *Research in Nursing & Health*. 1999;22(6):461-470.
333. Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, et al. Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure. *American Journal of Obstetrics & Gynecology*. 2002;187(1):171-177.
334. Suresh GK, Horbar JD, Kenny M, Carpenter JH. Major birth defects in very low birth weight infants in the Vermont Oxford Network. *The Journal of Pediatrics*. 2001;139(3):366-373.
335. Adams-Chapman I, Hansen NI, Shankaran S, Bell EF, Boghossian NS, Murray JC, et al. Ten-year review of major birth defects in VLBW infants. *Pediatrics*. 2013;132(1):49-61.

336. Turcotte LM, Georgieff MK, Ross JA, Feusner JH, Tomlinson GE, Malogolowkin MH, et al. Neonatal medical exposures and characteristics of low birth weight hepatoblastoma cases: A report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 2014;61(11):2018-2023.
337. Finer NN, Horbar JD, Carpenter JH. Cardiopulmonary resuscitation in the very low birth weight infant: the Vermont Oxford Network experience. *Pediatrics*. 1999;104(3 Pt 1):428-434.
338. Escobar GJ, Braveman PA, Ackerson L, Odouli R, Coleman-Phox K, Capra AM, et al. A randomized comparison of home visits and hospital-based group follow-up visits after early postpartum discharge. *Pediatrics*. 2001;108(3):719-727.
339. Pappas A, Kendrick DE, Shankaran S, Stoll BJ, Bell EF, Laptook AR, et al. Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. *JAMA Pediatrics*. 2014.
340. Hintz SR, Kendrick DE, Vohr BR, Poole WK, Higgins RD. Community supports after surviving extremely low-birth-weight, extremely preterm birth: special outpatient services in early childhood. *Archives of Pediatric and Adolescent Medicine*. 2008;162(8):748-755.
341. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. *Pediatrics*. 1997;99(6):838-845.
342. Oh W, Fanaroff AA, Carlo WA, Donovan EF, McDonald SA, Poole WK. Effects of delayed cord clamping in very-low-birth-weight infants. *Journal of Perinatology*. 2011;31 Suppl 1:S68-71.
343. Malloy MH, Onstad L, Wright E. The effect of cesarean delivery on birth outcome in very low birth weight infants. National Institute of Child Health and Human Development Neonatal Research Network. *Obstetrics and Gynecology*. 1991;77(4):498-503.
344. Wadhawan R, Vohr BR, Fanaroff AA, Perritt RL, Duara S, Stoll BJ, et al. Does labor influence neonatal and neurodevelopmental outcomes of extremely-low-birth-weight infants who are born by cesarean delivery? *American Journal of Obstetrics & Gynecology*. 2003;189(2):501-506.
345. Stoll BJ, Temprosa M, Tyson JE, Papile LA, Wright LL, Bauer CR, et al. Dexamethasone therapy increases infection in very low birth weight infants. *Pediatrics*. 1999;104(5):e63.

346. Hintz SR, Bann CM, Ambalavanan N, Cotten CM, Das A, Higgins RD. Predicting time to hospital discharge for extremely preterm infants. *Pediatrics*. 2010;125(1):e146-154.
347. Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. *The Journal of Pediatrics*. 2014;165(1):23-29.
348. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. *Pediatrics*. 2001;108(4):934-942.
349. Tyson JE, Parikh NA, Langer J, Green C, Higgins RD. Intensive care for extreme prematurity--moving beyond gestational age. *New England Journal of Medicine*. 2008;358(16):1672-1681.
350. Stephens BE, Bann CM, Poole WK, Vohr BR. Neurodevelopmental impairment: predictors of its impact on the families of extremely low birth weight infants at 18 months. *Infant Mental Health Journal*. 2008;29(6):570-587.
351. Malcolm WF, Gantz M, Martin RJ, Goldstein RF, Goldberg RN, Cotten CM. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. *Pediatrics*. 2008;121(1):22-27.
352. Boghossian NS, Hansen NI, Bell EF, Stoll BJ, Murray JC, Carey JC, et al. Mortality and morbidity of VLBW infants with trisomy 13 or trisomy 18. *Pediatrics*. 2014;133(2):226-235.
353. Boghossian NS, Hansen NI, Bell EF, Stoll BJ, Murray JC, Laptook AR, et al. Survival and morbidity outcomes for very low birth weight infants with Down syndrome. *Pediatrics*. 2010;126(6):1132-1140.
354. Boghossian NS, Horbar JD, Carpenter JH, Murray JC, Bell EF. Major chromosomal anomalies among very low birth weight infants in the Vermont Oxford Network. *The Journal of Pediatrics*. 2012;160(5):774-780.e711.
355. Boghossian NS, Horbar JD, Murray JC, Carpenter JH. Anthropometric charts for infants with trisomies 21, 18, or 13 born between 22 weeks gestation and term: the VON charts. *American Journal of Medical Genetics Part A*. 2012;158a(2):322-332.

356. Chee YY, Wong KY, Low L. Review of primary hypothyroidism in very low birthweight infants in a perinatal centre in Hong Kong. *Journal of Paediatrics and Child Health*. 2011;47(11):824-831.
357. Klein NP, Massolo ML, Greene J, Dekker CL, Black S, Escobar GJ. Risk factors for developing apnea after immunization in the neonatal intensive care unit. *Pediatrics*. 2008;121(3):463-469.
358. Navar-Boggan A, Halsey N, Escobar G, Golden W, Klein N. Underimmunization at discharge from the neonatal intensive care unit. *Journal of Perinatology*. 2012;32(5):363-367.
359. Navar-Boggan A, Halsey N, Golden W, Escobar G, Massolo M, Klein N. Risk of fever and sepsis evaluations after routine immunizations in the neonatal intensive care unit. *Journal of Perinatology*. 2010;30(9):604-609.
360. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. *New England Journal of Medicine*. 2001;344(26):1966-1972.
361. Doyle NM, Gardner MO, Wells L, Qualls C, Papile LA. Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis. *Journal of Perinatology*. 2005;25(5):336-340.
362. Schmidt B, Roberts RS, Fanaroff A, Davis P, Kirpalani HM, Nwaesei C, et al. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). *The Journal of Pediatrics*. 2006;148(6):730-734.
363. Mirza H, Oh W, Laptook A, Vohr B, Tucker R, Stonestreet BS. Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration. *The Journal of Pediatrics*. 2013;163(3):706-710.e701.
364. Batton B, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, et al. Use of antihypertensive therapies in extremely preterm infants. *Pediatrics*. 2013;131(6):e1865-1873.
365. Batton BJ, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, et al. Feasibility study of early blood pressure management in extremely preterm infants. *The Journal of Pediatrics*. 2012;161(1):65-69.e61.
366. Shankaran S, Bauer CR, Bain R, Wright LL, Zachary J. Prenatal and perinatal risk and protective factors for neonatal intracranial hemorrhage. National

Institute of Child Health and Human Development Neonatal Research Network. *Archives of Pediatric and Adolescent Medicine*. 1996;150(5):491-497.

367. Singh R, Gorstein SV, Bednarek F, Chou JH, McGowan EC, Visintainer PF. A predictive model for SIVH risk in preterm infants and targeted indomethacin therapy for prevention. *Scientific Reports*. 2013;3:2539.
368. Armstrong MA, Osejo VG, Lieberman L, Carpenter DM, Pantoja PM, Escobar GJ. Perinatal substance abuse intervention in obstetric clinics decreases adverse neonatal outcomes. *Journal of Perinatology*. 2003;23(1):3-9.
369. Goler N, Armstrong M, Taillac C, Osejo V. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. *Journal of Perinatology*. 2008;28(9):597-603.
370. Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. *Obstetrics & Gynecology*. 2011;118(3):583-591.
371. Phelps DL, Ward RM, Williams RL, Watterberg KL, Laptook AR, Wrage LA, et al. Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. *Pediatric Research*. 2013;74(6):721-729.
372. Hintz SR, Gaylord TD, Oh W, Fanaroff AA, Mele L, Stevenson DK, et al. Serum bilirubin levels at 72 hours by selected characteristics in breastfed and formula-fed term infants delivered by cesarean section. *Acta Paediatrica*. 2001;90(7):776-781.
373. Ehrenkranz RA, Das A, Wrage LA, Poindexter BB, Higgins RD, Stoll BJ, et al. Early nutrition mediates the influence of severity of illness on extremely LBW infants. *Pediatric Research*. 2011;69(6):522-529.
374. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Wright LL, Langer JC, et al. Beneficial effects of breast milk in the neonatal intensive care unit on the developmental outcome of extremely low birth weight infants at 18 months of age. *Pediatrics*. 2006;118(1):e115-123.
375. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Higgins RD, Langer JC, et al. Persistent beneficial effects of breast milk ingested in the neonatal intensive care unit on outcomes of extremely low birth weight infants at 30 months of age. *Pediatrics*. 2007;120(4):e953-959.
376. Heller CD, O'Shea M, Yao Q, Langer J, Ehrenkranz RA, Phelps DL, et al. Human milk intake and retinopathy of prematurity in extremely low birth weight infants. *Pediatrics*. 2007;120(1):1-9.

377. Meinzen-Derr J, Poindexter B, Wrage L, Morrow AL, Stoll B, Donovan EF. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. *Journal of Perinatology*. 2009;29(1):57-62.
378. Brownell EA, Lussier MM, Hagadorn JI, McGrath JM, Marinelli KA, Herson VC. Independent Predictors of Human Milk Receipt at Neonatal Intensive Care Unit Discharge. *American Journal of Perinatology*. 2013.
379. De Jesus LC, Pappas A, Shankaran S, Li L, Das A, Bell EF, et al. Outcomes of small for gestational age infants born at <27 weeks' gestation. *The Journal of Pediatrics*. 2013;163(1):55-60.e51-53.
380. Natarajan G, Shankaran S, McDonald SA, Das A, Stoll BJ, Higgins RD, et al. Circulating beta chemokine and MMP 9 as markers of oxidative injury in extremely low birth weight infants. *Pediatric Research*. 2010;67(1):77-82.
381. Poindexter BB, Langer JC, Dusick AM, Ehrenkranz RA. Early provision of parenteral amino acids in extremely low birth weight infants: relation to growth and neurodevelopmental outcome. *The Journal of Pediatrics*. 2006;148(3):300-305.
382. Poindexter BB, Ehrenkranz RA, Stoll BJ, Koch MA, Wright LL, Oh W, et al. Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants. *The American Journal of Clinical Nutrition*. 2003;77(3):737-743.
383. Poindexter BB, Ehrenkranz RA, Stoll BJ, Wright LL, Poole WK, Oh W, et al. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. *Pediatrics*. 2004;113(5):1209-1215.
384. Shankaran S, Langer JC, Kazzi SN, Laptook AR, Walsh M. Cumulative index of exposure to hypocarbia and hyperoxia as risk factors for periventricular leukomalacia in low birth weight infants. *Pediatrics*. 2006;118(4):1654-1659.
385. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. *Pediatrics*. 2000;105(1 Pt 1):14-20.
386. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. *The Journal of Pediatrics*. 2007;150(3):229-234, 234.e221.

387. Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenbergh MR, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2007;92(4):F244-247.
388. Madan JC, Kendrick D, Hagadorn JI, Frantz ID, 3rd. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. *Pediatrics*. 2009;123(2):674-681.
389. Benjamin JR, Smith PB, Cotten CM, Jagers J, Goldstein RF, Malcolm WF. Long-term morbidities associated with vocal cord paralysis after surgical closure of a patent ductus arteriosus in extremely low birth weight infants. *Journal of Perinatology*. 2010;30(6):408-413.
390. Archer JM, Yeager SB, Kenny MJ, Soll RF, Horbar JD. Distribution of and mortality from serious congenital heart disease in very low birth weight infants. *Pediatrics*. 2011;127(2):293-299.
391. Pappas A, Shankaran S, Hansen NI, Bell EF, Stoll BJ, Laptook AR, et al. Outcome of extremely preterm infants (<1,000 g) with congenital heart defects from the National Institute of Child Health and Human Development Neonatal Research Network. *Pediatric Cardiology*. 2012;33(8):1415-1426.
392. Natarajan G, Shankaran S, McDonald SA, Das A, Ehrenkranz RA, Goldberg RN, et al. Association between blood spot transforming growth factor-beta and patent ductus arteriosus in extremely low-birth weight infants. *Pediatric Cardiology*. 2013;34(1):149-154.
393. Horbar JD, Rogowski J, Plsek PE, Delmore P, Edwards WH, Hocker J, et al. Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. *Pediatrics*. 2001;107(1):14-22.
394. Cotten CM, Oh W, McDonald S, Carlo W, Fanaroff AA, Duara S, et al. Prolonged hospital stay for extremely premature infants: risk factors, center differences, and the impact of mortality on selecting a best-performing center. *Journal of Perinatology*. 2005;25(10):650-655.
395. McCormick MC, Escobar GJ, Zheng Z, Richardson DK. Factors influencing parental satisfaction with neonatal intensive care among the families of moderately premature infants. *Pediatrics*. 2008;121(6):1111-1118.
396. Binder S, Hill K, Meinzen-Derr J, Greenberg JM, Narendran V. Increasing VLBW deliveries at subspecialty perinatal centers via perinatal outreach. *Pediatrics*. 2011;127(3):487-493.

397. Smith PB, Ambalavanan N, Li L, Cotten CM, Laughon M, Walsh MC, et al. Approach to infants born at 22 to 24 weeks' gestation: relationship to outcomes of more-mature infants. *Pediatrics*. 2012;129(6):e1508-1516.
398. Lake ET, Staiger D, Horbar J, Cheung R, Kenny MJ, Patrick T, et al. Association between hospital recognition for nursing excellence and outcomes of very low-birth-weight infants. *JAMA*. 2012;307(16):1709-1716.
399. Soll RF, Edwards EM, Badger GJ, Kenny MJ, Morrow KA, Buzas JS, et al. Obstetric and neonatal care practices for infants 501 to 1500 g from 2000 to 2009. *Pediatrics*. 2013;132(2):222-228.
400. Puch-Kapst K, Juran R, Stoeber B, Wauer RR. Radiation exposure in 212 very low and extremely low birth weight infants. *Pediatrics*. 2009;124(6):1556-1564.
401. Escobar G, Greene J, Hulac P, Kincannon E, Bischoff K, Gardner M, et al. Rehospitalisation after birth hospitalisation: patterns among infants of all gestations. *Archives of Disease in Childhood*. 2005;90(2):125-131.
402. Morris BH, Gard CC, Kennedy K. Rehospitalization of extremely low birth weight (ELBW) infants: are there racial/ethnic disparities? *Journal of Perinatology*. 2005;25(10):656-663.
403. Ambalavanan N, Carlo WA, McDonald SA, Yao Q, Das A, Higgins RD. Identification of extremely premature infants at high risk of rehospitalization. *Pediatrics*. 2011;128(5):e1216-1225.
404. Ambalavanan N, Carlo WA, McDonald SA, Das A, Schendel DE, Thorsen P, et al. Cytokines and posthemorrhagic ventricular dilation in premature infants. *American Journal of Perinatology*. 2012;29(9):731-740.
405. Dollberg S, Demarini S, Donovan EF, Hoath SB. Maturation of thermal capabilities in preterm infants. *American Journal of Perinatology*. 2000;17(1):47-51.
406. McCormick MC, Escobar GJ, Zheng Z, Richardson DK. Place of birth and variations in management of late preterm ("near-term") infants. *Seminars in Perinatology*. 2006;30(1):44-47.
407. Escobar GJ, Joffe S, Gardner MN, Armstrong MA, Folck BF, Carpenter DM. Rehospitalization in the first two weeks after discharge from the neonatal intensive care unit. *Pediatrics*. 1999;104(1):e2-e2.

408. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. *Pediatrics*. 1999;104(4):894-899.
409. Wade K, Lorch S, Bakewell-Sachs S, Medoff-Cooper B, Silber J, Escobar G. Pediatric care for preterm infants after NICU discharge: high number of office visits and prescription medications. *Journal of Perinatology*. 2008;28(10):696-701.
410. Lorch SA, Baiocchi M, Silber JH, Even-Shoshan O, Escobar GJ, Small DS. The role of outpatient facilities in explaining variations in risk-adjusted readmission rates between hospitals. *Health Services Research*. 2010;45(1):24-41.
411. Ray KN, Escobar GJ, Lorch SA. Premature infants born to adolescent mothers: health care utilization after initial discharge. *Academic Pediatrics*. 2010;10(5):302-308.
412. Kuzniewicz MW, Parker S-J, Schnake-Mahl A, Escobar GJ. Hospital readmissions and emergency department visits in moderate preterm, late preterm, and early term infants. *Clinics in Perinatology*. 2013;40(4):753-775.
413. D'Angio CT, Heyne RJ, O'Shea TM, Schelonka RL, Shankaran S, Duara S, et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. *Pediatric Infectious Disease Journal*. 2010;29(7):600-606.
414. Wynn JL, Li L, Cotten CM, Phelps DL, Shankaran S, Goldberg RN, et al. Blood stream infection is associated with altered heptavalent pneumococcal conjugate vaccine immune responses in very low birth weight infants. *Journal of Perinatology*. 2013;33(8):613-618.
415. D'Angio CT, Murray TE, Li L, Heyne RJ, O'Shea TM, Schelonka RL, et al. Immunogenicity of Haemophilus influenzae type b protein conjugate vaccines in very low birth weight infants. *Pediatric Infectious Disease Journal*. 2013;32(12):1400-1402.
416. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. *New England Journal of Medicine*. 1999;340(25):1962-1968.
417. Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. *Pediatrics*. 2005;115(3):e249-254.

418. Londhe VA, Nolen TL, Das A, Higgins RD, Tyson JE, Oh W, et al. Vitamin A supplementation in extremely low-birth-weight infants: subgroup analysis in small-for-gestational-age infants. *American Journal of Perinatology*. 2013;30(9):771-780.
419. Bell EF, Hansen NI, Brion LP, Ehrenkranz RA, Kennedy KA, Walsh MC, et al. Serum tocopherol levels in very preterm infants after a single dose of vitamin e at birth. *Pediatrics*. 2013;132(6):e1626-e1633.
420. Wyckoff MH, Salhab WA, Heyne RJ, Kendrick DE, Stoll BJ, Laptook AR. Outcome of extremely low birth weight infants who received delivery room cardiopulmonary resuscitation. *The Journal of Pediatrics*. 2012;160(2):239-244.e232.
421. Morton RF, Hebel JR, McCarter RJ. *A study guide to epidemiology and biostatistics*: Jones & Bartlett Learning; 2004.
422. Colella-Santos MF, Hein TA, de Souza GL, do Amaral MI, Casali RL. Newborn hearing screening and early diagnostic in the NICU. *BioMed Research International*. 2014;2014:845308.